



**Scientific Opinion on Flavouring Group Evaluation 67 Revision 2 (FGE.67Rev2):
Consideration of 28 furan-substituted compounds evaluated by JECFA at the 55th,
65th and 69th meetings (JECFA, 2001, 2006a, 2009b)**

EFSA Publication

Link to article, DOI:
[10.2903/j.efsa.2015.4115](https://doi.org/10.2903/j.efsa.2015.4115)

Publication date:
2015

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):
EFSA Publication (2015). *Scientific Opinion on Flavouring Group Evaluation 67 Revision 2 (FGE.67Rev2):
Consideration of 28 furan-substituted compounds evaluated by JECFA at the 55th, 65th and 69th meetings
(JECFA, 2001, 2006a, 2009b)*. European Food Safety Authority. the EFSA Journal Vol. 13(5) No. 4115
<https://doi.org/10.2903/j.efsa.2015.4115>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

SCIENTIFIC OPINION

Scientific Opinion on Flavouring Group Evaluation 67 Revision 2 (FGE.67Rev2): Consideration of 28 furan-substituted compounds evaluated by JECFA at the 55th, 65th and 69th meetings (JECFA, 2001, 2006a, 2009b)¹

EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF)^{2,3}

European Food Safety Authority (EFSA), Parma, Italy

ABSTRACT

The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) of the European Food Safety Authority was requested to consider evaluations of flavouring substances assessed since 2000 by the Joint FAO/WHO Expert Committee on Food Additives (JECFA), and to decide whether further evaluation is necessary, as laid down in Commission Regulation (EC) No 1565/2000. The substances were evaluated through a stepwise approach (the Procedure) that integrates information on structure-activity relationships, intake from current uses, toxicological threshold of concern, and available data on metabolism and toxicity. The present consideration concerns a group of 28 furan-substituted compounds evaluated by the JECFA. This revision of FGE.67 is due to new data on toxicity for 3-(4-methyl-2-furyl) butanal [FL-no: 13.058] providing an appropriate NOAEL for the evaluation of candidate substance [FL-no: 13.058]. The Panel concluded that 11 substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 13.058, 13.074, 13.116 and 13.190] do not give rise to safety concerns at the levels of dietary intake, estimated on the basis of the MSDI approach. However, based on mTAMDI calculations, for these eleven candidate substances, except [FL-no: 13.058], more reliable intake data are required for a re-evaluation. Besides the safety assessment of these flavouring substances, the specifications for the materials of commerce have also been considered, which for all candidate substances are adequate. For 17 substances [FL-nos: 13.045, 13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 13.148 and 13.163] a concern for genotoxicity was raised and therefore these were not evaluated using the Procedure. The Panel noted further that for 7 of these 17 substances [FL-nos: 13.045, 13.052, 13.054, 13.059, 13.061, 13.069 and 13.083], use levels have not yet been submitted.

© European Food Safety Authority, 2015

¹ On request from the European Commission, Question No EFSA-Q-2014-00146, adopted on 07 May 2015.

² Panel members: Claudia Bolognesi, Laurence Castle, Jean-Pierre Cravedi, Karl-Heinz Engel, Paul Fowler, Konrad Grob, Rainer Gürtler, Trine Husøy, Wim Mennes, Maria Rosaria Milana, André Penninks, Vittorio Silano, Andrew Smith, Maria de Fátima Tavares Poças, Christina Tlustos, Fidel Toldrá, Detlef Wölfe and Holger Zorn. Correspondence: fip@efsa.europa.eu

³ Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings: Ulla Beckman Sundh, Leon Brimer, Karl-Heinz Engel, Paul Fowler, Rainer Gürtler, Trine Husøy, Wim Mennes, Gerard Mulder and Harriet Wallin for the preparatory work on this scientific opinion and the hearing experts: Vibe Beltoft and Karin Nørby and EFSA staff: Annamaria Rossi, Maria Carfi and Maria Anastassiadou for the support provided to this scientific opinion.

Suggested citation: EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 2015. Scientific Opinion on Flavouring Group Evaluation 67, Revision 2 (FGE.67Rev2): Consideration of 28 furan-substituted compounds evaluated by JECFA at the 55th, 65th and 69th meeting (JECFA, 2001, 2006a and 2009b). EFSA Journal 2015;13(5):4115, 107 pp. doi:10.2903/j.efsa.2015.4115

Available online: www.efsa.europa.eu/efsajournal

KEY WORDS

furan-substituted, genotoxic, JECFA 65th meeting, FGE.13Rev2, FGE.65Rev1, FGE.66Rev1, FGE.67Rev1, FGE.67Rev2

SUMMARY

Following a request from the European Commission, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion on the implications for human health of chemically defined flavouring substances used in or on foodstuffs in the Member States. In particular, the Panel was requested to consider the Joint FAO/WHO Expert Committee on Food Additives (the JECFA) evaluations of flavouring substances assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, which was adopted by Commission Decision 1999/217/EC and its consecutive amendments.

The present revision of FGE.67, FGE.67Rev2, which has been made due to new toxicity data provided for 3-(5-methyl-2-furyl) butanal, deals with 28 substances. Twenty-seven of these were previously considered by the JECFA in a group of 40 furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, sulfides, disulfides and ethers (JECFA, 2009a). One of these 40 substances [FL-no: 13.192] appeared to be a synonym of substance [FL-no: 13.178] which has already been evaluated in FGE.13Rev2. Therefore this substance [FL-no: 13.192] will not be further considered in this FGE and should be removed from the Register. Another substance [FL-no: 13.176] will be evaluated in FGE.99 rather than in FGE.67, because of better structural similarity with candidate substances in FGE.99. Furthermore, one candidate substance [FL-no: 13.031] from FGE.66Rev1 has been included in this revision of FGE.67, because this substance has better structural similarity to a candidate flavouring substance [FL-no: 13.074] in FGE.67 than to the other candidate flavouring substances in FGE.66Rev1.

Thirteen of the 40 substances considered by JECFA are α,β -unsaturated carbonyls, which have been evaluated by EFSA in FGE.19 context with respect to a concern for a possible genotoxic potential. This concern for genotoxicity could not be alleviated for six substances [FL-nos: 13.034, 13.043, 13.044, 13.046, 13.137 and 13.150], corresponding to FGE.19 subgroup 4.6. These six substances were therefore not further considered in this FGE.

For five substances the Flavourings Industry has announced that they do no longer support their use as flavouring substances in Europe [former FL-nos: 13.029, 13.030, 13.092, 13.107 and 13.191], these substances have been withdrawn from the safety evaluation in the present FGE.

The 28 candidate substances considered in this FGE [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.045, 13.047, 13.052, 13.054, 13.058, 13.059, 13.061, 13.066, 13.069, 13.070, 13.074, 13.083, 13.101, 13.103, 13.105, 13.106, 13.116, 13.123, 13.138, 13.148, 13.163 and 13.190] have been allocated to various subgroups, based on their chemical structures. These substances are structurally related to the group of 27 furfuryl and furan derivatives evaluated by EFSA in FGE.13Rev2. Part of the substances is also structurally related to a group of 33 sulphur-substituted furan derivatives used as flavouring agents, evaluated by EFSA in FGE.65Rev1 and another part is structurally related to 14 furfuryl derivatives evaluated in FGE.66Rev1.

The Panel agrees with the JECFA for 17 of the substances [FL-nos: 13.045, 13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 13.148 and 13.163] that these substances cannot be evaluated through the Procedure, based on concerns with respect to genotoxicity.

On the basis of the new data on toxicity for 3-(5-methyl-2-furyl) butanal [FL-no: 13.058] an appropriate NOAEL of 5.9mg/kg bw per day was derived, supporting the evaluation of this candidate substance.

In line with the approaches taken in previous FGEs (FGE.13Rev2, FGE.65Rev1 and FGE.66Rev1), the Panel considers that 11 substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 13.058, 13.074, 13.116 and 13.190] can be evaluated using the Procedure. It was concluded

for all 11 substances, that they would be of no safety concern at their estimated intake levels based on the MSDI approach.

In order to determine whether the conclusion for the evaluated substances can be applied to the materials of commerce, it is necessary to consider the available specifications. Adequate specifications including complete purity criteria and identity are available for all 28 substances. Thus, for the 11 furane derivatives evaluated through the Procedure [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 13.058, 13.074, 13.116 and 13.190], the Panel considered that the materials of commerce would not present a safety concern at their estimated levels of intake based on the MSDI approach.

The mTAMDI could be calculated for 4 of the 11 substances that were evaluated through the Procedure. For three substances [FL-nos: 13.031, 13.047 and 13.074] the mTAMDI exceeds the threshold for the corresponding structural class and therefore more reliable exposure data are required. For seven substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.116 and 13.190], use levels are needed in order to calculate the mTAMDI and identify those flavouring substances that need more refined exposure assessment to finalise the evaluation. On the basis of such additional data these flavouring substances should be reconsidered along the steps of the Procedure. Then, additional toxicological data might become necessary.

For 17 substances [FL-nos: 13.045, 13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 13.148 and 13.163] additional toxicity / genotoxicity data are required. The Panel noted further that for 7 of these 17 substances [FL-nos: 13.045, 13.052, 13.054, 13.059, 13.061, 13.069 and 13.083], use levels have not yet been submitted.

TABLE OF CONTENTS

Abstract	1
Summary	3
Background as Provided by the European Commission	7
Terms of Reference as Provided by the European Commission	7
Supporting documents	7
Interpretation of the terms of reference	7
Assesment	8
1. History of the Evaluation of the Substances in the Present FGE.....	9
2. Presentation of the Substances in the JECFA Flavouring Group	10
2.1. Description.....	10
2.1.1. JECFA Status.....	10
2.1.2. EFSA Considerations	11
2.2. Isomers	16
2.2.1. Status	16
2.2.2. EFSA Considerations	16
2.3. Specifications.....	16
2.3.1. Status	16
2.3.2. EFSA Considerations	16
3. Intake Estimation.....	16
3.1. Status.....	16
3.2. EFSA Considerations.....	16
Summary of Specification Data	17
4. Genotoxicity Data.....	23
4.1. Genotoxicity Studies – Text taken from the JECFA (JECFA, 2009a)	23
4.2. Genotoxicity Studies – Text taken from the JECFA (JECFA, 2001)	28
4.3. Genotoxicity Studies – Text taken from EFSA FGE.13Rev2 (EFSA CEF Panel, 2011c) ...	28
4.4. EFSA Considerations.....	34
5. New Toxicity Data Evaluated by the Panel in FGE.67Rev2.....	35
5.1. A 14-Day Oral (Dietary) Toxicity Study of 3-(5-methyl-2-furyl) butanal in Rats	35
5.2. A 90-Day Oral (Dietary) Toxicity Study of 3-(5-methyl-2-furyl) butanal in Rats	36
6. Application of the Procedure.....	37
6.1. JECFA Statement on the Application of the Procedure to 40 furan-substituted substances evaluated by JECFA (JECFA, 2009a)	37
6.2. JECFA Statement on the Application of the Procedure to one furfuryl alcohol related substance [FL-no: 13.031] evaluated by the JECFA (JECFA, 2001)	38
6.3. Application of the Procedure to 27 Furfuryl and furan derivatives with and without additional side-chain substituents and heteroatoms by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c) 38	
6.4. EFSA Considerations.....	42
Conclusion.....	45
Documentation as Provided to EFSA.....	47
References	50
Appendix A. Summary of Genotoxicity and Toxicity Data.....	59
Appendix B. Overview of Evaluation Status.....	82
Appendix C. Summary of Safety Evaluations	83
Appendix D. Exposure.....	104
Abbreviations	106

Table 1:	Sub-grouping of 41 furan-substituted substances considered by JECFA at the 55 th , 65 th and 69 th meetings.....	11
Table 2:	Summary of Specification Data for Substances Evaluated by the JECFA (JECFA, 2001, 2005).....	17
Table 3:	Genotoxicity Data for 40 Furan-Substituted Substances Evaluated by the JECFA (JECFA, 2009a).....	59
Table 4:	Genotoxicity Data (<i>in vitro</i>) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c).....	63
Table 5:	Genotoxicity (<i>In Vivo</i>) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c). 73	
Table 6:	Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by JECFA (JECFA, 2001).....	76
Table 7:	Summary of Toxicity Data Evaluated by the Panel in FGE.67Rev2	81
Table 8:	Overview of Evaluation Status	82
Table 9:	Summary of Safety Evaluation of Furan derivatives evaluated by the JECFA (JECFA, 2001; JECFA, 2009a)	83
Table 10:	Summary of Safety Evaluation of 27 Furan derivatives by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c).....	89
Table 11:	Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015)	93
Table 12:	Summary of Safety Evaluation of 15 JECFA-Evaluated Furfuryl Derivatives considered in FGE.66Rev1 (EFSA CEF Panel, 2011b)	101
Table 13:	Normal and Maximum Use Levels (mg/kg) Available for JECFA Evaluated Substances in FGE.67Rev2.....	104
Table 14:	Estimated Intakes Based on the MSDI- and the mTAMDI Approach for Substances in FGE.67Rev2.....	105

BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

The use of flavourings in food is regulated under Regulation (EC) No 1334/2008 of the European Parliament and Council of 16 December 2008⁴ on flavourings and certain food ingredients with flavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and approval are required for flavouring substances.

The Union list of flavourings and source materials was established by Commission Implementing Regulation (EC) No 872/2012.⁵ The list contains flavouring substances for which the scientific evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000.⁶

On 6 July 2011, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) adopted an opinion on FGE.67, Revision 1 (FGE.67Rev1): consideration of 40 furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, sulfides, disulfides and ethers evaluated by JECFA at the 65th meeting and re-evaluated at the 69th meeting.⁷

In its opinion the Panel stated that: “No NOAEL could be identified to support the evaluation of substance [FL-no: 13.058] at step B4. Therefore for this substance no conclusion as to its safety when used as a chemically defined flavouring substance can be reached”.

As a consequence, the Panel concluded that for this substance additional toxicity data were required.

Subsequently, the substance was included in the Union List with a Footnote 4.

On 23 January 2014, the applicant submitted additional relevant data on 3-(5-methyl-2-furyl)butanal [FL-no: 13.058] from FGE.67.

3-(5-Methyl-2-furyl) butanal is a stand-alone substance.

TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

The European Commission requests the European Food Safety Authority (EFSA) to evaluate this new information and, depending on the outcome, proceed to the full evaluation of this flavouring substance in accordance with Commission Regulation (EC) N° 1565/2000.

SUPPORTING DOCUMENTS

Submission by the European Flavour Association

INTERPRETATION OF THE TERMS OF REFERENCE

The present scientific opinion FGE.67Rev2 covers the safety assessment of the following flavouring substance: 3-(5-methyl-2-furyl) butanal [FL-no: 13.058].

⁴ Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50.

⁵ Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1-161.

⁶ Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16.

⁷ FGE.67rev1; EFSA Journal 2011; 9(10):2315.

ASSESSMENT

The approach used by EFSA for safety evaluation of flavouring substances is referred to in Commission Regulation (EC) No 1565/2000 (EC, 2000), hereafter named the “EFSA Procedure”. This Procedure is based on the opinion of the Scientific Committee on Food (SCF, 1999), which has been derived from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food Additives (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999), hereafter named the “JECFA Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the Panel) compares the JECFA evaluation of structurally related substances with the result of a corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring substances are of no safety concern at their estimated levels of intake, whether additional data are required or whether certain substances should not be put through the EFSA Procedure.

The following issues are of special importance.

Intake

In its evaluation, the Panel as a default uses the “Maximised Survey-derived Daily Intake” (MSDI) approach to estimate the *per capita* intakes of the flavouring substances in Europe.

In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both European and USA production figures. The highest of the two MSDI figures is used in the evaluation by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of these figures. For Register substances for which this is the case the Panel will need EU production figures in order to finalise the evaluation.

When the Panel examined the information provided by the European Flavour Industry on the use levels in various foods, it appeared obvious that the MSDI approach in a number of cases would grossly underestimate the intake by regular consumers of products flavoured at the use level reported by the Industry, especially in those cases where the annual production values were reported to be small. In consequence, the Panel had reservations about the data on use and use levels provided and the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting considered “how to improve the identification and assessment of flavouring agents, for which the MSDI estimates may be substantially lower than the dietary exposures that would be estimated from the anticipated average use levels in foods” (JECFA, 2006b).

In the absence of more accurate information that would enable the Panel to make a more realistic estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” (mTAMDI) approach based on the normal use levels reported by Industry.

As information on use levels for the flavouring substances has not been requested by the JECFA or has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on use levels in order to finalise the evaluation.

Threshold of 1.5 µg/Person per day (Step B5) Used by the JECFA

The JECFA uses the threshold of concern of 1.5 µg/person per day as part of the evaluation procedure:

“The Committee noted that this value was based on a risk analysis of known carcinogens which involved several conservative assumptions. The use of this value was supported by additional information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the

Committee, flavouring substances for which insufficient data are available for them to be evaluated using earlier steps in the Procedure, but for which the intake would not exceed 1.5 µg per person per day would not be expected to present a safety concern. The Committee recommended that the Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended to include the last step on the right-hand side of the original procedure (“Do the condition of use result in an intake greater than 1.5 µg per day?”) (JECFA, 1999).

In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does not make use of this threshold of 1.5 µg per person per day.

Genotoxicity

As reflected in the Opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible genotoxic potential of the flavouring substances or of structurally related substances. Generally, substances for which the Panel has concluded that there is an indication of genotoxic potential *in vitro*, will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. Substances for which a genotoxic potential *in vivo* has been concluded, will not be evaluated through the Procedure.

Specifications

Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of JECFA, since the Panel requests information on e.g. isomerism.

Structural Relationship

In the consideration of the JECFA evaluated substances, the Panel will examine the structural relationship and metabolism features of the substances within the flavouring group and compare this with the corresponding FGE.

1. History of the Evaluation of the Substances in the Present FGE

The first revision of FGE.67, FGE.67Rev1 included the consideration of eight additional substances.

Seven of the eight additional substances [FL-nos: 13.054, 13.066, 13.070, 13.083, 13.101, 13.105 and 13.163] were α,β -unsaturated ketones originally allocated to FGE.19 subgroup 4.5 (FGE.221) (EFSA, 2008b). This structural characteristic is a known alert for genotoxicity, which may preclude the evaluation of substances through the Procedure. EFSA concluded in November 2008 that the α,β -unsaturated structure in conjugation with an aromatic ring system, which is present in these seven substances, is comparable to acetophenone, i.e. no longer considered a structural alert for genotoxicity (EFSA Panel, 2011). These seven substances are shown in Table 1, Subgroup VI-B.

The eighth substance, 2-benzofurancarboxaldehyde [FL-no: 13.031], was also an α,β -unsaturated aldehyde originally allocated to FGE.19 subgroup 4.3 (FGE.219) (EFSA, 2008b). Also for this substance the α,β -unsaturated structure was in conjugation with an aromatic ring system which is comparable to the situation for benzaldehyde for which no genotoxic concern is present (EFSA Panel, 2008c). Accordingly, this substance can also be evaluated using the Procedure. Although the substance originally was allocated by the JECFA to the group of furfuryl alcohol derivatives covered in FGE.66Rev1, the Panel considered that the substance belongs to the benzofurans in group V-B of the present FGE.67 (see Table 1).

Finally, the sub-grouping of two ketones [FL-nos: 13.045 and 13.138] was changed from subgroup III to subgroup VI-B, and the evaluation of these two ketones was revised due to a concern for genotoxicity.

FGE	Opinion adopted	Link	No. of substances
FGE.67	26 November 2009	http://www.efsa.europa.eu/en/scdocs/scdoc/1404.htm	25
FGE.67Rev1	06 July 2011	http://www.efsa.europa.eu/en/efsajournal/pub/2315.htm	33
FGE.67Rev2	07 May 2015	http://www.efsa.europa.eu/en/efsajournal/pub/4115.htm	28

The present revision of FGE.67 (FGE.67Rev2) is due to submission of additional information, requested in FGE.67 and FGE.67Rev1, namely a 90-day dietary toxicity study for 3-(5-methyl-2-furyl) butanal [FL-no: 13.058] (IOFI, 2013). A search in the open literature did not reveal any pertinent new information.

Furthermore, requested data on specifications have been submitted for three substances [FL-nos: 13.031, 13.045 and 13.047] (EFFA, 2014).

Finally, the industry has informed the Commission that five substances [FL-nos: 13.029, 13.030, 13.092, 13.107 and 13.191], are no longer supported for use in the EU as flavouring substances. These five substances will no longer be considered in this FGE (DG SANCO, 2012).⁸ Accordingly FGE.67Rev2 deals with 28 flavouring substances.

For three substances [FL-nos: 13.052, 13.061 and 13.123] the Panel is aware that requested information has not been submitted before the deadline as indicated in Regulation EC 872/2012. The EU Commission has communicated (DG SANTE, 2015) that these three substances are now in the process leading to deletion from the Union List. However, since these substances have not been formally withdrawn, and are still mentioned in the Union list, they are maintained in the current revision of the FGE.

2. Presentation of the Substances in the JECFA Flavouring Group

2.1. Description

The JECFA has evaluated a group of 40 diverse furan derivatives, first at their 65th meeting (JECFA, 2006a) where a request for additional data was expressed. The furan group was on the agenda again at the 69th JECFA meeting (JECFA, 2009b) where additional data had been provided.

2.1.1. JECFA Status

The JECFA expressed at its 69th meeting (JECFA, 2009a): “At its 65th meeting (JECFA, 2006a), the JECFA reviewed a group of 40 furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, sulfides, disulfides and ethers. The JECFA at that meeting took note of the extensive evidence for the genotoxicity of several members of this group of flavouring agents related to furan, including the clastogenicity of 2-furyl methyl ketone (JECFA-no: 1503) (2-acetylfuran, [FL-no: 13.054]) in mouse bone marrow. This substance accounts for 87 – 96 % of total exposure to this group of flavouring agents. Noting also that furan is carcinogenic and is known to undergo epoxidation and ring opening to form a reactive 2-ene-1,4-dicarbonyl intermediate, the JECFA at its sixty-fifth meeting expressed concern that the observed genotoxicity might be due to formation of a reactive metabolite. Few data on genotoxicity *in vivo* were available, and specific assays to address potential carcinogenicity *in vivo* were lacking. The JECFA at its sixty-fifth meeting therefore concluded that the Procedure for the Safety Evaluation of Flavouring Agents could not be applied to this group because of the above concerns. It was also concluded that studies of metabolism and *in vivo* assays for deoxyribonucleic acid (DNA) reactivity, mutagenicity and carcinogenic

⁸ Commission Implementing Regulation (EU) No 246/2014 of 13 March 2014 amending Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council as regards removal from the Union list of certain flavouring substances. Official Journal of the European Communities 14.3.2014, L 74, 58-60.

potential of members of this group with representative structures would assist in resolving the concerns (JECFA, 2006a).

Additional studies of genotoxicity *in vitro* and *in vivo* with 2-furyl methyl ketone [FL-no: 13.054] were available to the Committee (the JECFA) at its present meeting (Durward, 2007a; Durward, 2007b; Sujatha, 2007). The Committee (JECFA, 2009b) included the new studies in its re-evaluation of the group of 40 furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, sulfides, disulfides and ethers.”

“The new data on 2-furyl methyl ketone (JECFA-no: 1503) (2-acetylfuran, [FL-no: 13.054]) available to the Committee at its present meeting were a study on UDS in cultured hepatocytes *in vitro*, a study on UDS in rat liver *in vivo/in vitro* and a test for SCEs in mouse bone marrow *in vivo*. 2-Furyl methyl ketone did not induce UDS either *in vitro* or *in vivo/in vitro*. However, it did induce SCEs, confirming the concern for clastogenicity as expressed by the Committee at its previous meeting. The Committee at its present meeting therefore considered that the new data available did not resolve the concerns expressed previously”.

“The Committee concluded that the Procedure for the Safety Evaluation of Flavouring Agents could not be applied to this group because of the unresolved toxicological concerns. Studies that would assist in the safety evaluation include investigations of the influence of the nature and position of ring substitution on metabolism and on covalent binding to macromolecules. Depending on the findings, additional studies might include assays related to the mutagenic and carcinogenic potential of representative members of this group”.

At its 55th meeting (JECFA, 2001) the JECFA has evaluated the substance 2-benzofuran carboxaldehyde [FL-no: 13.031] via the Procedure for the evaluation of flavouring substances. The JECFA conclude that the substance was of no safety concern.

2.1.2. EFSA Considerations

The group of furan derivatives evaluated by the JECFA is a very diverse group of 40 flavouring substances which can be subdivided into six major subgroups with further subdivision of subgroup V and VI, as depicted in the Table 1: . The substance [FL-no: 13.031], also included in Table 1: was evaluated by the JECFA at the 55th meeting (JECFA, 2001) in the group of furfuryl derivatives evaluated by EFSA in FGE.66Rev1, but as [FL-no: 13.031] has structural similarity to [FL-no: 13.074] considered in FGE.67, it has been included in FGE.67.

The structures of these 41 substances are given in Table 1.

Table 1: Sub-grouping of 41 furan-substituted substances considered by JECFA at the 55th, 65th and 69th meetings





Sub-group	FL-no JECFA-no	EU Register name	Structural formula	Supporting substances, represented in FGEs and subgroups
I	13.116 1523	2,5-Dimethyl-3-thioacetoxyfuran		FGE.65Rev1 (Thioesters)
I	13.190 1525	3-((2-Methyl-3-furyl)thio)-2-butanone		FGE.13Rev2, Subgroup IIa (Sulphides)
I	13.191 ^(a) 1526	o-Ethyl S-(2-furylmethyl)thiocarbonate		None in FGE.13Rev2, FGE.65Rev1 or FGE.66Rev1
I	13.192 ^(b) 1524	Furfuryl 2-methyl-3-furyldisulfide		FGE.13Rev2 Subgroup IIc (Disulphides)

Table 1: Sub-grouping of 41 furan-substituted substances considered by JECFA at the 55th, 65th and 69th meetings






































Sub-group	FL-no JECFA-no	EU Register name	Structural formula	Supporting substances, represented in FGEs and subgroups
II	13.006 1517	Phenethyl 2-furoate		FGE.13Rev2 Subgroup Ia (Related to furfuryl alcohol)
III	13.021 1516	Isopentyl 4-(2-furan)butyrate		FGE.13Rev2 Subgroup Ia
III	13.022 1513	Ethyl 3(2-furyl)propionate		FGE.13Rev2 Subgroup Ia
III	13.023 1515	Isopentyl 3-(2-furan)propionate		FGE.13Rev2 Subgroup Ia
III	13.024 1514	Isobutyl 3-(2-furyl)propionate		FGE.13Rev2 Subgroup Ia
III	13.047 1518	Propyl 3-(2-furyl)acrylate		FGE.13Rev2 Subgroup Ia
III	13.058 1500	3-(5-Methyl-2-furyl) butanal		FGE.13Rev2 Subgroup Ia
IV	13.029 ^(a) 1488	2,5-Dimethylfuran		FGE.13Rev2 Subgroup Ic (Alkyl-substituted furans)
IV	13.030 ^(a) 1487	2-Methylfuran		FGE.13Rev2 Subgroup Ic
IV	13.059 1491	2-Pentylfuran		FGE.13Rev2 Subgroup Ic
IV	13.069 1492	2-Heptylfuran		FGE.13Rev2 Subgroup Ic
IV	13.092 ^(a) 1489	2-Ethylfuran		FGE.13Rev2 Subgroup Ic
IV	13.103 1490	2-Butylfuran		FGE.13Rev2 Subgroup Ic
IV	13.106 1493	2-Decylfuran		FGE.13Rev2 Subgroup Ic
IV	13.148 1494	3-Methyl-2(3-methylbut-2-enyl)furan		FGE.13Rev2 Subgroup Ic
V-A	13.052 ^(c) 1520	Furfuryl methyl ether		None in FGE.13Rev2, FGE.65Rev1 or FGE.66Rev1
V-A	13.061 ^(c) 1522	Difurfuryl ether		None in FGE.13Rev2, FGE.65Rev1 or FGE.66Rev1
V-A	13.123 ^(c) 1521	Ethyl furfuryl ether		None in FGE.13Rev2, FGE.65Rev1 or FGE.66Rev1
V-B	13.031 751	2-Benzofurancarboxaldehyde		None in FGE.13Rev2, FGE.65Rev1 or FGE.66Rev1
V-B	13.074 1495	2,3-Dimethylbenzofuran		None in FGE.13Rev2, FGE.65Rev1 or FGE.66Rev1

Table 1: Sub-grouping of 41 furan-substituted substances considered by JECFA at the 55th, 65th and 69th meetings

Sub-group	FL-no JECFA-no	EU Register name	Structural formula	Supporting substances, represented in FGEs and subgroups
V-C	13.107 ^(a) 1496	2,4-Difurfurylfuran		None in FGE.13Rev2, FGE.65Rev1 or FGE.66Rev1
VI-A	13.034 ^(d) 1497	3-(2-Furyl)acrylaldehyde		Not yet considered due to genotoxicity concern.
VI-A	13.043 ^(d) 1501	Furfurylidene-2-butanal		Not yet considered due to genotoxicity concern.
VI-A	13.044 ^(d) 1511	4-(2-Furyl)but-3-en-2-one		Not yet considered due to genotoxicity concern.
VI-A	13.046 ^(d) 1498	3-(2-Furyl)-2-methylprop-2-enal		Not yet considered due to genotoxicity concern.
VI-A	13.137 ^(d) 1502	3-(2-Furyl)-2-phenylprop-2-enal		Not yet considered due to genotoxicity concern.
VI-A	13.150 ^(d) 1499	3-(5-Methyl-2-furyl)prop-2-enal		Not yet considered due to genotoxicity concern.
VI-B	13.045 1508	1-(2-Furyl)-propan-2-one		FGE.13Rev2 Subgroup Ib (Alkoyl-substituted furans)
VI-B	13.054 1503	2-Acetylfuran		FGE.13Rev2 Subgroup Ib
VI-B	13.066 1506	3-Acetyl-2,5-dimethylfuran		FGE.13Rev2 Subgroup Ib
VI-B	13.070 1512	2-Hexanoylfuran		FGE.13Rev2 Subgroup Ib
VI-B	13.083 1504	2-Acetyl-5-methylfuran		FGE.13Rev2 Subgroup Ib
VI-B	13.101 1505	2-Acetyl-3,5-dimethylfuran		FGE.13Rev2 Subgroup Ib
VI-B	13.105 1507	2-Butyrylfuran		FGE.13Rev2 Subgroup Ib
VI-B	13.138 1510	1-(2-Furyl)butan-3-one		FGE.13Rev2 Subgroup Ib
VI-B	13.163 1509	2-Pentanoylfuran		FGE.13Rev2 Subgroup Ib
VI-C	13.176 1519	Furaneyl butyrate		None in FGE.13Rev2, FGE.65Rev1 or FGE.66Rev1; Supporting substances in FGE.99.

(a): Substances no longer supported by the Industry for use as flavouring substances in the EU.

(b): [FL-no: 13.192] is a synonym of substance [FL-no: 13.178] which has already been evaluated in FGE.13Rev2.

(c): The Panel is aware that requested information for subgroup V-A has not been submitted before the deadline as indicated in Regulation EC 872/2012. The EU Commission has communicated that substances [FL-nos: 13.052, 13.061 and 13.123] are now in the process leading to deletion from the Union List (DG SANTE, 2015).

(d): Currently under evaluation for genotoxicity concern in FGE.222.

Group I

This subgroup comprises four substances. These substances [FL-nos: 13.116, 13.190, 13.191 and 13.192] are structurally related to 14 sulphur-substituted furan derivatives evaluated by EFSA in FGE.13Rev2 (see Appendix C, Table 1:) and 33 sulphur-substituted furan derivatives considered by EFSA in FGE.65Rev1 (see Appendix C). Substance [FL-no: 13.192] appeared to be a synonym of substance [FL-no: 13.178] which has already been evaluated in FGE.13Rev2. Substance [FL-no: 13.191] is no longer supported by Industry (DG SANCO, 2012). These two substances [FL-nos: 13.191 and 13.192] will not be further considered in this FGE. Consequently, from this subgroup only two candidate substances [FL-nos: 13.116, 13.190] will be considered in this FGE.

Group II

This subgroup comprises one substance [FL-no: 13.006] to be considered in this FGE, which is structurally related to five furoic acid esters considered by EFSA in FGE.66Rev1 (see Appendix C, Table 12).

Group III

This subgroup comprises six substances [FL-nos: 13.021, 13.022, 13.023, 13.024, 13.047 and 13.058] structurally related to a group of furfuryl and furoic acid substances evaluated by EFSA in FGE.13Rev2 in subgroup Ia. All six substances will be considered in this FGE.

Group IV

This subgroup comprises eight substances [FL-nos: 13.029, 13.030, 13.059, 13.069, 13.092, 13.103, 13.106 and 13.148]. All are alkyl-substituted furans and structurally related to two substances evaluated by EFSA in FGE.13Rev2 in subgroup Ic. In FGE.13Rev2 a concern for genotoxicity has been identified for these two structurally related substances. However, three of the substances in this subgroup are no longer supported by Industry [FL-nos: 13.029, 13.030 and 13.092].⁹ Consequently, only five substances [FL-nos: 13.059, 13.069, 13.103, 13.106 and 13.148] will be considered in this FGE.

Group V

The six substances in this group are not structurally related to any flavouring group evaluated or considered by EFSA. The six substances have been allocated to three subgroups (see below). Only five of these six substances (in subgroups V-A and V-B) will be considered in this FGE.

Subgroup V-A¹⁰

The three substances [FL-nos: 13.052, 13.061 and 13.123]: are furfuryl ethers. These three substances will be further considered in this FGE.

Subgroup V-B

The two substances [FL-nos: 13.031 and 13.074]: are benzofuran derivatives. Since substance [FL-no: 13.031] is an α,β -unsaturated carbonyl, it has been included in FGE.19 subgroup 4.3

⁹ Commission Implementing Regulation (EU) No 246/2014 of 13 March 2014 amending Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council as regards removal from the Union list of certain flavouring substances. Official Journal of the European Communities 14.3.2014, L 74, 58-60.

¹⁰ The Panel is aware that requested information for subgroup V-A has not been submitted before the deadline as indicated in Regulation EC 872/2012. The EU Commission has communicated that substances [FL-no: 13.052, 13.061 and 13.123] are now in the process leading to deletion from the Union List.

(EFSA, 2008b) and thereafter concluded to be of no concern with respect to genotoxicity based on structural considerations (EFSA Panel, 2008c, 2014). These two substances will be further considered in this FGE.

Subgroup V-C

The substance previously allocated to this subgroup [FL no: 13.107] is no longer supported for use as flavouring substance in Europe. Therefore, this substance will not be considered in this FGE (DG SANCO, 2012).

Group VI

This subgroup consists of 16 α,β -unsaturated carbonyls. These structures bear a structural alert for genotoxicity (EFSA, 2008b) and substances containing this structural characteristic have already been evaluated with respect to their genotoxic properties by EFSA in FGE.19 context (Subgroups 4.4b, 4.5 and 4.6 (EFSA, 2008b)). The substances in this group have been allocated to three subgroups (see below). Only the nine substances from subgroup VI-B will be further considered in this FGE.

Subgroup VI-A

For six substances (from FGE.19, subgroup 4.6, (EFSA, 2008b)) [FL-nos: 13.034, 13.043, 13.044, 13.046, 13.137 and 13.150] a need for additional information on genotoxicity was identified in FGE.222 (EFSA, 2012a). These six substances will not be considered in this revision of the FGE.

Subgroup VI-B

This subgroup comprises nine substances. For seven substances in this subgroup (from FGE.19, subgroup 4.5, (EFSA, 2008b)) [FL-nos: 13.054, 13.066, 13.070, 13.083, 13.101, 13.105 and 13.163] a need for additional information on genotoxicity was identified (EFSA, 2008b). After further considerations in the Panel it was concluded that these substances are comparable to acetophenone (EFSA, 2008a), an aromatic α,β -unsaturated ketone, which is not genotoxic. Therefore the α,β -unsaturated ketone moiety in these seven furan derivatives is no longer considered to represent an alert for genotoxicity (EFSA Panel, 2008c); (see also FGE.13Rev2). However, based on other considerations with respect to metabolism and possible genotoxic properties of substance [FL-no: 13.054] for all substances in this subgroup additional data on genotoxicity were still requested in FGE.67rev1. Based on these additional considerations, for the remaining two substances in this subgroup [FL-nos: 13.045 and 13.138] a concern for genotoxicity has also been identified (see FGE.67rev1). These nine substances will be further considered in this FGE.

Subgroup VI-C

One substance (from FGE.19, subgroup 4.4b, (EFSA, 2008b)) [FL-no: 13.176] for which a need for additional information on genotoxicity was identified (EFSA, 2009). After further evaluation of additional data submitted by the Industry, [FL-no: 13.176] has been cleared for genotoxicity in FGE.220Rev1 (EFSA CEF Panel, 2011a). Because this substance has closely related structural analogues in FGE.99, and no structural analogues in FGE.67, this substance will not be further considered in FGE.67, but has been evaluated in FGE.99.

Conclusion on subgroups

Of the 40 substances in the JECFA group of furan derivatives (JECFA, 2006a) the following will not be dealt with in the present revision of FGE.67: six substances from subgroup VI-A (corresponding to FGE.19 subgroup 4.6) for which there is still a genotoxicity concern; one substance from subgroup

VI-C [FL-no: 13.176] which has been transferred to FGE.99 for further consideration based on structural similarities; one substance from subgroup I [FL-no: 13.192] which is a duplicate of the substance [FL-no: 13.178] already evaluated in FGE.13Rev2. The Flavour Industry no longer supports the use as flavouring substances for: one substance in subgroup I [FL-no: 13.191], three substances in subgroup IV [FL-nos: 13.029, 13.030 and 13.092] and the one substance in subgroup V-C [FL-no: 13.107]. In conclusion, in the present FGE.67Rev2, 28 substances will be considered. These comprise 27 of the 40 substances in the JECFA group of furan derivatives and one additional benzofuran also evaluated by the JECFA in the group of furfuryl derivatives (JECFA, 2001)

2.2. Isomers

2.2.1. Status

Two substances [FL-nos: 13.058 and 13.190] in the group of JECFA evaluated furan-substituted substances have a chiral centre and [FL-no: 13.047] has geometrical isomerism.

2.2.2. EFSA Considerations

Information on stereoisomerism is adequate for all substances.

2.3. Specifications

2.3.1. Status

The JECFA specifications are available for all 28 substances (JECFA, 2005). See Table 2.

2.3.2. EFSA Considerations

The available specifications are considered adequate for all 28 JECFA-evaluated substances (see Table 2).

3. Intake Estimation

3.1. Status

For 26 JECFA evaluated substances production volumes are available for the EU and accordingly for these 26 substances, MSDI figures for the EU can be calculated, see Appendix D, Table 9.

3.2. EFSA Considerations

Tonnage data for use as a flavouring substance in Europe are missing for two [FL-no: 13.066 and 13.070] flavouring substances considered in this FGE.

For 14 substances [FL-nos: 13.031, 13.047, 13.058, 13.066, 13.070, 13.074, 13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 13.148 and 13.163], the Industry has submitted normal and maximum use levels (EFFA, 2005) (see Appendix D, Table 13:). Based on the normal use levels, mTAMDI values can be calculated (see Appendix D, Table 14:). For 12 substances [FL-nos: 13.031, 13.047, 13.066, 13.074, 13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 13.148 and 13.163], the mTAMDI values are above the threshold of concern for their respective structural class (90 and 540 µg/person per day for structural class III and II, respectively).

For the remaining 14 substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.045, 13.052, 13.054, 13.059, 13.061, 13.069, 13.083, 13.116 and 13.190] normal and maximum use levels are needed to calculate the mTAMDI. Only seven of these substances [FL-nos: 13.190, 13.006, 13.021, 13.022, 13.023, 13.024, 13.116 and 13.190] have been evaluated using the Procedure in the present FGE.

SUMMARY OF SPECIFICATION DATA

Table 2: Summary of Specification Data for Substances Evaluated by the JECFA (JECFA, 2001, 2005)








FL-no JECFA-no	EU Register name	Structural formula	FEMA no CoE no CAS no	Phys.form Mol.formula Mol.weight	Solubility ^(a) Solubility in ethanol ^(b)	Boiling point, °C ^(c) Melting point, °C ID test Assay minimum	Refrac. Index ^(d) Spec.gravity ^(e)	EFSA comments
13.006 1517	Phenethyl 2-furoate		2865 362 7149-32-8	Liquid C ₁₃ H ₁₂ O ₃ 216.24	Insoluble Soluble	275 NMR 96 %	1.585-1.593 1.136-1.142	
13.021 1516	Isopentyl 4-(2-furan)butyrate		2070 2080 7779-66-0	Liquid C ₁₃ H ₂₀ O ₃ 224.30	Insoluble Insoluble	263-265 NMR 95 %	1.551-1.555 0.975-0.981	
13.022 1513	Ethyl 3-(2-furyl)propionate		2435 2091 10031-90-0	Solid C ₉ H ₁₂ O ₃ 168.19	Very slightly soluble Soluble	n.a. 24-25 NMR 95 %	n.a. n.a.	Register name to be changed to: Ethyl 3-(2-furyl)propionate.
13.023 1515	Isopentyl 3-(2-furan)propionate		2071 2092 7779-67-1	Liquid C ₁₂ H ₁₈ O ₃ 210.27	Insoluble Soluble	258 NMR 96 %	1.549-1.557 0.987-0.993	
13.024 1514	Isobutyl 3-(2-furyl)propionate		2198 2093 105-01-1	Liquid C ₁₁ H ₁₆ O ₃ 196.25	Very slightly soluble Soluble	105 (4 hPa) NMR 96 %	1.531-1.537 1.007-1.013	
13.029 1488	2,5-Dimethylfuran		2208 625-86-5	Liquid C ₆ H ₈ O 96.13	Slightly soluble Soluble	93 IR NMR MS 95 %	1.437-1.443 0.892-0.898	No longer supported by industry.
13.030 1487	2-Methylfuran		4179 2209 534-22-5	Liquid C ₅ H ₆ O 82.10	Slightly soluble Soluble	64 IR NMR MS 97 %	1.431-1.437 0.908-0.917	No longer supported by industry.

Table 2: Summary of Specification Data for Substances Evaluated by the JECFA (JECFA, 2001, 2005)








FL-no JECFA-no	EU Register name	Structural formula	FEMA no CoE no CAS no	Phys.form Mol.formula Mol.weight	Solubility ^(a) Solubility in ethanol ^(b)	Boiling point, °C ^(c) Melting point, °C ID test Assay minimum	Refrac. Index ^(d) Spec.gravity ^(e)	EFSA comments
13.031 751	2-Benzofuran- carboxaldehyde		3128 2247 4265-16-1	Solid C ₉ H ₆ O ₂ 146.15	Insoluble Slightly soluble	130-131 (17hPa) 195-198 (cryst) MS 96 %	n.a. n.a.	
13.045 1508	1-(2-Furyl)- propan-2-one		2496 11837 6975-60-6	Liquid C ₇ H ₈ O ₂ 124.14	Very slightly soluble (EFFA, 2014) Soluble	179-180 NMR 97 %	1.499-1.505 1.074-1.080	
13.047 1518	Propyl 3-(2- furyl)acrylate		2945 11842 623-22-3	Liquid C ₁₀ H ₁₂ O ₃ 180.20	Insoluble Soluble	119 (9 hPa) NMR 97 %	1.520-1.526 1.071-1.077 (20°)	Mixture of isomers: 50-80 % E and 20 - 50 % Z (EFFA, 2014)
13.052 1520	Furfuryl methyl ether		3159 10944 13679-46-4	Liquid C ₆ H ₈ O ₂ 112.13	Insoluble Soluble	134-135 NMR 99 %	1.454-1.460 1.013-1.019	
13.054 1503	2-Acetylfuran		3163 11653 1192-62-7	Liquid C ₆ H ₆ O ₂ 110.11	Very slightly soluble Soluble	67 (13 hPa) IR 97 %	1.505-1.510 1.102-1.107	
13.058 1500	3-(5-Methyl-2- furyl) butanal		3307 10355 31704-80-0	Liquid C ₉ H ₁₂ O ₂ 152.19	Insoluble Soluble	88-91 (16 hPa) NMR 98 %	1.575-1.581 1.006-1.012	Racemate.
13.059 1491	2-Pentylfuran		3317 10966 3777-69-3	Liquid C ₉ H ₁₄ O 138.21	Slightly soluble Soluble	58-60 (13 hPa) NMR 99 %	1.443-1.449 0.886-0.893	

Table 2: Summary of Specification Data for Substances Evaluated by the JECFA (JECFA, 2001, 2005)








FL-no JECFA-no	EU Register name	Structural formula	FEMA no CoE no CAS no	Phys.form Mol.formula Mol.weight	Solubility ^(a) Solubility in ethanol ^(b)	Boiling point, °C ^(c) Melting point, °C ID test Assay minimum	Refrac. Index ^(d) Spec.gravity ^(e)	EFSA comments
13.061 1522	Difurfuryl ether		3337 10930 4437-22-3	Liquid C ₁₀ H ₁₀ O ₃ 178.19	Insoluble Soluble	88-89 (1 hPa) NMR 97 %	1.138-1.144 1.506-1.512	
13.066 1506	3-Acetyl-2,5-dimethylfuran		3391 10921 10599-70-9	Liquid C ₈ H ₁₀ O ₂ 138.17	Slightly soluble Soluble	83 (14 hPa) NMR 99 %	1.484-1.492 1.027-1.048	
13.069 1492	2-Heptylfuran		3401 10952 3777-71-7	Liquid C ₁₁ H ₁₈ O 166.26	Insoluble Soluble	209-210 NMR 99 %	1.446-1.452 0.860-0.866	
13.070 1512	2-Hexanoylfuran		3418 11180 14360-50-0	Liquid C ₁₀ H ₁₄ O ₂ 166.22	Slightly soluble Soluble	65-67 (0.7 hPa) NMR 99 %	1.490-1.496 0.992-0.998	
13.074 1495	2,3-Dimethylbenzofuran		3535 11913 3782-00-1	Liquid C ₁₀ H ₁₀ O 146.19	Insoluble Soluble	96-98 (20 hPa) NMR 97 %	1.554-1.563 1.031-1.037	
13.083 1504	2-Acetyl-5-methylfuran		3609 11038 1193-79-9	Liquid C ₇ H ₈ O ₂ 124.14	Slightly soluble Soluble	71-72 (10 hPa) IR NMR 99 %	1.511-1.517 1.066-1.072 (20°)	
13.092 1489	2-Ethylfuran		3673 11706 3208-16-0	Liquid C ₆ H ₈ O 96.13	Insoluble Soluble	92-93 NMR 95 %	1.444-1.450 0.909-0.915	No longer supported by industry.

Table 2: Summary of Specification Data for Substances Evaluated by the JECFA (JECFA, 2001, 2005)













FL-no JECFA-no	EU Register name	Structural formula	FEMA no CoE no CAS no	Phys.form Mol.formula Mol.weight	Solubility ^(a) Solubility in ethanol ^(b)	Boiling point, °C ^(c) Melting point, °C ID test Assay minimum	Refrac. Index ^(d) Spec.gravity ^(e)	EFSA comments
13.101 1505	2-Acetyl-3,5-dimethylfuran		4071 22940-86-9	Liquid C ₈ H ₁₀ O ₂ 138.17	Insoluble Soluble	195 18 MS 95 %	1.494-1.500 1.041-1.047	
13.103 1490	2-Butylfuran		4081 10927 4466-24-4	Liquid C ₈ H ₁₂ O 124.18	Insoluble Soluble	139 MS 95 %	1.444-1.450 0.884-0.890	
13.105 1507	2-Butyrylfuran		4083 11045 4208-57-5	Liquid C ₈ H ₁₀ O ₂ 138.17	Insoluble Soluble	195 NMR MS 95 %	1.489-1.495 1.050-1.056	
13.106 1493	2-Decylfuran		4090 83469-85-6	Solid C ₁₄ H ₂₄ O 208.34	Insoluble Soluble	30 NMR 95 %	n.a. n.a.	
13.107 1496	2,4-Difurfurylfuran		4095 64280-32-6	Solid C ₁₄ H ₁₂ O ₃ 228.24	Insoluble Soluble	153 NMR 95 %	n.a. n.a.	No longer supported by industry.
13.116 1523	2,5-Dimethyl-3-thioacetoxyfuran		4034 55764-22-2	Liquid C ₈ H ₁₀ O ₂ S 170.23	Practically insoluble Soluble	230 IR NMR MS 98 %	1.527-1.533 1.137-1.143	
13.123 1521	Ethyl furfuryl ether		4114 10940 6270-56-0	Liquid C ₇ H ₁₀ O ₂ 126.15	Slightly soluble Soluble	150 MS 95 %	1.449-1.455 0.982-0.988	

Table 2: Summary of Specification Data for Substances Evaluated by the JECFA (JECFA, 2001, 2005)

FL-no JECFA-no	EU Register name	Structural formula	FEMA no CoE no CAS no	Phys.form Mol.formula Mol.weight	Solubility ^(a) Solubility in ethanol ^(b)	Boiling point, °C ^(c) Melting point, °C ID test Assay minimum	Refrac. Index ^(d) Spec.gravity ^(e)	EFSA comments
13.138 1510	1-(2-Furyl)butan-3-one		4120 11084 699-17-2	Solid C ₈ H ₁₀ O ₂ 138.17	Slightly soluble Soluble	n.a. 37 MS 95 %	n.a. n.a.	
13.148 1494	3-Methyl-2(3-methylbut-2-enyl)furan		4174 15186-51-3	Liquid C ₁₀ H ₁₄ O 150.22	Slightly soluble Soluble	70 (15 hPa) MS 98 %	1.473-1.479 0.998-1.004	Register name to be changed to: 3-Methyl-2-(3-methylbut-2-enyl)furan.
13.163 1509	2-Pentanoylfuran		4192 3194-17-0	Liquid C ₉ H ₁₂ O ₂ 152.19	Slightly soluble Soluble	101 (13 hPa) MS 95 %	1.486-1.492 1.009-1.015	
13.190 1525	3-((2-Methyl-3-furyl)thio)-2-butanone		4056 61296-44-1	Liquid C ₉ H ₁₂ O ₂ S 184.25	Practically insoluble Soluble	70 (1 hPa) IR NMR MS 99 %	1.510-1.516 1.104-1.110	CASrn in Register is not valid; CASrn to be changed to: 61295-44-1 (The Good Scents Company, 2011). Register name to be changed to 3-((2-Methyl-3-furyl)thio)-2-butanone. Racemate.
13.191 1526	o-Ethyl S-(2-furylmethyl)thiocarbonate		4043 376595-42-5	Liquid C ₈ H ₁₀ O ₃ S 186.23	Practically insoluble Soluble	130-135 IR NMR MS 99 %	1.504-1.510 1.167-1.173	No longer supported by industry.

(a): Solubility in water, if not otherwise stated.

(b): Solubility in 95 % ethanol, if not otherwise stated.

(c): At 1013.25 hPa, if not otherwise stated.

- (d): At 20°C, if not otherwise stated.
(e): At 25°C, if not otherwise stated.

4. Genotoxicity Data

4.1. Genotoxicity Studies – Text taken¹¹ from the JECFA (JECFA, 2009a)

Genotoxicity testing has been performed on eight [FL-nos: 13.022, (former 13.029), (former 13.030), 13.034, 13.044, 13.054, 13.148 and (former 13.191)] representative furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, sulphides, disulphides and ethers in this group (JECFA, 2009a). The results of these tests are summarised in Appendix A, Table 3: of this FGE and described below.

In vitro

“In standard *Salmonella* mutagenicity assays, 2,5-dimethylfuran [former FL-no: 13.029], 3-methyl-2-(3-methylbut-2-enyl)-furan [FL-no: 13.148], 3-(2-furyl)acrolein [FL-no: 13.034], 4-(2-furyl)-3-buten-2-one [FL-no: 13.044], ethyl 3-(2-furyl)propanoate [FL-no: 13.022] and O-ethyl S-(2-furylmethyl)thiocarbonate [former FL-no: 13.191] were not mutagenic in *Salmonella typhimurium* strains TA97, TA98, TA100, TA102, TA1535, TA1537 or TA1538 when tested at concentrations of up to 10000 µg/plate, alone or in the presence of an exogenous rat liver metabolic activation system (S9-mix) (Wild et al., 1983; Mortelmans et al., 1986; Shinohara et al., 1986; Asquith, 1989; Eder et al., 1991a; Zeiger et al., 1992; Lee et al., 1994; Verspeek-Rip, 2000). Likewise, with the exception of a single assay in which equivocal results of mutagenicity were reported in *S. typhimurium* strains TA97 and TA107 (Zeiger et al., 1992)-methylfuran [former FL-no: 13.030] was consistently negative in several other strains of *S. typhimurium* (i.e. TA98, TA100, TA102 and TA1535) both alone and with an exogenous rat liver bioactivation system (S9-mix) (Shinohara et al., 1986; Aeschbacher et al., 1989). Evaluated alone and with an exogenous bioactivation system in *S. typhimurium* at concentrations of up to 0.660 µmol/plate (54.2 µg/plate), 2-furyl methyl ketone [FL-no: 13.054] exhibited a significant positive mutagenic potential only in strain TA98 with bioactivation at the two lower concentrations (i.e. 0.165 and 0.330 µmol/plate) (Shinohara et al., 1986). At higher concentrations, significant cytotoxicity was observed, which was reflected by a concentration-dependent decrease in the number of revertants.

Bacterial mutagenicity testing of furans that can be metabolically oxidized to reactive α,β -unsaturated dicarbonyl (2-ene-1,4-dicarbonyl) intermediates is problematic owing to their high bacterial toxicity. The cytotoxicity of these substances is believed to arise from their interactions with protein sulfhydryl and amino groups (Marnett et al., 1985; Eder et al., 1992). Owing to the nature of the glutathione (GSH) conjugation pathway, genotoxicity studies in which high concentrations of α,β -unsaturated carbonyl compounds are formed are likely to create oxidative stress. It is anticipated that cells exposed to high concentrations of these types of substances will rapidly deplete GSH levels, eventually leading to cellular damage and decreased cell viability, as indicated by the above study results.

O-Ethyl S-(2-furylmethyl)thiocarbonate [former FL-no: 13.191] showed no mutagenic potential when tested in *Escherichia coli* WP2uvrA at concentrations of up to 3330 µg/plate, either alone or with a bioactivation system (Verspeek-Rip, 2000). Evaluated in *E. coli* PQ37 under the conditions of the SOS chromotest, 3-(2-furyl)-acrolein [FL-no: 13.034] tested negative (Eder et al., 1991); however, in a subsequent evaluation, 3-(2-furyl)acrolein [FL-no: 13.034] as well as 2-furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] were slightly positive in the SOS chromotest without metabolic activation, as evidenced by 1.72- and 1.75-fold increases, respectively, in the SOS induction factor over a background value of 1 (results were considered to be significant if the induction factor was at least 1.5) (Eder et al., 1993).

In the rec assay, which is based on differential inhibition of growth of repair-deficient strains as a measure of DNA-damaging activity, *Bacillus subtilis* strains H17 (rec+) and M45 (rec-) were

¹¹ The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed.

incubated with 2-methylfuran [former FL-no: 13.030], 2,5-dimethylfuran [former FL-no: 13.029] and 2-furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] at concentrations of up to 55000 µg/disc, alone and with metabolic activation (Shinohara et al., 1986). 2-Furyl methyl ketone tested negative at a concentration of 550 µg/disc, but was reportedly positive at concentrations of 5500 µg/disc and greater alone and with metabolic activation. Likewise, 2,5-dimethylfuran was negative at the lowest concentration tested (i.e. 190 µg/disc) with metabolic activation, but tested positive at every concentration tested in the absence of metabolic activation. In contrast, 2-methylfuran was negative with metabolic activation and induced significant differences in the zones of inhibition only without metabolic activation. Additionally, 2-methylfuran and 2-furyl methyl ketone were reported to cleave the double strand of *lambda*-phage DNA in the presence of Cu²⁺; however, a negative control was not included, and, therefore, the statistical significance of these results was not ascertained. Also, it should be noted that potential concomitant cytotoxicity was not monitored in this study.

The potential mammalian cell clastogenicities of 2-methylfuran [former FL-no: 13.030], 2,5-dimethylfuran [former FL-no: 13.029] and 2-furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] were evaluated in Chinese hamster ovary (CHO) cells, in which induction of chromosomal aberrations was measured. Cells were exposed to substances from commercial sources (purity not given) for 3 hours, followed by 20 hours of maintenance. In the absence of exogenous metabolic activation, all three compounds produced increases in the number of chromosomal aberrations, mainly chromatid exchanges; however, in the presence of rat liver metabolic activation, only the clastogenicity of 2-furyl methyl ketone was increased, whereas the clastogenic activities of 2-methylfuran and 2,5-dimethylfuran were reduced in comparison with test systems without metabolic activation. Additionally, the authors noted that when NADP was eliminated from the activation system, the reduction in the chromosomal aberrations observed for 2-methylfuran and 2,5-dimethylfuran and the increase in the clastogenic activity observed with 2-furyl methyl ketone in the presence of the activation system were abolished. This suggests that mixed-function oxidases are integral in the metabolism of alkyl furan derivatives. It should be noted that the experiment with 2-furyl methyl ketone was performed at a limited number of concentrations (two), the active one of which far exceeded (112.6 mmol/l = 13220 µg/ml) standard concentration limits for this assay and was toxic (Stich et al., 1981b).

Beginning in the late 1980s, researchers began studying test conditions (osmolality, ionic strength, low pH) that could cause an increase in clastogenic activity (increased chromosomal aberrations and micronuclei) in the absence of any chemical-induced effect on DNA (Zajac-Kaye and Ts'o, 1984; Brusick, 1986; Bradley et al., 1987; Galloway et al., 1987; Seeberg et al., 1988; Morita et al., 1989; Scott et al., 1991). More recent research indicates that extreme culture conditions (hypo- and hyperosmolality and high pH) induce apoptosis and necrosis, leading to DNA fragmentation and producing false-positive responses in clastogenic assays (Meintieres and Marzin, 2004).

Apoptosis is a type of cell death that occurs under physiological conditions or in response to external stimuli (e.g. DNA-damaging agents, growth factor deprivation or receptor triggering). The mechanism of formation of apoptotic cells includes activation of cysteine proteases (caspases), leading to increased mitochondrial permeability, release of cytochrome c, DNA cleavage and redistribution of phosphatidylserine to the outer layers of the cell membrane, which enhances binding of cells to phagocytes. DNA cleavage, owing to irreversible activation of endonucleases, is followed by chromatin condensation and oligonucleosomal fragmentation due to double-strand cleavage of DNA in nucleosomal linker regions (Saraste and Pulkki, 2000). During chromatin condensation, the nucleus may split into a number of dense micronuclei. Fragmented DNA and chromatin condensation due to apoptotic events are not easily distinguished from direct action of a specific chemical.

In consideration of such knowledge, findings of chromosomal aberrations must be evaluated in the context of the potential for apoptosis to occur under test conditions. Relatively high concentrations (i.e. up to 1923 – 13220 µg/ml or 20 – 150 mmol/l) were used in the study conducted by Stich et al. (Stich et al., 1981b). The Km for most enzyme kinetic processes is at or below 100 µmol/l (Bu, 2006; Wang and James, 2006), and thus the high concentrations used in this study may not be relevant to the

human condition, especially with respect to the low levels of flavouring agents added to food. Furthermore, no information was available on culture conditions that may have promoted apoptosis. Results of chromosomal aberration and micronuclei assays are problematic to interpret in the absence of such information.

2-Furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] was evaluated for induction of unscheduled DNA synthesis (UDS) in human hepatocytes following Organization for Economic Cooperation and Development (OECD) guidelines. Human (sex not given) hepatocytes from two batches purchased from a commercial provider were incubated with concentrations of compound (purity not given) of between 2.19 and 280 µg/ml for 16 hours, and UDS was measured autoradiographically. No UDS was elicited, in contrast to the positive control, 2-acetylaminofluorene (Durward, 2007a).

In a study examining the effect of oxygen scavengers on cadmium chloride-induced chromosomal aberrations in Chinese hamster V79 cells, 2,5-dimethylfuran [former FL-no: 13.029] at 96.13 µg/ml (1 mmol/l) did not increase the frequency of chromosomal aberrations in comparison with control values. When 2,5-dimethylfuran at 96.13 µg/ml (1 mmol/l) was incubated with the V79 cells in the presence of cadmium chloride, no reduction in the clastogenic capacity of cadmium chloride was observed (Ochi and Ohsawa, 1985).

O-Ethyl-S-(2-furylmethyl)thiocarbonate [former FL-no: 13.191] was evaluated for potential clastogenicity in a series of tests in human peripheral lymphocytes. Doses at which chromosomal aberrations were evaluated were based on a preliminary evaluation of effects on the mitotic index in the cells. Generally, O-ethyl-S-(2-furylmethyl)thiocarbonate exhibited marked mitogenicity and cytotoxicity, and accordingly only a relatively narrow range of concentrations was used. In the first set of tests in which an exposure time of 3 hours was utilized, the substance did not induce an increase at concentrations ranging between 150 and 350 µg/ml alone or in the presence of a bioactivation system; however, in another test employing a 3-hour exposure period with metabolic activation, significant and dose-dependent increases in the number of chromosomal aberrations were observed at concentrations of 325 and 375 µg/ml, but not at 150 µg/ml. Moreover, following a 24- or 48-hour exposure period, O-ethyl-S-(2-furylmethyl)thiocarbonate (up to 280 µg/ml) also induced dose-dependent and statistically significant increases in the number of chromosomal aberrations in the absence of metabolic activation in comparison with a negative control (Meerts, 2000).

In vivo

As reported in an abstract, 2-methylfuran [former FL-no: 13.030] (purity not given) did not induce chromosomal aberrations in bone marrow cells or spermatocytes of Swiss albino mice evaluated at 24-hour intervals following administration in the diet at concentrations of 1000, 2000 or 4000 mg/kg (approximately 100, 200 and 400 mg/kg body weight (bw) per day, respectively) for a period of 5 days. No positive control was included. Moreover, the authors noted that 2-methylfuran did not inhibit spindle protein synthesis or cell division in the somatic cells. In the germ cells, which were evaluated at weekly intervals for a period of 5 weeks following final dosing, in order to cover one full spermatogenesis cycle, no structural sperm-head abnormalities were reported (Subramanyam et al., 1989).

2-Furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] was evaluated for clastogenic activity in bone marrow and germ cells of Swiss albino mice. Groups of two per dose per sampling time were administered the compound (99 % pure) orally at 0 (control), 1000, 2000 or 3000 mg/l in 0.5 ml of water (approximately 0, 20, 40 and 60 mg/kg bw, respectively) either as a single dose or once daily for 5 consecutive days. No positive control was included. Bone marrow cells were collected periodically for up to 72 hours following dosing, and meiotic and sperm preparations from testes and epididymis, respectively, were assessed at 24 hours and weekly for a total of 5 weeks post-dosing. In bone marrow cells, the substance at the high dose level was observed to inhibit mitosis beginning at 18 hours following single- or multiple-dose treatment. At 24 hours, mitodepression was also observed at the high dose level in the single-dose experiment, as well as at the middle and high dose levels in mice

administered multiple doses. In the repeat-dose test protocol, the effect remained significant for up to 36 hours post-treatment. Mitodepression was accompanied by increases in the frequency of structural chromosomal aberrations, mainly gaps and breaks, in the bone marrow cells. Specifically, at the high dose level (i.e. 3000 mg/l), between 18 and 24 hours following single-dose administration and 12 and 48 hours following final treatment of multiple-dose groups, the frequency of aberrations was elevated. Additionally, in animals receiving multiple doses of 2-furyl methyl ketone, significant increases in the number of chromosomal aberrations were also observed at the middle dose level (i.e. 2000 mg/l) between 24 and 36 hours post-treatment. In contrast to the dose- and time-dependent increase in chromosomal aberrations in the somatic cells, only a single isolated increase in structural chromosomal aberrations was observed in mouse spermatocytes 3 weeks following single-dose administrations of the substance, and only at the highest dose level. Following multiple-dose administration, abnormalities in germ cells were limited to significant increases in polyploidy and XY univalents occurring at weeks 3 and 4 at the highest dose level. Furthermore, no sperm-head abnormalities were observed at any dose level, irrespective of the treatment protocol. The absence of sperm-head abnormalities at all dose levels was indicative of a lack of sperm toxicity of the substance. The authors concluded that 2-furyl methyl ketone exhibits only mild clastogenic activity in mouse bone marrow and is not clastogenic in germ cells (Sujatha et al., 1993).

2-Furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] was evaluated for induction of sister chromatid exchanges (SCE) in bone marrow of female Swiss albino mice. Groups of two per dose per exposure regimen were administered compound (99 % pure) at 0, 1000, 2000 or 3000 mg/l via gavage either once or for 5 consecutive days. 5-Bromodeoxyuridine was injected intraperitoneally to label chromatids. The mice were sacrificed at 12, 24 or 48 hours after receiving the last dose, and slides of bone marrow were prepared and processed for differential staining. A dose-related increase up to about 2-fold in SCE was observed for the 12- and 24-hours groups of both the single-dose regimen and the multiple-dose regimen (Sujatha, 2007).

2-Furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] was evaluated for induction of UDS in hepatocytes isolated from livers of dosed male Sprague-Dawley rats. The assay was conducted according to Good Laboratory Practices (GLP) and OECD guidelines. In a preliminary range-finding toxicity study, lethality was observed at 30 mg/kg bw and greater, and signs of toxicity were observed at 20 mg/kg bw. No sex differences were observed, and therefore only males were used in the main study. Groups of four rats were administered compound (purity not given) at 0, 7 or 21 mg/kg bw via gavage. In experiment 1, the hepatocytes were isolated 16 hours post-dosing; in experiment 2, hepatocytes were isolated 2 hours post-dosing and cultured for autoradiographic measurement of UDS. No UDS was observed in either experiment, in contrast to the positive controls 2-acetylaminofluorene and N,N'-dimethylhydrazine (Durward, 2007b).

O-Ethyl S-(2-furylmethyl)thiocarbonate [former FL-no: 13.191] was evaluated for induction of micronuclei in bone marrow erythrocytes of NMRI BR mice. Groups of five per sex per dose per sampling time were administered single doses of compound (99 % pure) at 0 (vehicle control), 100, 250 or 500 mg/kg bw in corn oil via gavage. Dosed animals at every dose level and controls were killed at 24 hours post-dosing. Additionally, a second group of high-dose mice (i.e. 500 mg/kg bw) and the positive control (cyclophosphamide) group were terminated at 48 hours post-dosing. Bone marrow smears were prepared from the femurs. No increase in the incidence of micronucleated polychromatic erythrocytes (PCE) was observed in dosed mice compared with controls, in contrast to the positive control, which induced a 20-fold increase. However, the authors also noted that cells obtained from dosed animals did not exhibit a reduction in the ratio of polychromatic to normochromatic erythrocytes (NCE), indicating an absence of toxicity, which could be due to lack of adequate exposure of bone marrow (Verspeek-Rip, 2001)".

Conclusions on genotoxicity

“With few exceptions, eight representative substances of this group were consistently negative in mutation assays conducted in various strains of *S. typhimurium* and *E. coli* under appropriate testing conditions. Negative and positive results were obtained in the rec assay in *B. subtilis* for 2-methylfuran and 2,5-dimethylfuran. In mammalian genotoxicity assays conducted in CHO and V79 cells and human peripheral lymphocytes, study results were inconsistent, with both negative (2,5-dimethylfuran, O-ethyl-S-(2-furylmethyl)thiocarbonate) and positive (2-methylfuran, 2,5-dimethylfuran) results reported. Although positive results were reported in the chromosomal aberration assay in CHO cells with 2-methylfuran and 2,5-dimethylfuran, relatively high concentrations were utilized (i.e. up to 13220 and 1923 µg/ml, respectively); the statistical significance of the results was not specified, and the potential cytotoxicity was not monitored in the assay. Moreover, as previously discussed, positive *in vitro* results of chromosomal aberrations are difficult to interpret in the presence of concomitant cytotoxicity and cell cycle delay, which, based on the results of the studies, are a feature of the furan derivatives. Therefore, it may be expected that mammalian cells in culture might not have adequate metabolic capacities to counter this toxicity. In fact, with the exception of one assay in which clastogenic activity was reported for a single compound (i.e. 2-furyl methyl ketone) with a metabolic activation system, results obtained with other representative furan derivatives demonstrated a reduction in the frequency of chromosomal aberrations in the presence of metabolic activation. Furthermore, unlike the positive results reported for 2,5-dimethylfuran among several other compounds evaluated in CHO cells at the high concentrations used in the study of Stich et al. (Stich et al., 1981b)-dimethylfuran, tested at lower concentrations in V79 cells, did not exhibit clastogenic activity (Ochi and Ohsawa, 1985). The negative findings in the human hepatocyte DNA damage assay provide evidence that the chromosomal aberration findings are not due to a DNA-reactive mechanism.

Three representative compounds were studied in *in vivo* assays. With 2-methylfuran, no increase in chromosomal aberrations was found in either mouse bone marrow cells or spermatocytes. In a study in which mild clastogenic activity was reported in mouse bone marrow cells at the middle and high doses of 2-furyl methyl ketone (i.e. 40 and 60 mg/kg bw, respectively), at which the authors also reported significant mitodepression following single- and multiple dose administrations, no increase in chromosomal aberrations was observed in the spermatocytes obtained from the same mice, and the weak clastogenic effects achieved statistical significance only after repeated daily exposure to near-lethal doses. A study from the same laboratory reported induction of SCEs in mouse bone marrow cells by 2-furyl methyl ketone. However, 2-furyl methyl ketone did not elicit UDS in hepatocytes isolated from rat liver, suggesting that any possible *in vivo* genotoxicity is not attributable to DNA reactivity. The frequency of micronucleus formation in bone marrow cells of mice administered single doses of O-ethyl-S-(2-furylmethyl)thiocarbonate was comparable with control values (Verspeek-Rip, 2001), although adequacy of exposure was not demonstrated.

In conclusion, results of the *in vitro* genotoxicity/mutagenicity tests revealed mixed results, with positive results reported less frequently in the presence of an activation system. This could indicate metabolic detoxication of these substances. The *in vivo* single-dose studies with 2-furyl methyl ketone did not indicate evidence for genotoxicity, whereas two repeat-dose studies showed weak effects for induction of chromosomal aberrations and SCEs. However, evidence indicates that 2-furyl methyl ketone does not exhibit DNA reactivity. The basis for the positive clastogenicity findings remains unclear.”

For a summary of *in vitro* / *in vivo* genotoxicity data considered by JECFA see Appendix A, Table 3 Table 3: of this FGE.

4.2. Genotoxicity Studies – Text taken¹² from the JECFA (JECFA, 2001)

The JECFA did not provide a text on the genotoxicity in their evaluation of the group of furfuryl alcohol and related substances including flavouring substance [FL-no: 13.031]. The JECFA only presented the study results in table format.

For a summary of *in vitro* / *in vivo* genotoxicity data considered by the JECFA see Appendix A, Table 6 in this FGE

4.3. Genotoxicity Studies – Text taken¹³ from EFSA FGE.13Rev2 (EFSA CEF Panel, 2011c)

In the following text, which is taken from FGE.13Rev2, the FGE.13-subgrouping is maintained.

Genotoxicity studies were available only on some of the candidate substances included in main group I or on their related supporting substances. For subgroup Ia, data on *in vitro* genotoxicity were provided for the two candidate substances 5-hydroxymethyl furfural (5HMF) [FL-no: 13.139] and furoic acid [FL-no: 13.136] as well as for five supporting substances. Data on *in vivo* genotoxicity were only provided on two of the supporting substances from subgroup Ia. New genotoxicity data on the candidate substance 5HMF have become available and will be considered in this revision of FGE.13.

For the one candidate substance [FL-no. 13.155] in subgroup Ib no genotoxicity data are available, but *in vitro* and *in vivo* genotoxicity data are available for the supporting substance 2-acetylfuran [FL-no: 13.054].

For subgroup Ic, data on *in vitro* genotoxicity were provided for two supporting substances. Data on *in vivo* genotoxicity were only provided for one of the two supporting substances [former FL-no: 13.029 and former 13.030]. Since the supporting substance for subgroup Ib gives information on genotoxic properties of putative metabolites of the candidate substances in subgroup Ic, the information given for the evaluation of subgroup Ib is also relevant for subgroup Ic.

No genotoxicity data were available on candidate or on structurally related substances in main group II (i.e. furans with sulphur-containing ring substituents).

Subgroup Ia

Candidate substances:

5-hydroxymethyl furfural [FL-no: 13.139]

In the *in vitro* tests, 5HMF gave negative results in the traditional Ames test in strains TA98, TA100, TA104, TA1535 and TA1537 in five and positive results in two studies. The validity of these two studies could not be assessed. In one of these two studies (Omura et al., 1983) the positive response was observed in strain TA100, but not in TA98 and the mutagenic potential was higher in the absence of S9 than in the presence of S9. In the other study (Shinohara et al., 1986) mutagenicity was only observed in strain TA100 in the presence of metabolic activation (see Table 4:). A positive result was obtained also in the *Umu* assay, although only at high concentrations, resulting in reduced cell viability (Janzowski et al., 2000) and in a Rec assay on *B. subtilis* (Shinohara et al., 1986). In V79 cells, 5HMF induced a small (although statistically significant) increase in chromosomal aberrations, a reduction in mitotic index and, only at high concentrations resulting in reduced cell viability, also hypoxanthine phosphoribosyl transferase (HPRT) mutations (Janzowski et al., 2000). In TK6 human

¹² The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed.

¹³ The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed.

lymphoblast cells, 5HMF gave negative results in the HPRT and thymidine kinase (TK) assay (Surh and Tannenbaum, 1994).

In an Ames test with TA104 strain upon inclusion of 3'-Phosphoadenosine-5'-phosphosulfate (PAPS), a sulfo-group donor, and rat liver cytosol into the experimental model, 5HMF gave a positive result, suggesting that it can be activated to reactive metabolites following sulphation, with formation of sulphate-ester, [(sulphoxy)methyl]furfural, (SMF). Indeed, the mutagenic effect could be partly suppressed by the addition of sulphotransferase inhibitors. In accordance, SMF in TA104 was genotoxic in the absence of any metabolic system (cytotoxicity not specified); the effect was reduced by addition of GSH and GSH-transferases and restored when this latter enzyme was inhibited (Lee et al., 1995).

The formation of SMF was supported by the detection of an unstable conjugate, which disappeared within 60 minutes, when 5HMF was incubated with ³⁵S-PAPS and liver cytosol. The exact nature of SMF was not elucidated, but its molecular mass was consistent with that of the sulphate-ester of 5HMF (Surh and Tannenbaum, 1994).

When the genotoxicity of chemically synthesised SMF was tested in Salmonella strain TM677 (8-AG-resistance), without any metabolic activation, a clear positive response was obtained at concentrations that reduced cell survival to < 60 %. Genotoxicity was also observed with SMF in human lymphoblasts at the TK and HPRT loci, at concentrations (\geq 40 microg/ml) reducing cell survival to \geq 63 %. No genotoxicity was observed with 5HMF, with its acetate ester or with the sulphation product of 2-methyl furfuryl alcohol, suggesting that the genotoxicity of SMF requires the presence of both a reactive sulphate group and a free aldehyde group.

An assay for primary DNA damage (Comet assay) did not show an effect of 5HMF in V79 and Caco-2 cells up to cytotoxic concentrations (80 mM). 5HMF causes a slight but significant increase in DNA single strand breaks in primary rat hepatocytes at cytotoxic levels (40 – 100 mM), whereas in human colon biopsy material the same effect was seen in the absence of cytotoxicity. 5HMF at non-cytotoxic concentrations induced a substantial concentration-related GSH depletion in V79, Caco-2 and rat liver cells. The effect of sulphate conjugation was not directly studied, but since this activity is present at least in primary hepatocytes, it might have contributed to the depletion of GSH and to induction of DNA strand breaks in these cells. However, this study was not considered appropriate to evaluate the possible mutagenic activity of SMF in mammalian cells and consequently of 5HMF *in vivo* (Janzowski et al., 2000).

To support the genotoxic potential of 5HMF, some indications for tumorigenic activities of 5HMF have been obtained with rats and mice. It has been reported that 5HMF may act as both an initiator and a promoter in the induction of colonic aberrant cryptic foci in rats (Archer et al., 1992; Bruce et al., 1993; Zang et al., 1993). In addition induction of skin papillomas has been described after topical application of doses of 10 or 25 micromol 5HMF to mice (Surh et al., 1994).

Newly submitted data on 5-hydroxymethylfurfural¹⁴ (Included in Appendix A, Table 4: and Table 5: of this FGE)

Weak mutagenic activity was reported in *S. typhimurium* TA100 strain in the absence of metabolic activation, while no mutagenicity was observed in strains TA97, TA98, TA102 and TA1535 in a range of concentrations of 100 – 10 000 µg/plate; however, negative results were reported in another study with TA98 and TA100 strains and *E. coli* WP2 uvrA/pKM101 in a range of concentrations of 1500 – 10 000 µg/plate (NTP, 2010).

¹⁴ An *in vivo* micronucleus test in mouse bone marrow with neofuraneol was also submitted, but an adequate identification of the substance studied was not possible due to incomplete reporting. The study did not show an effect of neofuraneol on the occurrence of micronuclei. Since no target organ toxicity was seen, this evidence provided by this study is of very limited relevance. For these two reasons the study is not further discussed.

At the end of a 3-month toxicity study, peripheral blood samples were obtained from male and female B6C3F1 mice receiving 0, 47, 188, 375 or 750 mg/kg bw per day of 5HMF via gavage. Slides were scanned to determine the frequency of micronuclei in 1000 NCEs in 10 animals per sex per treatment group. In addition, the percentage of PCE in a population of 1000 erythrocytes was determined as a measure of bone marrow toxicity. No increases in the frequency of micronucleated erythrocytes were observed; in addition, no significant dose-related changes in the percentage of immature PCE were observed, suggesting that the chemical did not exhibit bone marrow toxicity (NTP, 2010).

The DNA-damaging potential of 5HMF was tested *in vitro* in the Comet assay with the following five cell lines with various degree of sulphotransferase 1A1 (SULT1A1) expression (Durling et al., 2009): two human lines (Caco-2, no detectable SULT1A1 activity; HEK293, high SULT1A1 activity); two cell lines from Chinese hamster (V79, no detectable SULT1A1 activity and V79-hp-PST, high SULT1A1 activity) and a one mouse lymphoma line (L5178Y, no detectable SULT1A1 activity). The cell lines were incubated with 0, 2.5, 7.5, 25, 50 or 100 mM (ca. 0, 0.3, 1.0, 3.3 6.3 or 12.6 mg/ml) of 5HMF for three hours and subjected to a Comet assay to study DNA damage.

DNA damage was observed at the highest concentration (100 mM) in all cell lines, with significant reduction in cell viability (from 11 to 30 %). The concentration of 100 mM is ten times higher than the highest concentration (10 mM or 5000 µg/ml) recommended by OECD guidelines for *in vitro* testing with mammalian cells. 100 mM was the lowest effective concentration for three cell lines: Caco-2, HEK293 and L5178Y. In the V79 (lowest SULT1A1) and V79-hp-PST (highest SULT1A1) DNA damage was induced also at lower concentrations (lowest effective concentration: 25 mM or 3193 µg/ml), without a reduction in cell viability. Surprisingly, the positive control (HMP, 0.01 mM) induced significant damage in Caco-2, V79 and V79-hp-PST cells, but not in HEK293. The authors (Durling et al., 2009) concluded that 5HMF DNA damage in all cell lines was unrelated to the expression of SULT1A1 but they mentioned that the SULT1A1 activities in these three cell lines (Caco-2, HEK293 and L5178Y) were much lower than those that can be found in human gut and liver. The possibility was left open that SULT1A1 activity was too low to efficiently bioactivate 5HMF also in the cell line with highest SULT1A1 activity. In V79 cells without SULT1A1 activity and in V79-hp-PST with SULT1A1 activity at the same level as in human gut and liver, no difference in extent of DNA-damage could be observed. This would indicate absence of a significant contribution of sulphate conjugation in the DNA-damaging activity of 5HMF.

These results are in conflict with the results of Glatt et al. (Glatt et al., 2005) who reported induction of SCE in 5HMF-exposed genetically modified V79 cells expressing high levels of human CYP2E1 and SULT1A1. They are also in conflict with the observations by Sommer et al. (Sommer et al., 2003) reporting the mutagenicity of 5HMF in a *S. typhimurium* strain genetically modified and expressing human SULT1A1. According to Durling et al. (Durling et al., 2009), the reasons of these discrepancies are unknown; one possibility is the different sensitivity of the Comet assay compared to other systems. Durling et al. (Durling et al., 2009) concluded that other important mechanisms for the observed DNA damage should be investigated, but that under the conditions of the test, 5HMF is a rather weak DNA-damaging agent.

In a new publication by Severin et al. (Severin et al., 2010), a dose dependent increase in DNA damage was observed in a Comet assay with HepG2 cells exposed to 5HMF (0, 5.35, 7.87, 11.57, 17, 25, 36.6 mM) for 20 hours, with a significant increase from 7.87 to 36.6 mM 5HMF. Cytotoxicity was observed at the two highest doses (25 and 36.6 mM), with estimated IC₅₀ of 38 mM. HepG2 cells express both CYP and SULT enzymes. In the same publication no effect of 5HMF was found in an *in vitro* micronucleus assay in the same cell line exposed to similar doses of 5HMF (20 hours). 5HMF was also tested in an Ames test performed according to the OECD guidelines 471. No increase in mutants was observed in *S. typhimurium* strains TA98, TA100, TA1535 and TA1537 exposed to 5HMF at 0.5 µg/mL up to 5000 µg/mL with or without metabolic activation (S9). However, no additional PAPS was added to the test system (Severin et al., 2010).

However, while 5HMF was unable to induce micronuclei *in vivo*, in mice (90-day study by gavage, NTP, 2010) and *in vitro*, using the Hep-G2 human cell line expressing both CYP and SULT enzymes, its metabolite SMF has been reported to induce micronuclei in peripheral erythrocytes in mice (Dahlberg, 2004) as cited by Glatt and Sommer, 2006 (no further data were available)).

According to Glatt and Sommer, incubation of DNA with SMF in a cell-free system led to the formation of DNA adducts that could be detected by the ^{32}P -postlabelling technique. No adducts were formed in incubations with 5HMF instead of SMF. In subsequent experiments, the authors searched for these adducts in mammalian and bacterial cells treated with SMF and in SULT-proficient cells treated with 5HMF. Although mutations were induced, adducts were not seen in these cells under the same conditions (no data are available to be listed in the genotoxicity table). The authors hypothesized that the lack of DNA adducts might be due to technical problems, since generally DNA adducts are a more sensitive endpoint than mutations as observed with many other compounds (Glatt and Sommer, 2006).

In conclusion, with respect to the genotoxicity of 5HMF, taking into account additional data on metabolism, the following picture emerges. The substance is negative in the conventional Ames test. Mutagenicity is observed only upon inclusion of PAPS, a sulpho-group donor and liver cytosol into the metabolic system, suggesting the formation of a SMF. In accordance, SMF was mutagenic in the absence of any metabolic activation system. In an *in vitro* assay, 5HMF induced concentration-dependent increase in DNA damage (Comet assay), but this study has major drawbacks and inconsistencies and has to be considered of limited validity. A major limitation is the use of too high concentrations that can produce unpredictable effects, not related to the real genotoxic potential of 5HMF, and this is particularly true for a test like the Comet assay. Furthermore, as also stated by the authors, DNA damage was unrelated to the expression of SULT1A1 activity. Also in another Comet assay in HepG2 cells, able to express both CYP and SULT enzymes, indications for DNA damage were observed, but the substance did not induce clastogenic or aneugenic effects (micronucleus assay) in the same cell system. *In vivo*, a non-standard micronucleus assay in peripheral blood erythrocytes associated to a sub-chronic study in mice, provided no indication of a genotoxic potential, but this study has limited validity since no bone marrow cell toxicity was observed.

Metabolic studies indicate that *in vivo*, in mice B6C3F1 and rats, the principal route of metabolism is oxidation of 5HMF to 5-hydroxymethylfuroic acid, followed by glycine conjugation and rapid elimination in the urine. However, a recent pharmacokinetic study in FVB/N mice has shown that SMF has been detected in plasma from animals given 5HMF, intravenously. This indicates that there is a competition for the substrate 5HMF between the oxidation pathway leading to furoic acid derivative and the sulphonation pathway leading to the SMF metabolite. The Panel noted that SMF is very hydrophilic and therefore will have problems crossing the cell membrane and entering cells. Therefore SMF is more likely to induce mutation at the site of formation, mainly the liver. In addition, the half-life was reported to be 4.2 minutes, and it is not likely that this metabolite will manage to reach the bone marrow and give any positive effect in an *in vivo* micronucleus test, taking into account that SMF will most likely be formed in the liver. However, 5HMF has been found unable to induce micronuclei also *in vitro*, using the HepG2 human cell line, expressing both CYP and SULT enzymes. In the rodent bioassays no carcinogenic response was observed and from this it may be concluded that the formation of the SMF metabolite is too low to result in a carcinogenic response. Assuming that in humans the ratio between the two competing pathways is not more favourable for the formation of SMF than in rodents, no genotoxicity or carcinogenicity is expected in humans either.

Furoic acid [FL-no: 13.136]

Furoic acid gave negative results in three studies in the Ames test in strains TA98 and TA100. Furoic acid was also negative in DNA repair test in *E.coli* and in a UDS assay using primary rat hepatocytes.

Supporting substances

In vitro genotoxicity data were available for five supporting substances: furfuryl acetate, furfuryl alcohol, furfural, 5-methylfurfural and methyl-2-furoate [FL-nos: 13.128, 13.019, 13.018, 13.139 and 13.002] and *in vivo* genotoxicity data for the two supporting substances furfuryl alcohol and furfural [FL-nos: 13.019 and 13.018]. Most studies were negative, although some positive results were reported.

However, the genotoxicity of furfural has been re-evaluated by the EFSA Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with Food (i.e. the former AFC Panel), which concluded that furfural did not induce gene mutations *in vivo*, on the basis of new studies with transgenic mice (EFSA, 2004).

Overall, the genotoxicity data available on the candidate furoic acid and on supporting substances do not give rise to concern with respect to genotoxicity of nine furfural-related candidate substances included in subgroup Ia [FL-nos: 13.011, 13.102, 13.122, 13.127, 13.129, 13.130, 13.132, 13.133 and 13.136]. Based on newly submitted data on the mutagenic activity of 5HMF [FL-no: 13.139] the concern for genotoxicity which was raised because of genotoxic properties of one of its metabolites (SMF) is overcome. Thus there are no further concerns for genotoxicity of the candidate substances in subgroup Ia, which could preclude their evaluation through the Procedure.

Subgroup Ib

No data are available for the one candidate substance in subgroup Ib [FL-no: 13.155]. However, several studies have been carried out with a structurally related flavouring substance, 2-acetylfuran [FL-no: 13.054] (2-furyl methyl ketone).

In vitro studies

For the supporting substance 2-acetylfuran [FL-no: 13.054] data were found showing an increased mutation frequency in a bacterial reverse gene mutation test in *S. typhimurium* TA98 with metabolic activation, but not in TA100. The study has limited validity. The increase was not concentration-related and no clear data on cytotoxicity were presented, but a decrease in the number of revertants was observed at the highest concentrations, which could indicate cytotoxicity. A second trial was not performed (Shinohara et al., 1986). Also with this substance a positive result was obtained in the *rec*-assay (Shinohara et al., 1986) and in an SOS-chromo test for bacterial DNA-repair (Eder et al., 1993), but the predictive value of these test systems is considered to be limited. With [FL-no: 13.054] also chromosomal aberrations in Chinese hamster ovary cells have been reported in a limited study by Stich et al. (Stich et al., 1981b).

2-Acetylfuran [FL-no: 13.054] was evaluated for induction of unscheduled DNA synthesis (UDS) in human hepatocytes following OECD guidelines. Human (gender not given) hepatocytes from two batches purchased from a commercial provider were incubated with concentrations of the compound (purity not given) between 2.19 and 280 µg/ml for 16 hours, and UDS was measured autoradiographically. No UDS was elicited, in contrast to the positive control, 2-acetylaminofluorene (Durward, 2007a)

In vivo studies

2-Acetylfuran [FL-no: 13.054] was also evaluated for induction of SCE in bone marrow of female Swiss albino mice. Groups of two per dose per exposure regimen were administered compound (99 % pure) at 0, 1000, 2000 or 3000 mg/l via gavage either once or for 5 consecutive days. 5-Bromodeoxyuridine was injected intraperitoneally to label chromatids. The mice were sacrificed at 12, 24 or 48 hours after receiving the last dose, and slides of bone marrow were prepared and processed for differential staining. A dose-related increase up to about 2-fold in SCE was observed for the 12-

and 24-hour groups of both the single-dose regimen and the multiple-dose regimen (Sujatha, 2007). This study was considered valid. In an earlier study by the same group (Sujatha et al., 1993) this substance was reported to cause chromosomal aberrations in mouse bone marrow at oral dose levels up to 60 mg/kg bw per day. Also this study was considered valid.

2-Acetylfuran was evaluated for induction of UDS in hepatocytes isolated from livers of dosed male Sprague-Dawley rats. The assay was conducted according to GLP and OECD guidelines. In a preliminary range-finding toxicity study, lethality was observed at 30 mg/kg bw and greater, and signs of toxicity were observed at 20 mg/kg bw. No sex differences were observed, and therefore only males were used in the main study. Groups of four rats were administered test compound (purity not given) at 0, 7 or 21 mg/kg bw via gavage. In experiment 1, the hepatocytes were isolated 16 hours post-dosing; in experiment 2, hepatocytes were isolated 2 hours post-dosing and cultured for autoradiographic measurement of UDS. No UDS was observed in either experiment (Durward, 2007b).

The candidate and supporting substance in this subgroup are α,β -unsaturated ketones. This structural characteristic has been considered as an additional reason for concern for genotoxic potential of these substances. However, due to structural similarity with acetophenone (i.e. the α,β -unsaturated double bond is part of an aromatic system and therefore less reactive) the concern for genotoxicity, resulting from the formation of such α,β -unsaturated ketones has been lifted (EFSA Panel, 2011). Nevertheless, the experimentally obtained genotoxicity data indicate that the supporting substance may give rise to DNA damage, which may result in chromosomal aberrations rather than gene mutations. Also from Section 4 and Annex III (FGE.13Rev2 (EFSA CEF Panel, 2011c)), the formation of DNA-reactive metabolites may be anticipated. In combination with this, the available genotoxicity data are sufficiently strong to raise a concern, which would preclude the evaluation of the candidate substance in subgroup Ib through the Procedure.

Subgroup Ic

No data are available on the genotoxic properties of the two candidate substances in this subgroup.

Several studies were found with the supporting substances 2-methylfuran [former FL-no: 13.030] and 2,5-dimethylfuran [former FL-no: 13.029]. Negative results were obtained in a limited bacterial reverse gene mutation test with *S. Typhimurium* (TA97 and TA100 strains only, no data on cytotoxicity, no duplicate trial; (Shinohara et al., 1986)). However, a clear concentration-related positive response with limited validity (e.g. no clear data on cytotoxicity; no clear description of scoring criteria) was obtained with both substances in a chromosome aberration test in Chinese hamster ovary cells with and without metabolic activation in presence or absence of metabolic activation (Stich et al., 1981b). Both substances also gave a positive response in a *rec*-assay for bacterial DNA-repair (Shinohara et al., 1986), but the predictive value of this test system is considered to be limited. With 2-methylfuran an equivocal result was obtained in a bacterial reverse gene mutation assay with *S. typhimurium* in strain TA97. This test was considered valid (Zeiger et al., 1992).

For a 2-alkyl- and 2,5-dialkyl-substituted furans, formation of reactive intermediates cannot be excluded (see section 4 and Annex III, FGE.13Rev2 (EFSA CEF Panel, 2011c)). These reactive intermediates can bind covalently to DNA, which might result in genotoxic events. In an alternative metabolic pathway, these flavouring substances may also be converted to ketones which are structurally related to the substances in subgroup Ib and for these substances a concern for genotoxicity has been identified. Therefore, owing to the anticipated metabolism of the two candidate substances in subgroup Ic into possible genotoxic metabolites a concern for genotoxicity cannot be excluded. For the two candidate substances in subgroup Ic [FL-nos: 13.125 and 13.162] this concern for genotoxicity would preclude their evaluation through the Procedure.

Main group II

No genotoxicity data were available on any of the 14 sulphur-containing candidate substances in main group II, nor on their related supporting substances. As it is anticipated that the predominant metabolic attack for these substances will be on the sulphur atom(s), for the candidate substances in main group II, ring opening is not considered to be a major metabolic route. The lack of data on the 14 sulphur-containing candidate substances included in main group II or on related supporting substances does not allow to conclude on their potential for genotoxicity. However, this would not preclude the evaluation of these 14 candidate substances from subgroup II using the Procedure.

For a summary of *in vitro* / *in vivo* genotoxicity data considered by EFSA see Appendix A, Table 4 and Table 5.

4.4. EFSA Considerations

The Panel considered that the entire group of furans used as chemically defined flavouring substances (i.e. all flavouring substances discussed in FGE.13Rev2, FGE.65Rev1, FGE.66Rev1 and FGE.67Rev1) is a very diverse group. Based on this diversity, the Panel considers it justified to differentiate between the various subgroups with respect to the way the substances are metabolised and therefore also with respect to their possible genotoxic activity. Information on furan ring oxidation and opening, which results in the formation of reactive intermediates, was already considered in FGE.13Rev2. In this FGE, for the substances containing oxygenated ring substituents (subgroup 1a of FGE.13rev2), ring-opening was not considered a major issue with respect to genotoxicity. This was also supported by the fact that for the supporting substance furfural, for which this ring opening also has been reported, data show that furfural is not genotoxic *in vivo*. Therefore for the corresponding candidate substances in subgroups II and III in FGE.67rev2 it is also concluded that these are not of concern with respect to genotoxicity. For the alkyl-substituted furans in FGE.13rev2 the concern for formation of reactive metabolites could not be taken away, because of insufficient data on genotoxicity. It may be considered that ring oxidation and opening would be more relevant for these alkyl-substituted furans because they lack other simple options for metabolism like hydrolysis and / or immediate conjugation. In addition, oxidation of the C₁'-carbon of the alkyl substituent results in the formation of a ketone and for one such ketone [FL-no: 13.054], data are available to indicate a genotoxic potential (see section on genotoxicity on substances in FGE13.Rev2, above and Section 4 and Annex III in FGE.13Rev2). Therefore, the two candidate alkyl-substituted furans in subgroup Ic of FGE.13Rev2 were not evaluated via the Procedure. The same would apply to the five alkyl-substituted furans [FL-nos: 13.059, 13.069, 13.103, 13.106 and 13.148] in group IV in FGE.67rev2.

Apart from the alkylfurans (subgroup IV, supported by subgroup Ic from FGE.13rev2), simple hydrolysis / conjugation reactions are also not possible for the substances in subgroup V-A. As ethers [FL-nos: 13.052, 13.061 and 13.123] are more resistant to hydrolysis than the corresponding esters, it may be anticipated that these ethers can also be more prone to ring oxidations and opening than the substances in subgroup Ia in FGE.13Rev2 or group III in FGE.67. Therefore, for the substances in this subgroup a concern for genotoxicity cannot be excluded. The concern is not identified for 2,3-dimethylbenzofuran [FL-no: 13.074] (subgroup V-B), because for this substance furan ring opening is considered unlikely due to the two methyl substituents at the double bond in the furan ring. The other substance in subgroup V-B [FL-no: 13.031] has been allocated to FGE.219 for consideration of genotoxic potential, because this substance is an α,β -unsaturated aldehyde. Afterwards, the Panel considered that since the double bond in α -position to the carbonyl group is part of an aromatic system, the reactivity of this double bond is less than in non-aromatic α,β -unsaturated carbonyls, and for that reason the concern for genotoxicity of this candidate substance [FL-no: 13.031] has been waived and further testing is no longer required. (EFSA Panel, 2008c, 2014).

Seven of the nine substances in subgroup VI-B are α,β -unsaturated ketones [FL-nos: 13.054, 13.066, 13.070, 13.083, 13.101, 13.105 and 13.163]. This structural characteristic has been considered as an additional reason for concern for genotoxic potential of these substances. However, due to structural

similarity with acetophenone (i.e. the α,β -unsaturated double bond is part of an aromatic system and therefore less reactive) the concern for genotoxicity, resulting from the formation of such α,β -unsaturated ketones has been lifted (EFSA Panel, 2008c). Nevertheless, the experimentally obtained genotoxicity data indicate that substance [FL-no: 13.054] may give rise to DNA damage, which may result in chromosomal aberrations rather than gene mutations. The formation of DNA-reactive metabolites may be anticipated (EFSA CEF Panel, 2011c). In combination with this, the available genotoxicity data are sufficiently strong to raise a concern, which would preclude the evaluation of the candidate substance in subgroup VI-B through the Procedure. Based on the concern raised by the genotoxicity data on [FL-no: 13.054] and the anticipation that keto-reduction is less favourable for biotransformation than e.g. alcohol or aldehyde oxidation and conjugation, the Panel considered it also necessary to re-evaluate the two remaining alkoyl-substituted furans in subgroup VI-B [FL-nos: 13.045 and 13.138]. In similarity with the other ketones in this subgroup VI-B in FGE.67Rev1 (supported by subgroup Ib in FGE.13Rev2), for these two substances now also a concern for genotoxicity is identified.

No data on genotoxicity are available for the previously evaluated (FGE.13Rev2) furans with sulphur-containing ring substituents. As it is anticipated that the predominant metabolic attack for these substances will be on the sulphur atom(s), for these substances ring opening is also not considered to be a major metabolic route. Although the genotoxicity of these substances could not be properly assessed, this did not preclude the evaluation of these substances through the Procedure. The same would apply to the two sulphur-containing substances [FL-nos: 13.116 and 13.190] in subgroup I in the present FGE.67Rev2.

Thus, in FGE.67rev2 the Panel concluded that 11 of the 28 substances evaluated in the FGE could be evaluated through the Procedure [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 13.058, 13.074, 13.116 and 13.190]. For all 17 substances in groups IV, V-A and VI-B ([FL-nos: 13.045, 13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 13.148 and 13.163] a concern for genotoxicity was identified, precluding these substances to be evaluated through the Procedure.

5. New Toxicity Data Evaluated by the Panel in FGE.67Rev2

In the previous revision of FGE.67 (rev1) the Panel concluded that no NOAEL could be identified to support the evaluation of 3-(5-methyl-2-furyl) butanal [FL-no: 13.058] at step B4 of the Procedure. The Industry has now submitted a new 90-day toxicity study for 3-(5-methyl-2-furyl) butanal which will be evaluated in the present revision of FGE.67.

5.1. A 14-Day Oral (Dietary) Toxicity Study of 3-(5-methyl-2-furyl) butanal in Rats

In a 14 day dietary study, groups (3/sex per dietary intake level) of male and female Crl:CD(SD) rats were fed a diet designed to provide 0 (dietary control), 50, 300 and 750 mg/kg bw of 3-(5-methyl-2-furyl) butanal, daily (Kappeler, 2013a). Due to the exploratory nature of this non-GLP study, homogeneity, concentration, and stability analyses of the test diets were not conducted. Calculated from nominal dietary concentrations and the measured feed intake, the estimated dietary exposure levels were 0, 52, 303 and 740 mg/kg bw per day for males and 0, 52, 298 and 772 mg/kg bw per day for females. Clinical observations were recorded daily and body weights and food consumption observations were made on Days 0, 7 and 14. All animals were observed twice daily for mortality or moribundity. No mortality was observed throughout the course of the study and no remarkable changes in the general condition of the rats were observed. Gross examination was comparable to controls for all test groups. There were however reductions in final body weight (not statistically significant) and body weight gain for males and females at the 300 and 750 mg/kg dietary concentrations from Day 0-7 and this continued into Day 7-14 for the 750 mg/kg males. This was attributed to reduced palatability of high concentrations of 3-(5-methyl-2-furyl) butanal in the diet. The dose levels in the subsequent 90-day oral toxicity study in rats (Kappeler, 2013b) were selected based on the findings in this oral 14-day study.

5.2. A 90-Day Oral (Dietary) Toxicity Study of 3-(5-methyl-2-furyl) butanal in Rats

A 90-day oral toxicity study in CrI:CD(SD) rats was performed with 3-(5-methyl-2-furyl) butanal [FL-no: 13.058] (Kappeler, 2013b). The study was performed according to OECD Guideline (TG 408) and under GLP. The substance (purity 99.5%) was administered via the diet to four groups of male and female CrI:CD(SD) rats (10/sex/dietary intake level), at doses designed to provide 0 (feed control), 10, 50 and 250 mg/kg bw per day. The feed was refreshed every seven days. By the end of the week the concentration in the feed had declined by 59%. Thus, the actual daily intakes were 0, 5.9, 30 and 150 mg/kg bw for males and females, when calculated based on body weights, feed consumption and concentration of the substance in the feed at the end of the seven day period.

Clinical observations of toxicity were performed on a daily basis and detailed physical exams, weekly. Animals were observed for signs of mortality and moribundity twice daily. Animals were weighed on day 0 at the start of the study and weekly thereafter. Body weights and food consumption were measured weekly. Ophthalmic examinations were performed during the week prior to the study and during week 13 of the study. Clinical pathology (haematology, coagulation, serum chemistry and urine analysis) were performed at necropsy. At termination of the study all survivors were sacrificed and subject to full necropsy. The following tissues were weighed wet post dissection: adrenals, brain, epididymis, heart, kidneys, liver, ovaries, testes, spleen, thymus, uterus with oviducts. For all animals, all required tissues were preserved for future histopathological examination. The dietary control groups and the high dietary concentration groups were subject to complete microscopic examination in addition to any gross lesions. Since the liver was a target organ, complete histopathology examinations of the liver were performed for all three test concentration groups.

There were no unscheduled deaths or clinical observations of toxicity during the study. No gross observations were attributed to 3-(5-methyl-2-furyl) butanal in the diet. There were no observed statistically significant effects on haematology and coagulation or serum chemistry parameters. Ophthalmic and macroscopic examinations were unremarkable and urine analysis showed no effects at any test concentration. No change in histopathology was observed except for the liver. Relative liver weights were increased for the 150 mg/kg bw per day male group. This finding correlated to minimal (5/10 animals), mild (4/10 animals) or moderate (1/10 animals) centrilobular, hepatocellular vacuolation characterised by scattered hepatocytes with a single large intracytoplasmic vacuole. In the study report there was no further detailed information as to the nature of this histological change, which was considered adverse and related to the presence of 3-(5-methyl-2-furyl) butanal in the diet. The same histopathological change in the liver was also observed in the mid-dose ("minimal" in 4/10 animals) and the low-dose group ("minimal" in 2/10 animals); none had a more severe score. Since the histopathological observation was also seen in the control group ("mild" in 1/10 animals) the histological change in the low-dose is not considered adverse (Kappeler, 2013b).

Based on this 90-day dietary toxicity study and based on the toxicological endpoints of liver pathology in the mid- and high dose males, which were observed at a higher incidence than in the controls, the CEF Panel derived a no-adverse-effect level (NOAEL) for 3-(5-methyl-2-furyl) butanal of 5.9 mg/kg bw per day. In females no toxicity was observed at dose levels up to 150 mg/kg bw per day (top dose).

A summary of the toxicity data is given in Appendix A, Table 7.

6. Application of the Procedure

6.1. JECFA Statement on the Application of the Procedure to 40 furan-substituted substances evaluated by JECFA¹⁵ (JECFA, 2009a)

As stated above, the main concern with this group arises primarily from the carcinogenicity of furan itself, which is believed to involve a reactive genotoxic metabolite formed by epoxidation and opening of the furan ring. Furan is not a member of this group of flavouring agents, but all the members of the group contain a furan ring with either one or two substituents of varying complexity. In some flavouring agents, a substituent is present on one side of the furan ring only, whereas in others, substituents are present on both sides. The presence of an extended side-chain attached to the furan ring would reduce the potential for epoxidation of the double bond and provide a site for detoxication via metabolism and elimination. The alkylated furan with the simplest structure and which would be predicted to have the greatest potential for ring oxidation is 2-methylfuran [former FL-no: 13.030]; there is evidence from studies *in vitro* and *in vivo* that this compound undergoes bioactivation to a reactive ring-opened metabolite that binds covalently to both protein and DNA. Data are not available on the influence of the nature and position of the ring substitution on potential for metabolic activation and adduct formation. After administration of a single dose, 2-methylfuran produced liver toxicity in rats from 50 mg/kg bw, but hepatotoxicity has not been reported for other members of this group in more extensive studies.

Testing for genotoxicity has been performed on eight members of this group of flavouring agents. The results of the studies of genotoxicity/mutagenicity *in vitro* that were already available to the Committee (the JECFA) at its previous meeting were both positive and negative, with most positive results reported for chromosomal aberration. These, however, were less frequent in the presence of metabolic activation, indicating possible metabolic detoxication rather than bioactivation. 2-Methylfuran [former FL-no: 13.030], for example, produced chromosomal aberrations *in vitro*, but the clastogenic activity was lower in the presence of a metabolising system. The limited data available on genotoxicity *in vivo* showed no evidence of chromosomal aberration in mouse bone marrow or spermatocytes for 2-methylfuran. 2-Furyl methyl ketone (2-acetylfuran) [FL-no: 13.054] also induced no chromosomal aberrations in mouse spermatocytes, but a weak, transient increase in chromosomal aberrations was observed in mouse bone marrow, associated with mitodepression. O-Ethyl-S-(2-furylmethyl)thiocarbonate [former FL-no: 13.191] appeared not to induce micronucleus formation in mouse bone marrow.

The new data on 2-furyl methyl ketone [FL-no: 13.054] available to the Committee (the JECFA) at its present meeting were a study on UDS in cultured hepatocytes *in vitro*, a study on UDS in rat liver *in vivo/in vitro* and a test for SCEs in mouse bone marrow *in vivo*. 2-Furyl methyl ketone did not induce UDS either *in vitro* or *in vivo/in vitro*. However, it did induce SCEs, confirming the concern for clastogenicity as expressed by the Committee (the JECFA) at its previous meeting. The Committee (the JECFA) at its present meeting therefore considered that the new data available did not resolve the concerns expressed previously.

The Committee (the JECFA) concluded that the Procedure for the Safety Evaluation of Flavouring Agents could not be applied to this group because of the unresolved toxicological concerns. Studies that would assist in the safety evaluation include investigations of the influence of the nature and position of ring substitution on metabolism and on covalent binding to macromolecules. Depending on the findings, additional studies might include assays related to the mutagenic and carcinogenic potential of representative members of this group.”

¹⁵ The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed

6.2. JECFA Statement on the Application of the Procedure to one furfuryl alcohol related substance [FL-no: 13.031] evaluated by the JECFA¹⁶ (JECFA, 2001)

Step 1

In applying the Procedure for the Safety Evaluation of Flavouring Agents to the above-mentioned substances, the Committee assigned substance 2-benzofurancarboxaldehyde (JECFA No. 751) [FL-no: 13.031] to structural class III.

Step 2

The JECFA provided no statement on the possible metabolism of substance [FL-no: 13.031]. The JECFA concluded that the evaluation of all substances (thus including substance [FL- no: 13.031]) in this group proceeded via the B-side of the scheme (i.e. they cannot be predicted to be readily metabolised to innocuous products).

Step B3

The estimated daily per capita intakes of substance [FL-no: 13.031] is below the threshold of concern for its structural class (i.e. 90 µg per day for structural class III). Accordingly, the evaluation of this substance proceeded to step B4.

Step B4

For 2-benzofurancarboxaldehyde [FL-no: 13.031], the NOEL of 25 mg/kg bw per day in a 90-day feeding study in rats (Posternak et al., 1969) provides an adequate margin of safety (> 10⁵) in relation to the known levels of intake of this substance.

6.3. Application of the Procedure to 27 Furfuryl and furan derivatives with and without additional side-chain substituents and heteroatoms by EFSA¹⁷ in FGE.13Rev2 (EFSA CEF Panel, 2011c)

In FGE.13Rev2 data have been presented, which indicate that the candidate substance 5-hydroxymethylfurfuraldehyde (5HMF) [FL-no: 13.139] from subgroup Ia may be metabolised to 5-[(sulphoxy)methyl]furfural (SMF), which shows genotoxic potential *in vitro*. Sufficient data have been provided to mitigate this concern with respect to genotoxic potential *in vivo*.

Based on genotoxicity data for the substance 2-acetylfuran [FL-no: 13.054] supporting to the candidate substance in subgroup Ib [FL-no: 13.155], a concern for genotoxicity is raised for candidate substance [FL-no: 13.155].

For the two substances, 2-ethyl-5-methylfuran [FL-no: 13.125] and 2-octylfuran [FL-no: 13.162] from subgroup Ic, genotoxicity may be anticipated based on formation of DNA-reactive metabolites and based on information available for the candidate substance in subgroup Ib [FL-no: 13.155].

In absence of sufficient experimental data on genotoxicity on these or structurally related substances, the Procedure cannot be applied to the candidate substance in subgroup Ib and the two candidate substances in subgroup Ic. A further extensive discussion on the genotoxicity of the candidate substances has been presented in Section 8.4 (FGE.13Rev2).

¹⁶ The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed.

¹⁷ The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed.

Thus, the Procedure for the safety evaluation of flavouring substances as outlined in Annex I (FGE.13Rev2) has been applied to 24 candidate substances from chemical group 14. The stepwise evaluations of the 24 substances are summarised in Appendix C.

Step 1

Five [FL-nos: 13.122, 13.130, 13.136, 13.139 and 13.145] of the 24 candidate substances evaluated via the Procedure are classified into structural class II and 19 [FL-nos: 13.011, 13.102, 13.108, 13.113, 13.114, 13.124, 13.127, 13.129, 13.132, 13.133, 13.135, 13.141, 13.143, 13.144, 13.146, 13.149, 13.178, 13.185 and 13.199] are classified into structural class III according to the decision tree approach by Cramer et al. (Cramer et al., 1978), see Appendix C.

Step 2

Taking into account the metabolic pathways described in Section 4 (FGE.13Rev2), none of the candidate substances is predicted to be metabolised to innocuous products. Therefore, the evaluation of the 24 candidate substances proceeds *via* the B-side of the evaluation scheme.

Step B3

The five candidate substances, which have been assigned to structural class II, have estimated European daily *per capita* intakes (MSDI) ranging from 0.0024 to 0.39 µg. These intakes are below the threshold of concern of 540 µg/person per day for structural class II. The estimated daily *per capita* intakes of the 19 candidate substances assigned to structural class III range from 0.0012 to 37 µg, which are also below the threshold of concern for the structural class of 90 µg/person per day. Therefore, the safety evaluation proceeds to step B4 for all 24 candidate substances.

Step B4

Subgroup Ia structurally related to furfuryl alcohol [FL-nos: 13.011, 13.102, 13.122, 13.127, 13.129, 13.130, 13.132, 13.133, 13.136 and 13.139]:

Considering that the ten candidate substances of subgroup Ia are metabolised to yield furfural and furoic acid or furanacrylic acid, the toxicity of the esters of furfuryl alcohol [FL-nos: 13.127, 13.129, 13.130, 13.132 and 13.133], furoic acid [FL-nos: 13.102 and 13.122] and furanacrylic acid [FL-no: 13.011] is expected to be similar to that of the structurally related supporting substance furfural [FL-no: 13.018] and of the candidate substance 2-furoic acid [FL-no: 13.136], which is the major metabolite of furfural. For furfural [FL-no: 13.018] an ADI value of 0.5 mg/kg bw per day has been recently established by EFSA (EFSA, 2004). The estimated daily *per capita* intakes based on the MSDI approach expressed in µg/kg bw per day of candidate substances in subgroup Ia of the present FGE.13Rev2 are more than 30000 fold below the ADI value.

For 5HMF [FL-no: 13.139] a substantial amount of substance-specific data are available, including 13-week subchronic studies and chronic studies in B6C3F₁ mice and F344/N rats (NTP, 2010). The carcinogenicity study in mice demonstrated that 5HMF may induce liver tumours, but these are considered irrelevant for humans. In contrast, no carcinogenic responses have been reported in the study with rats. The data have shown that the critical effect is cytoplasmic alterations in renal proximal tubule epithelium in mice, observed in the 13-weeks study with mice at 188 mg/kg bw for 5 days per week and above with an intermittent dose regimen of five days per week. For this effects a BMDL of 20.2 mg/kg bw per day for 5 days/week can be derived, which would be equivalent to 14.4 mg/kg bw per day, when corrected for continuous daily administration (see Section 8.2 and Annex V (FGE.13Rev2)). When this BMDL of 14.4 mg/kg bw per day derived from the 13-weeks study in mice is compared to the MSDI of 0.39 µg/*capita* per day for this substance, a margin of safety of 2.2×10^6 can be calculated. From this it is concluded that 5HMF [FL-no: 13.139] does not raise a safety concern as a flavouring substance, at its current level of use in foods.

Since no toxicity data are available on the sulphur-containing candidate substances in main group II, the relevant No Observed Adverse Effect Level (NOAEL) values originate from structurally related supporting substances.

Subgroup IIa sulphides [FL-nos: 13.114, 13.124, 13.135, 13.141, 13.143, 13.145 and 13.199]:

The candidate substances ethyl furfuryl sulfide [FL-no: 13.124], methyl 5-methylfurfuryl sulfide [FL-no: 13.145] and 2,5-dimethyl-3-(methylthio)furan [FL-no: 13.114] are expected to participate in the same metabolic pathways as the supporting substance furfuryl isopropyl sulfide [FL-no: 13.032] and therefore to have same toxicological properties. No effects were observed for furfuryl isopropyl sulfide in a 90-day dietary study with rats at a single dose level (1.34 mg/kg bw per day) (Posternak et al., 1969). Comparison of the only level tested with no effect taken as a no observed adverse effect level (NOAEL) with the estimated daily *per capita* intakes based on the MSDI approach and expressed in µg/kg bw per day for ethyl furfuryl sulfide [FL-no: 13.124], methyl 5-methylfurfuryl sulfide [FL-no: 13.145] and 2,5-dimethyl-3-(methylthio)furan [FL-no: 13.114] provides adequate margins of safety $> 10^5$.

After ester hydrolysis, the candidate substances methyl (2-furfurylthio)acetate and methyl 3-furfurylthio)propionate [FL-nos: 13.141 and 13.143] are anticipated to be metabolised and to have toxicological properties similar to the supporting substance ethyl-3-(2-furfurylthio)propionate [FL-no: 13.093]. For this substance an NOAEL of 5.78 mg/kg bw per day has been identified in a 90-day study (Bio-Research Laboratory, 1980). Comparison of this NOAEL with the estimated daily *per capita* intakes based on the MSDI approach and expressed in µg/kg bw per day of methyl (2-furfurylthio)acetate and methyl 3-furfurylthio)propionate [FL-nos: 13.141 and 13.143] provides an adequate margin of safety of 3.2×10^7 for both substances.

Candidate substances 1-(2-furfurylthio)propanone [FL no: 13.135] and 3-[(2-methyl-3-furyl)thio]-butanal [FL-no: 13.199] may be evaluated by comparison of their exposure estimates with the NOAEL from supporting substance 3-[(2-methyl-3-furyl)thio]-4-heptanone [FL-no: 13.077]. 3-[(2-Methyl-3-furyl)thio]-4-heptanone was tested in rats at a single dose level of 3.76 mg/kg bw per day in the diet for 90 days without treatment-related effects (Gallo et al., 1976). Comparison of the estimated daily *per capita* intake based on the MSDI approach for 3-[(2-methyl-3-furyl)thio]-butanal [FL-no: 13.199] with the NOAEL of 3.76 mg/kg bw per day for the supporting substance provided an adequate margin of safety of 1.9×10^5 . Comparison of the estimated daily *per capita* intake based on the MSDI approach for 1-(2-furfurylthio)propanone [FL-no: 13.135] with the NOAEL of 3.76 mg/kg bw per day for the supporting substance provides an adequate margin of safety of 2.1×10^7 .

Subgroup IIb thiols [FL-no: 13.108 and 13.149]:

The candidate substances 5-methyl-2-furanmethanethiol [FL-no: 13.149] is structurally related to the supporting substance 2-furanmethanethiol [FL-no: 13.026]. The NOAEL of 2-furanmethanethiol in a multiple dose level 91-day oral gavage study with rats was 3 mg/kg bw per day (Phillips et al., 1977). Comparison of the NOAEL for 2-furanmethanethiol with the estimated daily *per capita* intake based on the MSDI approach expressed in µg/kg bw per day of 5-methyl-2-furanmethanethiol [FL-no: 13.149] provides an adequate margin of safety of 3.7×10^5 .

The candidate substance 4,5-dihydro-3-mercapto-2-methylfuran [FL-no: 13.108] is structurally related to the supporting substance 2-methyl-3-thioacetoxy-4,5-dihydrofuran [FL-no: 13.086] from subgroup IIe (of FGE13Rev1). Several subchronic studies have been carried out with this supporting substance. A NOAEL of 1.4 mg/kg bw per day has been derived in a multiple dose level 13 weeks dietary study with rats (Munday and Gellatly, 1973). Comparison of the NOAEL for 2-methyl-3-thioacetoxy-4,5-dihydrofuran with the estimated daily *per capita* intake based on the MSDI approach expressed in µg/kg bw per day of 4,5-dihydro-3-mercapto-2-methylfuran [FL-no: 13.108] provided an adequate margin of safety of 2.3×10^3 .

Subgroup IIc disulphides [FL-nos: 13.113, 13.144, 13.178 and 13.185]:

In the previous version of this FGE, the candidate substance 2,5-dimethyl-3-(methylthio)furan [FL-no: 13.113] was evaluated against a NOAEL which turned out to belong to a structurally unrelated substance. Therefore this evaluation was not valid and thus substance [FL-no: 13.113] had to be reconsidered. It may be anticipated that this disulphide will be subject to fission of the disulphide bridge. The resulting furan-containing fragment, which is more reactive than the disulphide itself, could be evaluated by comparison with the toxicity of 2-methyl-3-furanthiol [FL-no: 13.055] from subgroup IIb. The NOAEL of 2-methyl-3-furanthiol in a multiple dose level 90-day oral gavage study with rats was 5 mg/kg bw per day (Oser, 1970b). When the NOAEL for 2-methyl-3-furanthiol is compared with the estimated daily *per capita* intake based on the MSDI approach expressed in µg/kg bw per day for 2,5-dimethyl-3-(methylthio)furan [FL-no: 13.113] an adequate margin of safety of 25×10^7 can be calculated.

For the candidate substances methyl 5-methylfurfuryl disulfide [FL-no: 13.144] and 2-furfuryl 3-oxo-2-butyl disulphide [FL-no: 13.185] a NOAEL for a comparable substance is not available. However, after fission of the disulphide bridge the resulting furan-containing fragment, which is more reactive than the disulphide itself, could be evaluated by comparison with the toxicity of furfuryl mercaptan [FL-no: 13.026] from subgroup IIb. The NOAEL of furfuryl mercaptan in a multiple dose level 91-day oral gavage study with rats was 3 mg/kg bw per day (Phillips et al., 1977). When the NOAEL for furfuryl mercaptan is compared with the estimated daily *per capita* intakes based on the MSDI approach expressed in µg/kg bw per day for methyl 5-methylfurfuryl disulfide [FL-no: 13.144] and 2-furfuryl 3-oxo-2-butyl disulphide [FL-no: 13.185], adequate margins of safety of 75×10^6 and 16×10^6 , respectively, can be calculated.

The Panel noted that the candidate substance 3-(furfuryldithio)-2-methylfuran [FL-no: 13.178] is identical to [FL-no: 13.192]. The latter substance has been assigned the JECFA number 1524 in the report of the 69th meeting (JECFA, 2009a). For this substance, in the JECFA evaluation, an MSDI for Europe of 0.24 µg *per capita* per day was given. This figure, which is higher and more recent than the exposure estimate in the previous version of this FGE (0.0012 µg *per capita* per day), will be used in the current revision of this FGE. The candidate substance 3-(furfuryldithio)-2-methylfuran [FL-no: 13.178] is structurally related to the supporting substance bis(2-methyl-3-furyl) disulfide [FL-no: 13.016] which has been tested in two single-dose-level 90-day dietary studies with rats at 5 mg/kg bw per day and 0.45 mg/kg bw per day, respectively (Oser, 1970a; Morgareidge and Oser, 1970a). Treatment-related effects were seen at the intake level of 5.0 mg/kg bw per day, but the intake level of 0.45 mg/kg bw per day was determined to be a NOAEL. The disulphide bridge fission products are related to [FL-no: 13.026] (of subgroup IIb), for which a NOAEL of 3 mg/kg bw per day has been derived. When the estimated daily *per capita* intake based on the MSDI approach expressed in µg/kg bw per day of 3-(furfuryldithio)-2-methylfuran [FL-no: 13.178] is compared to this NOAEL an adequate margins of safety of 7.5×10^5 can be calculated for [FL-no: 13.178].

Alternatively, the two fission products may be considered separately. These fission products are [FL no: 13.055] and [FL-no: 13.026], for which NOAELs of 5 mg/kg bw per day and 3 mg/kg bw per day, respectively, have been derived (Oser, 1970b; Phillips et al., 1977). Exposure to [FL-no: 13.178] at the level of its MSDI would correspond to exposures to [FL-no: 13.026] and [FL-no: 13.055] of 0.12 µg per person per day for both fragments. Comparison of these exposure estimates to the NOAELs for these two fragments provides adequate margins of safety of 1.5×10^6 and 2.5×10^6 for [FL-no: 13.026] and [FL-no: 13.055], respectively.

Subgroup IId polysulphide [FL-no: 13.146]:

The one candidate flavouring substance in this subgroup methyl furfuryl trisulphide [FL-no: 13.146] is a trisulphide which may be anticipated to release perthiols upon metabolism. Similar reactive products may be anticipated for bis-(2-methyl-3-furyl)tetrasulphide [FL-no: 13.017] for which a NOAEL of 0.56 mg/kg bw per day in a 90-day study has been derived (Morgareidge and Oser, 1970b). Comparison of this NOAEL with the estimated daily *per capita* intake of methyl furfuryl trisulphide [FL-no: 13.146] based on the MSDI approach expressed in µg/kg bw per day of 0.0024 µg provides an adequate margin of safety of 14×10^6 .

Summary:

For the ten, seven, two, four and one substances in subgroups Ia [FL-nos: 13.011, 13.102, 13.122, 13.127, 13.129, 13.130, 13.132, 13.133, 13.136 and 13.139], IIa [FL-nos: 13.114, 13.124, 13.135, 13.141, 13.143, 13.145 and 13.199], IIb [FL-no: 13.108 and 13.149], IIc [FL-nos: 13.113, 13.144, 13.178 and 13.185] and IId [FL-no: 13.146], respectively, which have been evaluated through the Procedure, it can be concluded at step B4 of the Procedure that these 24 candidate substances do not pose a safety concern when used as flavouring substances at the estimated levels of intake based on the MSDI approach

6.4. EFSA Considerations

For seven of the 28 flavouring substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.116 and 13.190] in FGE.67rev2, the classification according to Cramer et al., 1977 was revised from structural class II to III. These revisions are due to the question of natural occurrence for the substances involved and were consistent with FGE.13Rev2 and FGE.65Rev1. The Panel notes that for the substances involved, this will not affect the final conclusions.

The Panel agrees with the JECFA (JECFA, 2009a) for 17 of the 28 substances [FL-nos: 13.045, 13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 13.148 and 13.163] in the group of furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, sulphides, disulphides and ethers that these substances cannot be evaluated through the Procedure, based on concerns with respect to genotoxicity.

The Panel also agrees with the conclusion reached by the JECFA at its 55th meeting (JECFA, 2001) that substance [FL-no: 13.031] can be evaluated using the Procedure, and that this substance poses no safety concern when used as a flavouring substance.

Contrary to the JECFA (JECFA, 2009a) and in line with the decisions taken in previous FGEs (FGE.13.Rev2, FGE.66Rev1, FGE.67; (EFSA CEF Panel, 2011c; EFSA CEF Panel, 2011b; EFSA CEF Panel, 2010b), the Panel considers that the remaining 10 substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.047, 13.058, 13.074, 13.116 and 13.190] can be evaluated using the Procedure.

Step 1

The 10 substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.047, 13.058, 13.074, 13.116, and 13.190] have been allocated to structural class III according to the Cramer et al. decision tree.

Step 2

In line with the previous evaluations in FGE.13Rev2 (EFSA CEF Panel, 2011c), FGE.66Rev1 (EFSA CEF Panel, 2011b) and FGE.65Rev1 (EFSA CEF Panel, 2015), none of the 10 substances can be anticipated to be metabolised to innocuous products. Therefore all 10 substances should be evaluated through the B-side of the Procedure.

Step B3

At step B3 of the Procedure, all 10 substances have exposure estimates less than the thresholds for their respective classes, and therefore these substances should proceed to step B4 of the Procedure.

Step B4

Subgroup I

2,5-Dimethyl-3-thioacetoxymethoxyfuran [FL-no: 13.116]

At step B4 of the Procedure the exposure estimate of 3 µg *per capita* per day for [FL-no: 13.116] can be compared to the NOAEL of 0.73 mg/kg bw per day for the supporting substance 2,5-dimethyl-3-(isopentylthio)furan [FL-no: 13.041] (FGE.65Rev1 (EFSA CEF Panel, 2015) as determined in a 90-day study reported by Morgareidge et al. (Morgareidge et al., 1974) and Cox et al., (Cox et al., 1974). An adequate margin of safety of 14.6×10^3 can be calculated.

3-((2-Methyl-3-furyl)thio)-2-butanone [FL-no: 13.190]

At step B4 of the Procedure the exposure estimate of 0.012 µg *per capita* per day for [FL-no: 13.190] can be compared to the NOAEL of 3.76 mg/kg bw per day for the supporting substance 3-((2-methyl-3-furyl)thio)heptan-4-one [FL-no: 13.077] (FGE.65Rev1 (EFSA CEF Panel, 2015) as determined in a 90-day study reported by Gallo et al. (Gallo et al., 1976). An adequate margin of safety of 1.9×10^7 can be calculated.

Subgroup II

Phenethyl 2-furoate [FL-no: 13.006]

After hydrolysis this substance will yield 2-furoic acid [FL no: 13.019] and phenethyl alcohol [FL no: 02.019]. At an exposure at the level of the MSDI (0.012 µg *per capita* per day), the respective amounts of 2-furoic acid and phenethyl alcohol would amount to 0.006 µg per person per day and 0.007 µg per person per day, respectively. In FGE.13Rev1 2-furoic acid has been evaluated by comparison with the ADI of 0.5 mg/kg bw for the related substance 2-furfural (EFSA, 2004). Phenethyl alcohol was considered of no safety concern at step A3 of the Procedure by the Panel in FGE.53. Based on these considerations, it is concluded that at the estimated level of exposure, based on the MSDI approach, phenethyl 2-furoate [FL-no: 13.006] is of no safety concern.

Subgroup III

Isopentyl 4-(2-furan)butyrate [FL-no: 13.021], Ethyl 3-(2-furyl)propionate [FL-no: 13.022], Isopentyl 3-(2-furan)propionate [FL-no: 13.023] and Isobutyl 3-(2-furyl)propionate [FL-no: 13.024]

At step B4 of the Procedure for substance [FL-no: 13.024] a NOAEL of 35 mg/kg bw per day, determined in a 90-day study, has been reported (Lough et al., 1985). When at step B4 the NOAEL for this substance is compared to its exposure estimate of 0.12 µg *per capita* per day based on the MSDI approach, an adequate margin of safety of 18×10^6 can be calculated. The same NOAEL can also be used to evaluate [FL-nos: 13.021, 13.022 and 13.023], for which exposure estimates of 0.24, 0.012 and 0.24 µg *per capita* per day were calculated. Comparison of these MSDI exposure estimates with the NOAEL for [FL-no: 13.024] provides adequate margins of safety of 8.9×10^6 , 1.8×10^8 and 8.9×10^6 for [FL-nos: 13.021, 13.022 and 13.023], respectively.

Propyl 3-(2-furyl)acrylate [FL-no: 13.047]

This substance can be anticipated to be hydrolysed into propanol and 2-furanacrylic acid. The latter fragment should be further considered. At an exposure at the level of the MSDI (2.2 µg *per capita* per day) for [FL no: 13.047], the amount of 2-furanacrylic acid released would amount to 1.7 µg per person per day. In FGE.13Rev1 2-furanacrylic acid has been evaluated by comparison with the ADI of 0.5 mg/kg bw for the related substance 2-furfural (EFSA, 2004). It may be concluded that at the estimated level of exposure, based on the MSDI approach, propyl 3-(2-furyl)acrylate [FL-no: 13.047] is of no safety concern.

3-(5-Methyl-2-furyl) butanal [FL-no: 13.058]

For [FL-no: 13.058] a NOAEL of 5.9 mg/kg bw per day was derived, based on a 90-day study with dietary exposure (Kappeler, 2013b). When at step B4 the NOAEL for this substance is compared to its exposure estimate of 0.0012 µg *per capita* per day based on the MSDI approach, an adequate margin of safety of 3×10^8 can be calculated.

*Subgroup V-B**2,3-Dimethylbenzofuran [FL-no: 13.074]*

At step B4 of the Procedure for substance [FL-no: 13.074] a NOAEL of 0.6 mg/kg bw per day, determined in a 90-day study has been reported (Long et al. (Long, 1977)). When at step B4 the NOAEL for this substance is compared to its exposure estimate of 0.52 µg *per capita* per day based on the MSDI approach, an adequate margin of safety of 69×10^3 can be calculated.

CONCLUSION

The present revision of FGE.67, FGE.67Rev2, which has been made due to new toxicity data provided for 3-(5-methyl-2-furyl) butanal, deals with 28 substances. Twenty-seven candidate substances considered in this FGE were previously considered by the JECFA in a group of 40 furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, sulphides, disulphides and ethers. One of these 40 substances [FL-no: 13.192] appeared to be a synonym of substance [FL-no: 13.178] which has already been evaluated in FGE.13Rev2. Therefore this substance [FL-no: 13.192] will not be further considered in this FGE and should be removed from the Register. Another substance [FL-no: 13.176] has been evaluated in FGE.99 rather than FGE.67, because of better structural similarity with candidate substances in FGE.99. Furthermore, one candidate substance [FL-no: 13.031] from FGE.66Rev1 has been included in this revision of FGE.67, because this substance has better structural similarity to a candidate flavouring substance [FL-no: 13.074] in FGE.67 than to the other candidate flavouring substances in FGE.66Rev1.

Thirteen of the 40 substances considered by JECFA are α,β -unsaturated carbonyls, which have been evaluated by EFSA in FGE.19 context with respect to a concern for a possible genotoxic potential. This concern for genotoxicity could not be alleviated for six substances [FL-nos: 13.034, 13.043, 13.044, 13.046, 13.137 and 13.150], corresponding to FGE.19 subgroup 4.6. These six substances were therefore not further considered in this FGE.

For five substances the Flavourings Industry has announced that they are no longer supported for use as flavouring substances in Europe [former FL-no: 13.029, 13.030, 13.092, 13.107 and 13.191]. Therefore, these substances have been withdrawn from the safety evaluation in the present FGE.

The 28 candidate substances considered in this FGE [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.045, 13.047, 13.052, 13.054, 13.058, 13.059, 13.061, 13.066, 13.069, 13.070, 13.074, 13.083, 13.101, 13.103, 13.105, 13.106, 13.116, 13.123, 13.138, 13.148, 13.163 and 13.190] have been allocated to various subgroups, based on their chemical structures. These substances are structurally related to the group of 27 furfuryl and furan derivatives evaluated by EFSA in FGE.13Rev2. Part of the substances is also structurally related to a group of 33 sulphur-substituted furan derivatives used as flavouring agents, evaluated by EFSA in FGE.65Rev1 and another part is structurally related to 14 furfuryl derivatives evaluated in FGE.66Rev1.

For five alkyl-substituted furans [FL-nos: 13.059, 13.069, 13.103, 13.106 and 13.148] and for three furfuryl ethers [FL-nos: 13.052, 13.061 and 13.123] a concern for genotoxicity was identified. For seven α,β -unsaturated substances [FL-nos: 13.054, 13.066, 13.070, 13.083, 13.101, 13.105 and 13.163], corresponding to FGE.19 subgroup 4.5 the concern for genotoxicity with respect to this α,β -unsaturation could be ruled out based on additional evaluation of their chemical structures. However, based on available genotoxicity data, a concern for genotoxicity was still identified, which was also relevant for two other alkyl substituted furans [FL-nos: 13.045 and 13.138].

Thus, the Panel agrees with JECFA for 17 of the 28 substances [FL-nos: 13.045, 13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 13.148 and 13.163] that these substances cannot be evaluated through the procedure, based on concerns with respect to genotoxicity.

On the basis of the new data on toxicity for 3-(5-methyl-2-furyl) butanal [FL-no: 13.058] an appropriate NOAEL of 5.9mg/kg bw per day was derived, supporting the evaluation of this candidate substance.

In line with the decisions taken in previous FGEs (FGE.13Rev2, FGE.65Rev1 and FGE.66Rev1), the Panel considers that 11 substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 13.058, 13.074, 13.116 and 13.190] can be evaluated using the Procedure. It was concluded for all 11 substances, that they would be of no safety concern at their estimated intake levels based on the MSDI approach.

In order to determine whether the conclusion for the evaluated substances can be applied to the materials of commerce, it is necessary to consider the available specifications. Adequate specifications including complete purity criteria and identity are available for all 28 substances. For 11 furan derivatives [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 13.058, 13.074, 13.116 and 13.190] the Panel concluded that the materials of commerce would be of no safety concern at estimated levels of intake as flavouring substances based on the MSDI approach.

The mTAMDI could be calculated for four of the 11 substances that were evaluated through the Procedure. For three substances [FL-nos: 13.031, 13.047 and 13.074] the mTAMDI exceeds the threshold for the corresponding structural class and therefore more reliable exposure data are required. For seven substances [FL-nos: 13.006, 13.021, 13.022, 13.023, 13.024, 13.116 and 13.190], use levels are needed in order to calculate the mTAMDI and identify those flavouring substances that need more refined exposure assessment to finalise the evaluation. On the basis of such additional data these flavouring substances should be reconsidered along the steps of the Procedure. Then, additional toxicological data might become necessary.

For 17 substances [FL-nos: 13.045, 13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 13.101, 13.103, 13.105, 13.106, 13.123, 13.138, 13.148 and 13.163] additional toxicity / genotoxicity data are required. The Panel noted further that for 7 of these 17 substances [FL-nos: 13.045, 13.052, 13.054, 13.059, 13.061, 13.069 and 13.083,], use levels have not yet been submitted.

The Panel is aware that for the substances in subgroup V-A [FL-nos: 13.052, 13.061 and 13.123] the requested information has not been submitted before the deadline as indicated in Regulation EC 872/2012. The European Commission has communicated that these three substances are now in the process leading to deletion from the Union List.

An overview of the evaluation status of the substances in the present FGE is given in Appendix B, Table 8.

DOCUMENTATION AS PROVIDED TO EFSA

1. Asquith JC, 1989. Bacterial reverse mutation assay ST 15C 89. Firmenich SA. Toxicol study no. M/AMES/18216. September 1989. Unpublished report submitted by EFFA to FLAVIS Secretariat.
2. Beevers, 2014. Furan-2(5H)-one: Combined Comet assay in the liver and a bone marrow micronucleus test in treated rats. Covance Laboratories Ltd. Study no. 8262050. 10 April 2014. Unpublished final report submitted by EFFA to FLAVIS Secretariat.
3. Bio-Research Laboratory, 1980. Ethyl-beta-furfural-alpha-thiopropionate (EFTP). Unpublished report submitted by EFFA to FLAVIS Secretariat.
4. CIVO-TNO, 2003. In vivo gene mutation by use of lambdaZ-transgenic mice with furfural. Steenwinkel, M.-J.S.T. Project no. 01044074. 1 May 2003. Unpublished report submitted to EFSA.
5. Cox GE, Bailey DE and Morgareidge K, 1974. 90-day feeding study in rats with compound 14935 (2-mercapto-3-butanol). Food and Drug Research Laboratories, Inc. Lab. no. 2107d. December 30, 1974. Unpublished report submitted by EFFA to SCF.
6. DG SANCO (Directorate General for Health and Consumer Affairs), 2012. Information from DG SANCO 07/02 2012, concerning two lists of 85 and 15 non-supported substances and one list of 30 substances for which no data have been submitted or which are duplicates. FLAVIS.2.23rev1.
7. DG SANTE (Directorate General for Health and Food safety), 2015. Information from DG SANTE concerning the status of the substances [FL-nos: 13.052, 13.061 and 13.123] in FGE.67 (http://ec.europa.eu/food/committees/regulatory/scfcach/toxic/docs/sum_20150211_en.pdf).
8. Durward R, 2007a. Furyl methyl ketone: unscheduled DNA synthesis (UDS) assay liver in vitro. Safepharm Laboratories Ltd. Project no. 1834/0005. Unpublished report submitted by EFFA to FLAVIS Secretariat.
9. Durward R, 2007b. Furyl methyl ketone: in vivo liver unscheduled DNA synthesis (UDS) assay. Safepharm Laboratories Ltd. Project no. 1834/0004. Unpublished report submitted by EFFA to FLAVIS Secretariat.
10. EFFA (European Flavour and Fragrance Association), 2005. Submission 2004/Add. 2003-3. Assessment of 40 flavouring substances of the chemical groups 14 (Annex I of 1565/2000/EC), aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids, and related esters, sulfides, disulfides and ethers containing furan substitution used as flavouring substances. 12 April 2005. Unpublished report submitted by EFFA to FLAVIS Secretariat.
11. EFFA (European Flavour and Fragrance Association), 2013. Addendum of Additional Data Relevant to the Flavouring Group Evaluation of the Chemical Group 14 (Annex I of 1565/2000/EC) Furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, sulfides, disulfides and ethers evaluated by EFSA in FGE.67Rev1. Addendum to FGE.67Rev1. 06/04/2013. FLAVIS/8.214.
12. EFFA (European Flavour Association), 2014. E-mail from EFFA to FLAVIS Secretariat, Danish Food Institute, Technical University of Denmark, dated 25 April 2014. Information on substances [FL-no: 13.031, 13.045 and 13.047] in FGE.67Rev2. FLAVIS/8.236.
13. Gallo MA, Cox GE and Babish JG, 1976. 90-Day feeding study in rats with compound 75-15963 (3-[(2-methyl-3-furyl)-thio]-4-heptanone). Food and Drug Research Laboratories, Inc. Lab. no. 2689d. December 30, 1976. Unpublished report submitted by EFFA to FLAVIS Secretariat.

14. Gudi R and Schadly EH, 1996. In vitro mammalian cytogenetic test with an independent repeat assay of furfural, final report, with cover letter dated 11/22/1996 (sanitized). Furfural. Microbiological Associates, Inc. EPA Doc 88970000074S, microfiche no. OTS0559061. November 19, 1996. Unpublished report submitted by EFA to FLAVIS Secretariat.
15. IOFI (International Organization of the Flavor Industry), 2013. Addendum of Additional Data Relevant to the Flavouring Group Evaluation of the Chemical Group 14 (Annex I of 1565/2000/EC) Consideration of 40 furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, sulphides, disulfides and ethers Evaluated by JECFA at the 65th meeting [JECFA/WHO FAS 56] and re-evaluated at the 69th meeting [JECFA/WHO FAS 60] as Evaluated by EFSA in FGE.67. Addendum to FGE.67. 30/12/2013. FLAVIS/8.230.
16. Kappeler, K.V., 2013a. A 14-day oral (dietary) toxicity study of 3-(5-methyl-2-furyl) butanal in Sprague-Dawley rats. Study number WIL-968001. WIL Research, Ashland, OH, USA. Unpublished report to the International Organization of the Flavor Industry (IOFI), Brussels, Belgium.
17. Kappeler, K.V., 2013b. A 90-day oral (dietary) toxicity study of 3-(5-methyl-2-furyl) butanal in rats. Study number WIL-968002. WIL Research, Ashland, OH, USA. Unpublished report to the International Organization of the Flavor Industry (IOFI), Brussels, Belgium.
18. Long DW, 1977. Acute oral toxicity and 3 month oral toxicity study in the rat. 2,3-Dimethylbenzofuran. Institut Francais de Recherches et Essais Biologiques. IFREB-R 770261. Unpublished report submitted by EFA to FLAVIS Secretariat.
19. Lough R, Trepanier S, Bier C, Losos G, Broxup B, Tellier P, Osborne BE and Proctor BG, 1985. A combined 28-day and 90-day toxicity study of four test articles [2-furyl methyl ketone, benzophenone, 3-(2-furyl) acrolein and isobutyl 3-(2-furyl) propionate] administered orally (in the diet) to the albino rat. Bio-Research Laboratories Ltd. Project no. 81238. January 30, 1985. Unpublished report submitted by EFA to FLAVIS Secretariat.
20. Meerts Ir IATM, 2000. Evaluation of the ability of coffee precursor to induce chromosome aberrations in cultured peripheral human lymphocytes. NOTOX B.V., Hambakenwetering 7, 5231DD's-Hertogenbosch. NOTOX project 301286. Date 18/12/2000. Unpublished report submitted by EFA to FLAVIS Secretariat.
21. Morgareidge K and Oser BL, 1970a. 90-Day feeding studies in rats with bis-(2-methyl-3-furyl)-disulfide (31001). Food and Drug Research Laboratories, Inc. Lab. no. 0028. August 24, 1970. Report submitted by EFA to FLAVIS Secretariat.
22. Morgareidge K and Oser BL, 1970b. 90-Day feeding studies in rats with bis-(2-methyl-3-furyl)-tetrasulfide (31058). Food and Drug Research Laboratories, Inc. Lab. no. 0031. August 24, 1970. Report submitted by EFA to FLAVIS Secretariat.
23. Morgareidge K, Cox GE and Bailey DE, 1974. 90-Day feeding study in rats with compound 15124 (2, 5-dimethyl-3-thioisovaleryl-furan). Food and Drug Research Laboratories, Inc. Lab. No. 2107g. December 30, 1974. Report submitted by EFA to FLAVIS Secretariat.
24. Munday R and Gellatly JB, 1973. Biological evaluation of feeding trial with DUS-5. Part 4. 13-week rat. Unilever Research Colworth/ Welwyn. NCW 73 1159. Project CW 22390. July 11, 1972. Report submitted by EFA to FLAVIS Secretariat.
25. Oser BL, 1970a. 90-Day feeding studies with bis-(2-methyl-3-furyl) disulfide in rats. Food and Drug Research Laboratories, Inc. Lab. no. 90616. January 22, 1970. Unpublished report submitted by EFA to FLAVIS Secretariat.

26. Oser BL, 1970b. 90-Day feeding studies with 2-methyl-3-furanthiol in rats. Food and Drug Research Laboratories, Inc. Lab. no. 90615. January 22, 1970. Unpublished report submitted by EFFA to FLAVIS Secretariat.
27. Verspeek-Rip CM, 2000. Evaluation of the mutagenic activity of coffee precursor in the Salmonella typhimurium reverse mutation assay and the Escherichia coli reverse mutation assay (with independent repeat). NOTOX B.V., 's-Hertogenbosch. NOTOX project 301275. 25 September, 2000. Unpublished report submitted by EFFA to FLAVIS Secretariat.
28. Verspeek-Rip CM, 2001. Micronucleus test in bone marrow cells of the mouse with coffee precursor. NOTOX B.V., 's-Hertogenbosch. NOTOX project 312143. 27 December, 2000. Unpublished report submitted by EFFA to FLAVIS Secretariat.

REFERENCES

- Aaron CS, Harbach PR, Wiser SK, Grzegorzczak CR and Smith AL, 1989. The in vitro unscheduled DNA synthesis (UDS) assay in rat primary hepatocytes: Evaluation of 2-furoic acid and 7 drug candidates. *Mutation Research* 223(2), 163-169.
- Adams TB, Lake BG, Beamad JA, Price RJ, Ford RA and Goodman JI, 1998. An investigation of the effect of furfural on the unscheduled DNA synthesis in cultured human liver slices. *Toxicologist* 42(1-S), 79.
- Adams TB, McGowen MM, Williams MC, Cohen SM, Feron VJ, Goodman JI, Marnett LJ, Munro IC, Portoghese PS, Smith RL, Waddell WJ, 2007. The FEMA GRAS assessment of aromatic substituted secondary alcohols, ketones, and related esters used as flavor ingredients. *Food Chem. Toxicol.*, 45(2), 171-201.
- Aeschbacher HU, Chappus C, Manganel M and Aeschbach R, 1981. Investigation of maillard products in bacterial mutagenicity test systems. *Progress in Food and Nutrition Science* 5, 279-294.
- Aeschbacher HU, Wolleb U, Loliger J, Spadone JC and Liardon R, 1989. Contribution of coffee aroma constituents to the mutagenicity of coffee. *Food and Chemical Toxicology* 27(4), 227-232.
- Archer MC, Bruce WR, Chan CC, Corpet DE, Medline A, Roncucci L, Stamp D and Zhang X-M, 1992. Aberrant crypt foci and microadenoma as markers for colon cancer. *Environmental Health Perspectives* 98(0), 195-197.
- Bradley MO, Taylor VL, Armstrong MJ and Galloway SM, 1987. Relationship among cytotoxicity, lysosomal breakdown, chromosome aberrations and DNA double-strand breaks. *Mutation Research* 189, 69-79.
- Bruce WR, Archer MC, Corpet DE, Medline A, Minkin S, Stamp D, Yin Y and Zhang XM, 1993. Diet, aberrant crypt foci and colorectal cancer. *Mutation Research* 290, 111-118.
- Brusick DJ, 1986. Genotoxic effects in cultured mammalian cells produced by low pH treatment conditions and increased ion concentrations. *Environmental Mutagenesis* 8, 879-886.
- Bu HZ, 2006. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. *Current Drug Metabolism*, 7(3), 231-249
- Burka LT and MR Boyd, 1985. Furans. In: Anders MW (Ed.). *Bioactivation of Foreign Compounds*. Academic Press, Orlando, pp. 243-257.
- Burka LT, Washburn KD and Irwin RD, 1991. Disposition of [¹⁴C]furan in the male F344 rat. *Journal of Toxicology and Environmental Health* 34, 245-257.
- Byrns MC, Vu CC, Neidigh JW, Abad J-L, Jones RA and Peterson LA, 2006. Detection of DNA adducts derived from the reactive metabolite of furan, cis-2-butene-1,4-dial. *Chemical Research in Toxicology* 19(3), 414-420.
- Costa M, Zhitkovich A, Harris M, Paustenbach D and Gargas M, 1997. DNA-protein cross-links produced by various chemicals in cultured human lymphoma cells. *Journal of Toxicology and Environmental Health* 50(5), 433-449.

- Cramer GM, Ford RA and Hall RL, 1978. Estimation of toxic hazard - a decision tree approach. *Food and Cosmetics Toxicology* 16(3), 255-276.
- Dahlberg J, 2004. "Genotoxiciteten av HMF: s metabolit SMF studerad med det flödescytometerbaserade mikrokärntestet in vivo", Examination work supervised by Abramsson-Zetterberg L, University of Uppsala, Uppsala, 34 pp. (as cited by Glatt and Sommer 2006).
- Dillon D, Combes R and Zeiger E, 1998. The effectiveness of *Salmonella* strains TA100, TA102 and TA104 for detecting mutagenicity of some aldehydes and peroxides. *Mutagenesis* 13(1), 19-26.
- Ding W, Petibone DM, Latendresse JR, Pearce MG, Muskhelishvili L, White GA, Chang CW, Mittelstaedt RA, Shaddock JG, McDaniel LP, Doerge DR, Morris SM, Bishop ME, Manjanatha MG, Aidoo A, Heflich RH, 2012. In vivo genotoxicity of furan in F344 rats at cancer bioassay doses. *Toxicol. Appl. Pharmacol.*, 261, 164-171.
- Duerksen-Hughes PJ, Yang J and Ozcan O, 1999. p53 induction as a genotoxic test for twenty-five chemicals undergoing in vivo carcinogenicity testing. *Environmental Health Perspectives* 107(10), 805-812.
- Durling LJK, Busk L and Hellman BE, 2009. Evaluation of the DNA damaging effect of the heat-induced food toxicant 5-hydroxymethylfurfural (HMF) in various cell lines with different activities of sulfotransferases. *Food Chem Toxicol.* 47, 880-884.
- Eder E, Hoffman C and Deininger C, 1991a. Identification and characterization of deoxyguanosine adducts of methyl vinyl ketone and ethyl vinyl ketone. Genotoxicity of the ketones in the SOS chromotest. *Chemical Research in Toxicology* 4, 50-57.
- Eder E, Deininger C and Muth D, 1991b. Genotoxicity of P-nitrocinnamaldehyde and related α,β -unsaturated carbonyl compounds in two bacterial assays. *Mutagenesis* 6(4), 261-269.
- Eder E, Deininger C, Neudecker T and Deininger D, 1992. Mutagenicity of beta-alkyl substituted acrolein congeners in the *Salmonella* thyphimurium strain TA100 and genotoxicity testing in the SOS chromotest. *Environmental and Molecular Mutagenesis* 19, 338-345.
- Eder E, Scheckenbach S, Deininger C and Hoffman C, 1993. The possible role of α,β -unsaturated carbonyl compounds in mutagenesis and carcinogenesis. *Toxicology Letters* 67, 87-103.
- Edwards A, 1999. Draft report. An in vivo unscheduled DNA synthesis assay in the mouse with furfural. Report no. 3389/1/1/99. BIBRA International, Carshalton.
- EFSA (European Food Safety Authority), 2004. Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with food on a request from the Commission related to furfural and furfural diethylacetal. *The EFSA Journal* 2004, 67, 1-27.
- EFSA (European Food Safety Authority), 2008a. Scientific Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with food related to Flavouring Group Evaluation 69: Consideration of aromatic substituted secondary alcohols, ketones and related esters evaluated by JECFA (57th meeting) structurally related to aromatic ketones from chemical group 21 evaluated by EFSA in FGE.16 (2006) (Commission Regulation (EC) No 1565/2000 of 18 July 2000). *The EFSA Journal* 2008, 869, 1-35.
- EFSA (European Food Safety Authority), 2008b. Minutes of the 26th Plenary meeting of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food, Held in Parma on 27 - 29 November 2007. [Online]. Available from: http://www.efsa.europa.eu/EFSA/Event_Meeting/afc_minutes_26thplen_en.pdf.

- EFSA (European Food Safety Authority), 2008c. Scientific Opinion. List of alpha, beta-unsaturated aldehydes and ketones representative of FGE.19 substances for genotoxicity testing - Statement of the Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF). The EFSA Journal 2008, 910, 1-7.
- EFSA (European Food Safety Authority), 2009. Scientific Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with food related to Flavouring Group Evaluation 220: α,β -Unsaturated ketones and precursors from chemical subgroup 4.4 of FGE.19: 3(2H)-Furanones (Commission Regulation (EC) No 1565/2000 of 18 July 2000). The EFSA Journal 2009, 1061, 1-23.
- EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 2010b. Scientific Opinion on Flavouring Group Evaluation 67 (FGE.67): Consideration of 40 furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, sulfides, disulfides and ethers evaluated by JECFA (65th meeting, and re-evaluated at the 69th meeting). EFSA Journal 2010;8(10):1404, 76 pp. doi:10.2903/j.efsa.2010.1404
- EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 2011a. Scientific Opinion on Flavouring Group Evaluation 220, Revision 1 (FGE.220Rev1): α,β -Unsaturated ketones and precursors from chemical subgroup 4.4 of FGE.19: 3(2H)-Furanones. EFSA Journal 2011;9(3):1841, 26 pp. doi:10.2903/j.efsa.2011.1841
- EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 2011b. Scientific Opinion on Flavouring Group Evaluation 66, Revision 1 (FGE.66Rev1): Consideration of Furfuryl Alcohol and Related Flavouring Substances Evaluated by JECFA (55th meeting). EFSA Journal 2011;9(9):2314, 44 pp. doi:10.2903/j.efsa.2011.2314
- EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 2011c. Scientific Opinion on Flavouring Group Evaluation 13, Revision 2 (FGE.13Rev2): Furfuryl and furan derivatives with and without additional side-chain substituents and heteroatoms from chemical group 14. EFSA Journal 2011;9(8):2313, 126 pp. doi:10.2903/j.efsa.2011.2313
- EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 2012a. Scientific Opinion on Flavouring Group Evaluation 222: Consideration of genotoxicity data on representatives for alpha,beta-unsaturated furyl derivatives with the α,β -unsaturation in the side chain from subgroup 4.6 of FGE.19 by EFSA. EFSA Journal 2012;10(5):2748. 18 pp. doi:10.2903/j.efsa.2012.2748
- EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 2012b; Scientific Statement on List of Representative Substances for Testing. EFSA Journal 2012;10(3):2639. 9 pp. doi:10.2903/j.efsa.2012.2639
- EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 2014. Statement of the Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) on List of alpha, beta-Unsaturated Aldehydes and Ketones representative of FGE.19 substances for Genotoxicity Testing. The EFSA Journal (2008) 910, 1-7.
- EFSA CEF Panel (EFSA Panel on Food Contact Material, Enzymes, Flavourings and Processing Aids (CEF), 2015. Scientific Opinion on Flavouring Group Evaluation 65, Revision 1 (FGE.65Rev1): Consideration of sulfur-substituted furan derivatives used as flavouring agents evaluated by JECFA (59th meeting) structurally related to a subgroup of substances within the group of 'Furfuryl and furan derivatives with and without additional side-chain substituents and heteroatoms from chemical group 14' evaluated by EFSA in FGE.13Rev2 (2011). EFSA journal 2015;13(2):4024, 44 pp. doi:10.2903/j.efsa.2015.4024

- Florin I, Rutberg L, Curvall M and Enzell CR, 1980. Screening of tobacco smoke constituents for mutagenicity using the Ames' test. *Toxicology* 18, 219-232.
- Galloway SM, Armstrong MJ, Reuben C, Colman S, Brown B, Cannon C, Bloom AD, Nakamura F, Ahmed M, Duk S, Rimpio J, Margolin BH, Resnick MA, Anderson B and Zeiger E, 1987. Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells: evaluations of 108 chemicals. *Environmental and Molecular Mutagenesis* 10(Suppl. 10), 1-175.
- Gill S, Bondy G, Lefebvre DE, Becalski A, Kavanagh M, Hou Y, Turcotte AM, Barker M, Weld M, Vavasour E and Cooke GM, 2010. Subchronic oral toxicity study of furan in fischer-344 rats. *Toxicologic Pathology* 38, 619-630.
- Gill S, Kavanagh M, Barker M, Weld M, Vavasour E, Hou Y and Cooke GM, 2011. Subchronic oral toxicity study of furan in B6C3F1 mice. *Toxicologic Pathology* 39, 787-794.
- Glatt HR and Sommer Y, 2006. Health risks by 5-hydroxymethylfurfural (HMF) and related compounds. In: *Acrylamide and Other Health Hazardous Compounds in Heat-treated Foods* (Skog K., Alexander J., eds.), Woodhead Publishing, Cambridge, 2006, 328-357.
- Glatt H, Schneider H and Liu Y, 2005. V79-hCYP2E1-hSULT1A1, a cell line for the sensitive detection of genotoxic effects induced by carbohydrate pyrolysis products and other food-borne chemicals. *Mutation Research* 580, 41-52.
- Gomez-Arroyo S and Souza VS, 1985. In vitro and occupational induction of sister-chromatid exchanges in human lymphocytes with furfuryl alcohol and furfural. *Mutation Research* 156, 233-238.
- Ichikawa M, Yamamoto K, Tanaka A, Swaminathan S, Hatcher JF, Erturk E and Bryan GT, 1986. Mutagenicity of 3,4-diphenyl-5-nitrofurans analogs in *Salmonella typhimurium*. *Carcinogenesis* 7(8), 1339-1344.
- Jansson T, Curvall M, Hedin A and Enzell C, 1986. In vitro studies of biological effects of cigarette smoke condensate. II. Induction of sister-chromatid in human lymphocytes by weakly acidic, semivolatile constituents. *Mutation Research* 169, 129-139.
- Janzowski C, Glaab V, Samimi E, Schlatter J and Eisenbrand G, 2000. 5-Hydroxymethylfurfural: assessment of mutagenicity, DNA-damaging potential and reactivity towards cellular glutathione. *Food and Chemical Toxicology* 38(9), 801-809.
- JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1995. Evaluation of certain food additives and contaminants. Forty-fourth Meeting of the Joint FAO/WHO Expert Committee on Food Additives. 14-23 February 1995. WHO Technical Report Series, no. 859. Geneva.
- JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1996. Toxicological evaluation of certain food additives. Forty-fourth Meeting of the Joint FAO/WHO Expert Committee on Food Additives and contaminants. WHO Food Additives Series: 35. IPCS, WHO, Geneva.
- JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1997. Evaluation of certain food additives and contaminants. Forty-sixth report of the Joint FAO/WHO Expert Committee on Food Additives. Geneva, 6-15 February 1996. WHO Technical Report Series, no. 868. Geneva.
- JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1999. Evaluation of certain food additives and contaminants. Forty-ninth report of the Joint FAO/WHO Expert Committee on Food Additives. Rome, 17-26 June 1997. WHO Technical Report Series, no. 884. Geneva.

- JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2001. Safety evaluation of certain food additives and contaminants. Fifty-fifth Meeting of the Joint FAO/WHO Expert Committee on Food Additives, WHO Food Additives Series: 46. IPCS, WHO, Geneva.
- JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2004. Safety evaluation of certain food additives and contaminants. Sixty-first Meeting of the Joint FAO/WHO Expert Committee on Food Additives, WHO Food Additives Series: 52. IPCS, WHO, Geneva.
- JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2005. Compendium of food additive specifications. Addendum 13. Joint FAO/WHO Expert Committee of Food Additives 65th session. Geneva, 7-16 June 2005. FAO Food and Nutrition paper 52 Add. 13.
- JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2006a. Evaluation of certain food additives. Sixty-fifth report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Technical Report Series, no. 934. Geneva, 7-16 June 2005.
- JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2006b. Sixty-seventh Meeting. Rome, 20-29 June 2006, Summary and Conclusions. Issued 7 July 2006.
- JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2009a. Safety evaluation of certain food additives and contaminants. Sixty-ninth Meeting of the Joint FAO/WHO Expert Committee on Food Additives, WHO Food Additives Series: 60. IPCS, WHO, Geneva 2009. http://whqlibdoc.who.int/publications/2009/9789241660600_eng.pdf (May 2009).
- JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2009b. Evaluation of certain food additives. Sixty-ninth report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Technical Report Series, no. 952. Rome, 17-26 June 2008. http://whqlibdoc.who.int/trs/WHO_TRS_952_eng.pdf (May 2009).
- Kerckaert GA, Isfort RJ, Carr GJ, Aardema MJ and LeBoeuf RA, 1996. A comprehensive protocol for conducting the Syrian hamster embryo cell transformation assay at pH 6.70. *Mutation Research* 356, 64-84.
- Kim SB, Hayase F and Kato H, 1987b. Desmutagenic effect of α -dicarbonyl and α -hydroxycarbonyl compounds against mutagenic heterocyclic amines. *Mutation Research* 177, 9-15.
- Kitamura S, Koga H, Tatsumi K, Yoshimura H and Horiuchi T, 1978. Relationship between biological activities and enzymatic reduction of nitrofurans derivatives. *Journal of Pharmacobiodynamics* 1, 15-21.
- Kowalski LA, Assi KP, Wee RK-H and Madden Z, 2001. In vitro prediction of carcinogenicity using a bovine papillomavirus DNA-carrying C3H/10T1/2 cell line (T1). II: Results from the testing of 100 chemicals. *Environmental and Molecular Mutagenesis* 37(3), 231-240.
- Lee H, Bian SS and Chen YL, 1994. Genotoxicity of 1,3-dithiane and 1,4-dithiane in the CHO/SCE assay and the Salmonella/microsomal test. *Mutation Research* 321, 213-218.
- Lee YC, Shlyankevich M, Jeong HK, Douglas JS and Surh YJ, 1995. Bioactivation of 5-hydroxymethyl-2-furaldehyde to an electrophilic and mutagenic allylic sulfuric acid ester. *Biochemical and Biophysical Research Communications* 209(3), 996-1002.
- Loquet C, Toussaint G and LeTalaer JY, 1981. Studies on the mutagenic constituents of apple brandy and various alcoholic beverages collected in western France, a high incidence area for oesophageal cancer. *Mutation Research* 88, 155-164.

- Majeska JB and McGregor DB, 1992. Effects of plate preparation on results in microbial mutation assays. *Environmental and Molecular Mutagenesis*. 19(3), 244-252.
- Marnett LJ, Hurd HK, Hollstein MC, Levin DE, Esterbauer H and Ames BN, 1985. Naturally-occurring carbonyl compounds are mutagens in *Salmonella* tester strain TA104. *Mutation Research* 148, 25-34.
- Matsui S, Yamamoto R and Yamada H, 1989. The *Bacillus Subtilis*/Microsome rec-assay for the detection of DNA damaging substances which may occur in chlorinated and ozonated waters. *Water Science & Technology* 21, 875-887.
- McDaniel LP, Ding W, Dobrovolsky VN, Shaddock JG Jr, Mittelstaedt RA, Doerge DR, Heflich RH, 2012. Genotoxicity of furan in Big Blue rats. *Mutat. Res.*, 742, 72-78.
- McGregor DB, McConville ML, Prentice RDM and Riach CG, 1981. Mutagenic activity of 123 compounds with known carcinogenic potential. Presented at 7th International Symposium on Chemical & Toxicological Aspects of Environmental Quality. September 7-10, London. Inveresk Research International Limited, Musselburgh.
- McGregor DB, Brown A, Cattnach P, Edwards I, McBride D and Caspary WJ, 1988. Responses of the L5178Y tk⁺/tk⁻ mouse lymphoma cell forward mutation assay II: 18 coded chemicals. *Environmental and Molecular Mutagenesis* 11, 91-118.
- McMahon RE, Cline JC and Thompson CZ, 1979. Assay of 855 test chemicals in ten tester strains using a new modification of the ames test for bacterial mutagens. *Cancer Research* 39, 682-693.
- Meintieres S and Marzin D, 2004. Apoptosis may contribute to false-positive results in the in vitro micronucleus test performed in extreme osmolality, ionic strength and PH conditions. *Mutation Research* 560, 101-118.
- Morita T, Watanabe Y, Takeda K and Okumura K, 1989. Effects of pH in the in vitro chromosomal aberration test. *Mutation Research* 225, 55-60.
- Moro S, Chipman JK, Antczak P, Turan N, Dekant W, Falciani F, Mally A, 2012. Identification and pathway mapping of furan target proteins reveal mitochondrial energy production and redox regulation as critical targets of furan toxicity. *Toxicol. Sci.*, 126, 336-352.
- Mortelmans K, Haworth S, Lawlor T, Speck W, Tainer B and Zeiger E, 1986. *Salmonella* mutagenicity tests II. Results from the testing of 270 chemicals. *Environmental and Molecular Mutagenesis* 8(Suppl. 7), 1-119.
- Moser GJ, Foley J, Burnett M, Goldsworthy TL and Maronpot R, 2009. Furan-induced dose-responderelationshipsforlivercytotoxicity, cell proliferation,andtumorigenicity(furan-induced liver tumorigenicity). *Experimental and Toxicologic Pathology* 61, 101–111.
- Muñoz ER and Barnett MB, 1999. Meiotic nondisjunction induced by furfural in *Drosophila melanogaster* females. *Environ. Molec. Mutagen.* 34(1), 61-63.
- Nakamura SI, Oda Y, Shimada T, Oki I and Sugimoto K, 1987. SOS-inducing activity of chemical carcinogens and mutagens in *Salmonella typhimurium* TA1535/pSK1002: examination with 151 chemicals. *Mutation Research* 192, 239-246.
- Neuwirth C, Mosesso P, Pepe G, Fiore M, Malfatti M, Turteltaub K, Dekant W, Mally A, 2012. Furan carcinogenicity: DNA binding and genotoxicity of furan in rats in vivo. *Mol. Nutr. Food Res.*, 56(9), 1363-1374.

- Nishi Y, Miyakawa Y and Kato K, 1989. Chromosome aberrations induced by pyrolysates of carbohydrates in Chinese hamster V79 cells. *Mutation Research* 227, 117-123.
- NTP (National Toxicology Program), 1990. NTP technical report on the toxicology and carcinogenesis studies of furfural (CAS no. 98-01-1) in F344/N rats and B6C3F1 mice (gavage studies). March 1990. NTP-TR 382. NIH Publication no. 90-2837.
- NTP (National Toxicology Program), 1999a. Toxicology and carcinogenesis studies of furfuryl alcohol (CAS no. 98-00-0) in F344/N rats and B6C3F1 mice (inhalation studies). February 1999. NTP-TR 482. NIH Publication no. 99-3972. NC.
- NTP (National Toxicology Program), 1999b. NTP report on carcinogens background for furan. March 1999. Prepared for the November 18-19, 1996, Meeting of the Report on Carcinogens Subcommittee of the Board of Scientific Counselors. Prepared by Integrated Laboratory Systems Research Triangle Park, NC.
- NTP (National Toxicology Program), 2010. National Toxicology Program. Toxicology and carcinogenesis studies of 5-(hydroxymethyl)-2-furfural (CAS No. 67-47-0) in F344/N rats and B6C3F1 mice (gavage studies). National Toxicology Program, Research Triangle, NC, USA. TR-554. NIH Publication No. 10-5895. [Online] http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/TR554.pdf
- Ochi T and Ohsawa M, 1985. Participation of active oxygen species in the induction of chromosomal aberrations by cadmium chloride in cultured Chinese hamster cells. *Mutation Research* 143, 137-142.
- Omura H, Jahan N, Shinohara K and Murakami H, 1983. Formation of mutagens by the maillard reaction. In: Waller GR and Feather MS (Eds.). *The Maillard Reaction in Foods and Nutrition*. ACS Symposium Series, 215. American Chemical Society, Washington D.C., pp. 537-563.
- Osawa T and Namiki M, 1982. Mutagen formation in the reaction of nitrite with the food components analogous to sorbic acid. *Agricultural and Biological Chemistry* 45, 2299-2304.
- Phillips JC, Gaunt IF, Hardy J, Kiss IS, Gangolli SD and Butterworth KR, 1977. Short-term toxicity of furfuryl mercaptan in rats. *Food and Cosmetics Toxicology* 15, 383-387.
- Phillips BJ, Jackson LI, Tate B, Price RJ, Adams TB, Ford RA, Goodinan JI and Lake BJ, 1997. Furfural does not induce unscheduled DNA synthesis (UDS) in the in vivo rat hepatocyte DNA repair assay. Presented 1997 Society of Toxicol. Annu. Meeting, Cincinnati Ohio.
- Posternak NM, Linder A and Vodoz CA, 1969. Summaries of toxicological data. Toxicological tests on flavouring matters. *Food and Cosmetics Toxicology* 7, 405-407.
- Ravindranath V and Boyd MR, 1985. Metabolic activation of 2-methylfuran by rat microsomal systems. *Toxicology and Applied Pharmacology* 78, 370-376.
- Ravindranath V, Burka LT and Boyd MR, 1983. Isolation and characterization of the reactive metabolites of 2-methylfuran (2-MF) and 3-methylfuran (3-MF). *Pharmacologist* 25, 171.
- Ravindranath V, Burka LT and Boyd MR, 1984. Reactive metabolites from the bioactivation of toxic methylfurans. *Science* 224, 884-886.
- Ravindranath V, McMenamin MG, Dees JH and Boyd MR, 1986. 2-Methylfuran toxicity in rats - role of metabolic activation in vivo. *Toxicology and Applied Pharmacology* 85, 78-91.

- Reynolds SH, Stowers SJ, Patterson RM, Maronpot RR, Aaronson SA and Anderson MW, 1987. Activated oncogenes in B6C3F1 mouse liver tumors: Implications for risk assessment. *Science* 237, 1309-1316.
- Rodriquez-Arnaiz R, Morales PR, Moctezuma RV and Salas RMB, 1989. Evidence for the absence of mutagenic activity of furfuryl alcohol in tests of germ cells in *Drosophila melanogaster*. *Mutation Research* 223, 309-311.
- Rodriquez-Arnaiz R, Morales PR and Zimmering S, 1992. Evaluation in *Drosophila melanogaster* of the mutagenic potential of furfural in the mei-9(a) test for chromosome loss in germ-line cells. *Mutation Research* 280, 75-80.
- Saraste A and Pulkki K, 2000. Morphologic and biochemical hallmarks of apoptosis. *Cardiovascular Res.* 45, 528-537.
- SCF (Scientific Committee for Food), 1999. Opinion on a programme for the evaluation of flavouring substances (expressed on 2 December 1999). Scientific Committee on Food. SCF/CS/FLAV/TASK/11 Final 6/12/1999. Annex I to the minutes of the 119th Plenary meeting. European Commission, Health & Consumer Protection Directorate-General.
- Scott D, Galloway SM, Marshall RR, Ishidate M, Brusick D, Ashby J and Myhr BC, 1991. Genotoxicity under extreme culture conditions. A report from ICPEMC task group 9. *Mutation Research* 257(2), 147-205.
- Seeberg AH, Mosesso P and Forster R, 1988. High-dose-level effects in mutagenicity assays utilizing mammalian cells in culture. *Mutagenesis* 3(3), 213-218.
- Severin I, Dumont C, Jondeau-Cabaton A, Graillot V and Chagnon M-C, 2010. Genotoxic activities of the food contaminant 5-hydroxymethylfurfural using different in vitro bioassays. *Toxicology Letters* 192, 189-194.
- Shane BS, Troxclair AM, McMillin DJ and Henry CB, 1988. Comparative mutagenicity of nine brands of coffee to *Salmonella typhimurium* TA100, TA102, and TA104. *Environmental and Molecular Mutagenesis* 11, 195-206.
- Shinohara K, Kim E and Omura H, 1986. Furans as the mutagens formed by amino-carbonyl reactions. In: Fujimaki M, Namiki M and Kato H, (Eds.). *Amino-Carbonyl Reactions in Food and Biological Systems*. Elsevier, New York.
- Sommer Y, Hollnagel H, Schneider H and Glatt HR, 2003. Metabolism of 5-hydroxymethyl-2-furfural (HMF) to the mutagen, 5-sulfoxymethyl-2-furfural (SMF) by individual human sulfotransferases. *Naunyn Schmiedebach's Arch. Pharmacol.* 367, Issue Supplement 1, R166.
- Soska J, Koukalova B and Ebringer L, 1981. Mutagenic activities of simple nitrofurans derivatives. I. Comparison of related compounds in the phage inductest, chloroplast-bleaching and bacterial repair and mutagenicity tests. *Mutation Research* 81(1), 21-26.
- Spalding JW, French JE, Stasiewicz S, Furedi-Machacek M, Conner F, Tice RR and Tennant RW, 2000. Responses of transgenic mouse lines p53(+/-) and Tg.AC to agents tested in conventional carcinogenicity bioassays. *Toxicol. Sci.* 53(2), 213-223.
- Stich HF, Rosin MP, San RHC, Wu CH and Powrie WD, 1981a. Intake, formation and release of mutagens by man. *Banbury Rep.* 7, 247-266.

- Stich HF, Rosin MP, Wu CH and Powrie WD, 1981b. Clastogenicity of furans found in food. *Cancer Letters* 13, 89-95.
- Subramanyam S, Sailaja D and Rathnaprabha D, 1989. Genotoxic assay of two dietary furans by some in vivo cytogenetic parameters. *Environmental and Molecular Mutagenesis* 14(15), 239.
- Sujatha PS and Subramanyam S, 1994. Clastogenicity of furfuryl alcohol in a mouse bone marrow system. *Medical Science Research* 22(4), 281-284.
- Sujatha PS, Jayanthi A and Subramanyam S, 1993. Evaluation of the clastogenic potential of 2-furyl methyl ketone in an in vivo mouse system. *Medical Science Research* 21(18), 675-678.
- Sujatha PS, 2007. Genotoxic evaluation of furfuryl alcohol and 2-furyl methyl ketone by sister chromatid exchange (SCE) analysis. *Journal of Health Science* 53(1), 124-127.
- Surh Y-J and Tannenbaum SR, 1994. Activation of the Maillard reaction product 5-(hydroxymethyl)furfural to strong mutagens via allylic sulfonation and chlorination. *Chemical Research in Toxicology* 7, 313-318.
- Surh Y-J, Liem A, Miller JA and Tannenbaum SR, 1994. 5-Sulfooxymethylfurfural as a possible ultimate mutagenic and carcinogenic metabolite of the Maillard reaction product, 5-hydroxymethylfurfural. *Carcinogenesis* 15(10), 2375-2377.
- The Good Scents Company, 2011. Information on substance [FL-no: 13.190] 3-((2-Methyl-3-furyl)thio)-2-butanone. <http://www.thegoodscentscompany.com>.
- Wang LQ and James MO, 2006. Inhibition of sulfotransferases by xenobiotics. *Current Drug Metabolism*. 7(1), 83-104
- Wild D, King MT, Gocke E and Eckhard K, 1983. Study of artificial flavouring substances for mutagenicity in the Salmonella/microsome, BASC and micronucleus tests. *Food and Chemical Toxicology* 21(6), 707-719.
- Woodruff RC, Mason JM, Valencia R and Zimmering S, 1985. Chemical mutagenesis testing in *Drosophila*. V. Results of 53 coded compounds tested for the National Toxicology Program. *Environmental Mutagenesis* 7, 677-702.
- Zajac-Kaye M and Ts'o POP, 1984. DNAase I encapsulation in liposomes can induce neoplastic transformation of Syrian hamster embryo cells in culture. *Cell* 39, 427-437.
- Zang XM, Chan CC, Stamp D, Minkin S, Archer MC and Bruce WR, 1993. Initiation and promotion of colonic aberrant crypt foci in rats by 5-hydroxymethyl-2-furaldehyde in thermolyzed sucrose. *Carcinogenesis* 14, 773-775.
- Zdzienicka M, Tudek B, Zielenska M and Szymczyk T, 1978. Mutagenic activity of furfural in *Salmonella typhimurium* TA 100. *Mutation Research* 58, 205-209.
- Zeiger E, Anderson B, Haworth S, Lawlor T and Mortelmans K, 1992. *Salmonella* mutagenicity tests: V. Results from the testing of 311 chemicals. *Environmental and Molecular Mutagenesis* 19(21), 2-141.

Appendix A. Summary of Genotoxicity and Toxicity Data

Table 3: Genotoxicity Data for 40 Furan-Substituted Substances Evaluated by the JECFA (JECFA, 2009a)

FL-no: JECFA-no:	Chemical name	End-point	Test system	Concentration/dose	Results	References
<i>In vitro</i>						
13.030 1487	2-Methylfuran	Reverse mutation	<i>S. typhimurium</i> TA98 and TA100	0.165, 0.330, 0.495 or 0.660 µmol/plate (13.5, 27.1, 40.6 or 54.2 µg/plate) ^(a)	Negative ^(b)	(Shinohara et al., 1986)
		Reverse mutation	<i>S. typhimurium</i> TA98, TA100, TA102 and TA1535	Up to 10 000 µg/plate	Negative ^(b,c,d)	(Zeiger et al., 1992)
		Reverse mutation	<i>S. typhimurium</i> TA97 and TA104	Up to 10 000 µg/plate	Equivocal ^(b,c,d)	(Zeiger et al., 1992)
		Reverse mutation	<i>S. typhimurium</i> TA98, TA100 and TA102	11 nmol/plate to 1.1 mmol/plate (0.9 - 90310 µg/plate) ^(a)	Negative ^(b)	(Aeschbacher et al., 1989)
		DNA damage	<i>B. subtilis</i> H17 (rec ⁺) and M45 (rec ⁻)	0.16, 16 or 1600 µg/disc	Negative Positive ^(b,e)	(Shinohara et al., 1986)
		Chromosomal aberration	CHO cells	0 - 150 mmol/l (0 - 12315 µg/ml) ^(a)	Positive ^(b,f)	(Stich et al., 1981b)
13.029 1488	2,5-Dimethylfuran	Reverse mutation	<i>S. typhimurium</i> TA98 and TA100	0.165, 0.330, 0.495 or 0.660 µmol/plate (13.5, 27.1, 40.6 or 54.2 µg/plate) ^(g)	Negative ^(b)	(Shinohara et al., 1986)
		Reverse mutation	<i>S. typhimurium</i> TA98 and TA100	Not specified	Negative ^(b)	(Lee et al., 1994)
		Reverse mutation	<i>S. typhimurium</i> TA97, TA98, TA100 and TA1535	Up to 3333 µg/plate	Negative ^(b,c,d)	(Zeiger et al., 1992)
		DNA damage	<i>B. subtilis</i> H17 (rec ⁺) and M45 (rec ⁻)	190, 1900 or 9500 µg/disc	Negative Positive ^(b,h)	(Shinohara et al., 1986)
		Chromosomal aberration	Chinese hamster V79 cells	1 mmol/l (96.13 µg/ml) ^(g)	Negative	(Ochi and Ohsawa, 1985)
		Chromosomal aberration	CHO cells	0 - 20 mmol/l (0 - 1923 µg/ml) ^(g)	Positive ^(b,f)	(Stich et al., 1981b)

Table 3: Genotoxicity Data for 40 Furan-Substituted Substances Evaluated by the JECFA (JECFA, 2009a)

FL-no: JECFA-no:	Chemical name	End-point	Test system	Concentration/dose	Results	References
13.148 1494	3-Methyl-2-(3-methylbut-2-enyl)-furan	Reverse mutation	<i>S. typhimurium</i> TA98, TA100, TA1535 and TA1537	3.2, 16, 80, 400 or 2000 µg/plate	Negative ^(b)	(Asquith, 1989)
13.034	3-(2-Furyl)acrolein	Reverse mutation	<i>S. typhimurium</i> TA100	Not specified	Negative ^(b,c)	(Eder et al., 1991b)
		DNA damage (SOS chromotest)	<i>E. coli</i> PQ37	Not specified	Negative ⁽ⁱ⁾	(Eder et al., 1991b)
		DNA damage (SOS chromotest)	<i>E. coli</i> PQ37	Not specified	Weakly positive ^(j)	(Eder et al., 1993)
13.054 1503	2-Furyl methyl ketone	Reverse mutation	<i>S. typhimurium</i> TA98 and TA100	0.165, 0.330, 0.495 or 0.660 µmol/plate (13.5, 27.1, 40.6 or 54.2 µg/plate) ⁽ⁱ⁾	Negative Positive ^(b,k)	(Shinohara et al., 1986)
		DNA damage	<i>E. coli</i> PQ37 (SOS chromotest)	Not specified	Slightly positive ^(j)	(Eder et al., 1993)
		DNA damage	<i>B. subtilis</i> H17 (rec ⁺) and M45 (rec ⁻)	550, 5500 or 55000 µg/disc	Negative Positive ^(b,l)	(Shinohara et al., 1986)
		Chromosomal aberration	CHO cells	0 - 112.6 mmol/l (0 - 13220 µg/ml) ^(j)	Positive ^(b,m,n)	(Stich et al., 1981b)
		UDS	Human hepatocytes	2.19, 4.38, 8.75, 17.5, 35, 70, 140 or 280 µg/ml	Negative	(Durward, 2007a)
13.044 1511	4-(2-Furyl)-3-buten-2-one	Reverse mutation	<i>S. typhimurium</i> TA98, TA100, TA1535 and TA1537	33, 100, 333, 1000, 2166 or 3333 µg/ plate	Negative ^(b,c,o)	(Mortelmans et al., 1986)
13.022 1513	Ethyl 3-(2-furyl)propanoate	Reverse mutation	<i>S. typhimurium</i> TA98, TA100, TA1535, TA1537 and TA1538	Up to 3600 µg/plate	Negative ^(b)	(Wild et al., 1983)
13.191 1526	O-Ethyl-S-(2-furylmethyl)thio-carbonate	Reverse mutation	<i>S. typhimurium</i> TA98, TA100, TA1535 and TA1537	33, 100, 333, 1000 or 3330 µg/plate	Negative ^(b,p)	(Verspeek-Rip, 2000)
		Reverse mutation	<i>E. coli</i> WP2uvrA	33, 100, 333, 1000 or 3330 µg/plate	Negative ^(b,q)	(Verspeek-Rip, 2000)

Table 3: Genotoxicity Data for 40 Furan-Substituted Substances Evaluated by the JECFA (JECFA, 2009a)

FL-no: JECFA-no:	Chemical name	End-point	Test system	Concentration/dose	Results	References
		Chromosomal aberration	Human peripheral lymphocytes	150, 300 or 350 µg/ml	Negative ^(b,r)	(Meerts, 2000)
		Chromosomal aberration	Human peripheral lymphocytes	130, 240 or 280 µg/ml	Positive ^(i,s)	(Meerts, 2000)
		Chromosomal aberration	Human peripheral lymphocytes	100, 130 or 240 µg/ml	Positive ^(i,t)	(Meerts, 2000)
		Chromosomal aberration	Human peripheral lymphocytes	150, 325 or 375 µg/ml	Negative Positive ^(r,u,v)	(Meerts, 2000)
<i>In vivo</i>						
13.030 1487	2-Methylfuran	Chromosomal aberration	Mouse bone marrow cells and spermatocytes	1000, 2000 or 4000 mg/kg (100, 200 or 400 mg/kg bw per day) ^(w)	Negative	(Subramanyam et al., 1989)
13.054 1503	2-Furyl methyl ketone	Chromosomal aberration	Mouse bone marrow	1000, 2000 or 3000 mg/l (20, 40 or 60 mg/kg bw) ^(x)	Positive ^(y,z)	(Sujatha et al., 1993)
		Chromosomal aberration	Mouse spermatocytes	1000, 2000 or 3000 mg/l (20, 40 or 60 mg/kg bw) ^(x)	Negative ^(aa)	(Sujatha et al., 1993)
		SCE	Mouse bone marrow	1000, 2000 or 3000 mg/l (20, 40 or 60 mg/kg bw) ^(x)	Positive	(Sujatha, 2007)
		UDS	Rat liver	7 or 21 mg/kg bw	Negative	(Durward, 2007b)
13.191 1526	O-Ethyl-S-(2-furylmethyl)thio-carbonate	Micronucleus induction	Mouse bone marrow	100, 250 or 500 mg/kg bw ^(bb)	Negative	(Verspeek-Rip, 2001)

CHO: Chinese hamster ovary; SCE, sister chromatid exchange; UDS, unscheduled DNA synthesis.

(a): Calculated using relative molecular mass of 2-methylfuran = 82.1.

(b): With and without metabolic activation.

(c): Preincubation method.

(d): Occasional incidences of slight to complete clearing of the background lawn at the higher concentrations.

(e): Negative at all concentrations with metabolic activation; positive without metabolic activation.

(f): Clastogenic activity decreased with metabolic activation (statistical significance of results was not specified).

(g): Calculated using relative molecular mass of 2,5-dimethylfuran = 96.13.

(h): Positive at every concentration without metabolic activation; with metabolic activation, negative at 190 µg/disc, but positive at higher concentrations.

(i): Without metabolic activation.

(j): Calculated using relative molecular mass of 2-furyl methyl ketone = 110.11.

- (k): Positive only in strain TA98 with an increase in the presence of metabolic activation.
- (l): Negative at 550 µg/disc; positive at 5500 and 55 000 µg/disc (with and without metabolic activation).
- (m): Cytotoxicity was observed at 12 398 µg/ml (112.6 mmol/l) in the presence of metabolic activation.
- (n): Clastogenic activity increased with metabolic activation (statistical significance of results was not specified).
- (o): Cytotoxicity was observed at 3333 µg/plate in all *S. typhimurium* strains and at 2166 µg/plate in *S. typhimurium* strains TA100 and TA1537.
- (p): Cytotoxicity was observed at the 3330 µg/plate level in all *S. typhimurium* strains and at 1000 µg/plate in *S. typhimurium* strains TA100 and TA1535.
- (q): Cytotoxicity was observed at 3330 µg/plate in the absence of metabolic activation.
- (r): 3-hour continuous exposure time.
- (s): 24-hour continuous exposure time.
- (t): 48-hour continuous exposure time.
- (u): With metabolic activation.
- (v): Statistically significant dose-dependent increases in chromosomal aberrations were seen at the two highest concentrations only, 325 and 375 µg/ml.
- (w): Mice received 2-methylfuran in the diet for 5 consecutive days at 24-hour intervals.
- (x): Two experimental protocols were utilised. In one experiment, animals received single oral dose administrations of the test compound. In the other experiment, the test compound was orally administered once per day at the same concentrations as in the single-dose study for 5 consecutive days with 24-h intervals between doses.
- (y): No effects observed at 20 mg/kg bw dose level and only mild, but significant ($p < 0.05$) effects seen at higher concentrations in bone marrow cells.
- (z): Chromosomal aberrations were observed in the presence of significant mitodepression.
- (aa): A single statistically significant occurrence of increased chromosomal aberrations observed 3 weeks following a single dose administration in the 60 mg/kg bw test group; statistically significant increases in polyploidy and XY univalents observed at weeks 3 and 4 at 60 mg/kg bw in multipledose-treated rats.
- (bb): Single dose administered by gavage.

Table 4: Genotoxicity Data (*in vitro*) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)

Chemical Name [FL-no:]*	Test system	Test Object	Concentration	Result	Reference	Comments
Main group I – Non-sulphur-containing Furan Derivatives						
(Furfuryl alcohol [13.019])	Ames test	<i>S. typhimurium</i> TA98, TA100, TA1535 and TA1537	294 µg/plate	Negative ^(a)	(Florin et al., 1980)	
	Ames test	<i>S. typhimurium</i> TA98, TA100, TA1535 and TA1537	10000 µg/plate	Negative ^(a)	(Mortelmans et al., 1986) (NTP, 1999a)	
	Ames test	<i>S. typhimurium</i> TA100	2500 - 12500 µg/ml	Negative ^(a)	(Stich et al., 1981a)	
	Ames test	<i>S. typhimurium</i> TA98, TA100 and TA102	198000 µg/plate	Negative ^(a)	(Aeschbacher et al., 1989)	
	Ames test	<i>S. typhimurium</i> TA98 and TA100	81 - 323 µg/plate	Negative ^(a)	(Shinohara et al., 1986)	
	Modified Ames test	<i>S. typhimurium</i> TA1535, TA100 and TA1537	200000 µg/ml	Positive ^(a)	(McGregor et al., 1981)	
	Rec assay	<i>B. subtilis</i>	2000 - 20000 µg/disk	Positive ^(a)	(Shinohara et al., 1986)	
	Sister chromatid exchange	CHO cells	245 µg/ml	Positive ^(a)	(Stich et al., 1981a)	
	Sister chromatid exchange	CHO cells	500 µg/ml	Positive/weakly positive ^(b) Negative ^(c)	(NTP, 1999a)	
	Sister chromatid exchange	Human Lymphocytes	Up to 196 µg/ml	Negative	(Jansson et al., 1986)	
	Sister chromatid exchange	Human Lymphocytes	Up to 970 µg/ml	Negative	(Gomez-Arroyo and Souza, 1985)	
	Chromosomal aberration	CHO cells	2000 µg/ml	Positive	(Stich et al., 1981a)	
	Chromosomal aberration	CHO cells	1600 µg/ml	Negative ^(a)	(NTP, 1999a)	

Table 4: Genotoxicity Data (*in vitro*) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)

Chemical Name [FL-no:]*	Test system	Test Object	Concentration	Result	Reference	Comments
	SHE test	Syrian hamster embryo cells	NR	Negative ^(c)	(Kerckaert et al., 1996)	
	Gene Conversion Assay	<i>S. cerevisiae</i> strain D7	13500 - 16000 µg/ml	Positive ^(b)	(Stich et al., 1981b)	
	Mammalian cell assay	Mouse embryo fibroblast cells (T1)	10 µg/ml	Negative ^(b)	(Kowalski et al., 2001)	
	p53 – induction assay	Mouse embryo fibroblast cells (NCTC 929)	50 µg/ml	Negative ^(b)	(Duerksen-Hughes et al., 1999)	
(Furfuryl acetate [13.128])	Ames test	<i>S. typhimurium</i> TA1535, TA98 and TA100	33 - 666 µg/plate	Positive ^(b)	(Mortelmans et al., 1986)	
(Furfural [13.018])	Ames test	<i>S. typhimurium</i> TA 1535, TA100, TA1537, TA1538, TA98	0.1 - 1000 µg/ml	Negative ^(a)	(McMahon et al., 1979)	
	Ames test	<i>S. typhimurium</i> TA100, TA98 and TA1535	Up to 3460 µg/plate 5766 µg/plate	Negative ^(a) Positive ^(b) (weak)	(Loquet et al., 1981)	
	Ames test	<i>S. typhimurium</i> TA100, TA98 and TA102	Up to 115320 µg/plate	Negative ^(a)	(Aeschbacher et al., 1989)	
	Ames test	<i>S. typhimurium</i> TA100 and TA98	15 - 63 µg/plate	Negative ^(a)	(Shinohara et al., 1986)	
	Ames test	<i>S. typhimurium</i> TA104	5 - 500 µg/plate	Positive ^(c)	(Shane et al., 1988)	
	Ames test	<i>S. typhimurium</i> TA100 and TA102	5 - 500 µg/plate	Negative ^(c)	(Shane et al., 1988)	
	Ames test	<i>S. typhimurium</i> TA104 and TA102	96 µg/plate	Negative	(Marnett et al., 1985)	
	Ames test	<i>S. typhimurium</i> TA98, TA100 and TA1535	Up to 6667 µg/plate	Negative ^(a)	(Mortelmans et al., 1986)	
	Ames test	<i>S. typhimurium</i> TA98, TA100	Up to 1000 µg	Negative ^(b)	(Osawa and Namiki, 1982)	
	Ames test	<i>S. typhimurium</i> TA98, TA100, TA1535, TA1537	33 - 6666 µg/plate	Negative ^(a) TA100 equivocal ^(b)	(NTP, 1990)	

Table 4: Genotoxicity Data (*in vitro*) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)

Chemical Name [FL-no:]*	Test system	Test Object	Concentration	Result	Reference	Comments
	Ames test	<i>S. typhimurium</i> TA100	8000 µg/plate	Positive ^(a)	(Zdzienicka et al., 1978)	
	Ames test	<i>S. typhimurium</i> TA98	8000 µg/plate	Negative ^(a)	(Zdzienicka et al., 1978)	
	Ames test	<i>S. typhimurium</i> TA100, TA102	100 - 10000 µg/plate	Negative ^(b)	(Dillon et al., 1998)	
	Ames test	<i>S. typhimurium</i> TA104	100 - 10000 µg/plate	Equivocal ^(b)	(Dillon et al., 1998)	
	Ames test	<i>S. typhimurium</i> TA102, TA104	100 - 10000 µg/plate	Negative ^(c)	(Dillon et al., 1998)	
	Ames test	<i>S. typhimurium</i> TA100	100 - 10000 µg/plate	Equivocal ^(c)	(Dillon et al., 1998)	
	Modified Ames test	<i>S. typhimurium</i> TA100	426 µg/plate	Negative	(Kim et al., 1998)	
	Modified Ames test	<i>S. typhimurium</i> TA100, TA1535 and TA1537	200000 µg/ml	Negative	(McGregor et al., 1981)	
	Modified Ames test	<i>E. coli</i> WP2 and WP2 uvrA	0.1 - 1000 µg/ml	Negative ^(a)	(McMahon et al., 1979)	
	SOS induction	<i>S. typhimurium</i> TA1535/pSK1002	1932 µg/ml	Negative ^(a)	(Nakamura et al., 1987)	
	Rec-assay	<i>B. subtilis</i> H17 and M45	Up to 1000 µg	Negative	(Osawa and Namiki, 1982)	
	Rec-assay	<i>B. subtilis</i> H17 and M45	0.6 ml	Negative ^(a)	(Matsui et al., 1989)	
	Rec-assay	<i>B. subtilis</i> strains H17 and M45	1700 - 17000 µg/disk	Positive ^(a)	(Shinohara et al., 1986)	
	Forward mutation assay	L5178Y tk+/- Mouse Lymphoma Cells	25 - 100 µg/ml 200 µg/ml	Negative ^(a) Positive ^(b)	(McGregor et al., 1988)	
	Sister chromatid exchange	CHO cells	2500 - 4000 µg/ml	Positive ^(a)	(Stich et al., 1981a)	
	Sister chromatid exchange	CHO cells	Up to 1170 µg/ml	Positive ^(a)	(NTP, 1990)	
	Sister chromatid exchange	Human Lymphocytes	Up to 0.035 mM ^(d) 0.07 - 0.14 Mm ^(d)	Negative ^(a) Positive ^(a)	(Gomez-Arroyo and Souza, 1985)	
	Chromosomal aberration	CHO cells	500 µg/ml 1000 - 2000 µg/ml	Negative Positive	(Nishi et al., 1989)	

Table 4: Genotoxicity Data (*in vitro*) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)

Chemical Name [FL-no:]*	Test system	Test Object	Concentration	Result	Reference	Comments
	Chromosomal aberration	CHO cells	Up to 40 mM (3840 mg)	Positive ^(a)	(Stich et al., 1981a)	
	Chromosomal aberration	CHO cells	3000 µg/ml	Positive	(Stich et al., 1981b)	
	Chromosomal aberration	CHO cells	375 µg/ml ^(b) 750 µg/ml ^(c)	Positive	(Gudi and Schadly, 1996)	
	Chromosomal aberration	CHO cells	Up to 1230 µg/ml	Positive ^(a)	(NTP, 1990)	
	Unscheduled DNA Synthesis	Human liver slices	0.005 - 10 mM	Negative	(Adams et al., 1998)	
	DNA-protein cross-links	EBV- human Burkitt's lymphoma cells	25 mM	Positive ^(e)	(Costa et al., 1997)	
5-Hydroxymethyl-furfuraldehyde [13.139]	Ames test	<i>S. typhimurium</i> TA98, TA100	0.2 - 1 µmol/plate	Negative	(Surh et al., 1994)	The study is considered valid Purity 99 %.
	Ames test	<i>S. typhimurium</i> TA98, TA100	0.2 - 2.0 µg/plate	Positive ^(c)	(Omura et al., 1983)	Positive dose related response in TA100 only, most potent without S9. Purity and other experimental details not reported. The validity of the study can not be evaluated.

Table 4: Genotoxicity Data (*in vitro*) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)

Chemical Name [FL-no:]*	Test system	Test Object	Concentration	Result	Reference	Comments
	Ames test	<i>S. typhimurium</i> TA98, TA100	0.17 - 0.66 μmol/plate	Positive ^(c)	(Shinohara et al., 1986)	Positive results only obtained in TA 100 with S9. Reverse dose-response relationship. Experimental details are lacking.
	Ames test	<i>S. typhimurium</i> TA104	0.1 - 0.8 mM	Negative ^(b) Positive	(Lee et al., 1995)	Positive result was obtained by inclusion of PAPS and the rat liver cytosol in the assay. The study is considered valid.
	Ames test	<i>S. typhimurium</i> TA98, TA100	1 - 50 μl/plate ^(c)	Negative ^(a)	(Aeschbacher et al., 1981)	The study is considered valid.
	Ames test	<i>S. typhimurium</i> TA100	4.44 μM/plate	Negative ^(b)	(Kim et al., 1998)	Single dose only.
	Ames test	<i>S. typhimurium</i> TA98, TA100, TA1535, TA1537	3 μmol/plate	Negative ^(a)	(Florin et al., 1980)	Spot test. The study is considered valid.
	Ames test	<i>S. typhimurium</i> TA100	10 μg/plate	Negative ^(b)	(Majeska and McGregor, 1992)	The study is considered valid.
	Ames test	<i>S. typhimurium</i> TA97, TA98, TA102, TA1535	100 - 10000 μg/plate	Negative ^(a)	(NTP, 2010)	
	Ames test	<i>S. typhimurium</i> TA100	100 - 10000 μg/plate	Weakly positive ^(b)	(NTP, 2010)	
	Ames test	<i>S. typhimurium</i> TA100 and TA98	1500 - 10000 μg/plate	Negative ^(a)	(NTP, 2010)	
	Ames test	<i>S. typhimurium</i> TA98, TA100, TA1535, TA1537	At 0.5 μg/mL up to 5000 μg/mL	Negative ^(a)	(Severin et al., 2010)	
	Reverse mutation assay	<i>E. coli</i> WP2 uvrA/pKM101	1500 - 10000 μg/plate	Negative ^(a)	(NTP, 2010)	

Table 4: Genotoxicity Data (*in vitro*) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)

Chemical Name [FL-no:]*	Test system	Test Object	Concentration	Result	Reference	Comments
	Micronucleus assay	HepG2 cells	0, 5.35, 7.87, 11.57, 17, 25, 36.6 mM	Negative ^(y)	(Severin et al., 2010)	
	SCE induction	V79-hCYP2E1-hSULT1A1 cells	19.8 - 3808 µM	Positive	(Glatt et al., 2005)	
	SCE induction	V79-Mz cells	238 - 3808 µM	Positive ^(z)	(Glatt et al., 2005)	
	<i>Umu</i> assay	<i>S. typhimurium</i> TA1535	20 mM	Positive ^(t)	(Janzowski et al., 2000)	Positive results were only obtained at high concentrations resulting in reduced cell viability and growth. The study is considered valid but interpretation of data is questionable.
	Rec assay	<i>B. subtilis</i> H 17 rec+; M 45 rec-	0.25 - 12.5 mg/disk	Positive ^(a)	(Shinohara et al., 1986)	Experimental details are lacking. The validity of the study can not be evaluated.
	Chromosomal aberration	Chinese hamster V79 cells	Up to 2000 µg/ml	Positive ¹⁰	(Nishi et al., 1989)	Weak positive response were only obtained at high concentrations. The study is considered valid.
	Comet assay	V79, Caco-2, primary human colon cells and primary rat hepatocytes	Up to 80 mM	Negative ^(b)	(Janzowski et al., 2000)	The study is considered valid but interpretation of data is questionable.
	Comet assay	HepG2 cells	0, 5.35, 7.87, 11.57, 17, 25, 36.6 mM	Positive ^(x,y)	(Severin et al., 2010)	
	Comet assay	Human Caco-2 cells	3153 - 12611 µg/mL (25 - 100 mM)	Positive ^(v)	(Durling et al., 2009)	

Table 4: Genotoxicity Data (*in vitro*) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)

Chemical Name [FL-no:]*	Test system	Test Object	Concentration	Result	Reference	Comments
	Comet assay	Human HEK293 cells	3153 - 12611 µg/mL (25 - 100 mM)	Positive ^(v)	(Durling et al., 2009)	
	Comet assay	Mouse lymphoma L5178Y cells	3153 - 12611 µg/mL (25 - 100 mM)	Positive ^(v)	(Durling et al., 2009)	
	Comet assay	Chinese hamster V-79 cells	315 - 12611 µg/mL (2.5 - 100 mM)	Positive ^(w)	(Durling et al., 2009)	
	Comet assay	Chinese hamster V-79-hP-PST cells	315 - 12611 µg/mL (2.5 - 100 mM)	Positive ^(w)	(Durling et al., 2009)	
	HPRT assay	V79 cells	Up to 140 mM	Positive ^(a,h)	(Janzowski et al., 2000)	Positive response were only obtained at high concentrations resulting in reduced cell viability and growth. The study is considered valid but interpretation of data is questionable.
	HPRT and tk assay	TK6 human lymphoblast cells	20 - 75 µg/ml	Negative	(Surh and Tannenbaum, 1994)	The study is considered valid.
(5-Methylfurfural [13.001])	Ames test	<i>S. typhimurium</i> TA1537, TA100 and TA1535	288 µg/plate	Negative ^(a)	(Florin et al., 1980)	
	Ames test	<i>S. typhimurium</i> TA98, TA100 and TA102	96100 µg/plate	Negative ^(a)	(Aeschbacher et al., 1989)	
	Ames test	<i>S. typhimurium</i> TA98 and TA100	79 - 316 µg/plate	Negative ^(a)	(Shinohara et al., 1986)	
	Rec-assay	<i>B. subtilis</i> strains H17 and M45	0.55 - 5500 µg/disk	Positive ^(a)	(Shinohara et al., 1986)	
	Sister chromatid exchange	CHO cells	2200 - 4070 µg/ml	Positive ^(a)	(Stich et al., 1981a)	
2-Furoic acid [13.136]	Ames test	<i>S. typhimurium</i> TA98, TA100	25 - 100 µg/plate	Negative ^(b)	(Ichikawa et al., 1986)	The study is considered valid.
	Ames test	<i>S. typhimurium</i> TA100		Negative	(Soska et al., 1981)	Dose not reported.

Table 4: Genotoxicity Data (*in vitro*) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)

Chemical Name [FL-no:]*	Test system	Test Object	Concentration	Result	Reference	Comments
	Ames test	<i>S. typhimurium</i> TA100	1000 µg/plate	Negative	(Kitamura et al., 1978)	The validity of the study cannot be evaluated.
	DNA repair test	<i>E. coli</i> WP21 WP2 uvrA, WP67, WP100, CM 561, CM 571, CM 611	1000 µg/disk	Negative	(Soska et al., 1981)	The study is considered valid.
	Unscheduled DNA synthesis	Primary rat hepatocytes	1000 µg/ml	Negative ^(g,i)	(Aaron et al., 1989)	Study performed in accordance with GLP. The study is considered valid.
(Methyl-2-furoate [13.002])	Ames test	<i>S. typhimurium</i> TA98, TA100	100 µg/plate	Negative ^(g)	(Ichikawa et al., 1986)	
(2-Furyl methyl ketoneAcetylfuran [13.054])	UDS	Human hepatocytes	2.19, 4.38, 8.75, 17.5, 35, 70, 140 or 280 µg/ml	Negative	(Durward, 2007a)	New study submitted to JECFA for the 69th meeting.
	Reverse mutation	<i>S. typhimurium</i> TA98 and TA100	0.165, 0.330, 0.495 or 0.660 µmol/plate (13.5, 27.1, 40.6 or 54.2 µg/plate) ^(q)	Negative/positive ^(a,r)	(Shinohara et al., 1986)	Study reported by JECFA at the 65th meeting.
	DNA damage	<i>E. coli</i> PQ37 (SOS chromotest)	Not specified	Slightly positive	(Eder et al., 1993)	Study reported by JECFA at the 65th meeting.
	DNA damage	<i>B. subtilis</i> H17 (rec ⁺) and M45 (rec ⁻)	550, 5500 or 55000 µg/disc	Negative/positive ^(a,s)	(Shinohara et al., 1986)	Study reported by JECFA at the 65th meeting.
	Chromosomal aberration	CHO cells	0 - 112.6 mmol/l (0 - 13220 µg/ml) ^(q)	Positive ^(s,t,u)	(Stich et al., 1981b)	Study reported by JECFA at the 65th meeting.

Table 4: Genotoxicity Data (*in vitro*) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)

Chemical Name [FL-no:]*	Test system	Test Object	Concentration	Result	Reference	Comments
(2-Methylfuran [13.030])	Reverse mutation	<i>S. typhimurium</i> TA98 and TA100	0.165, 0.330, 0.495 or 0.660 µmol/plate (13.5, 27.1, 40.6 or 54.2 µg/plate) ⁽ⁱ⁾	Negative ^(a)	(Shinohara et al., 1986)	Study reported by JECFA at the 65th meeting.
	Reverse mutation	<i>S. typhimurium</i> TA98, TA100, TA102 and TA1535	Up to 10 000 µg/plate	Negative ^(a,k,l)	(Zeiger et al., 1992)	Study reported by JECFA at the 65th meeting.
	Reverse mutation	<i>S. typhimurium</i> TA97 and TA104	Up to 10 000 µg/plate	Equivocal ^(a,k,l)	(Zeiger et al., 1992)	Study reported by JECFA at the 65th meeting.
	Reverse mutation	<i>S. typhimurium</i> TA98, TA100 and TA102	11 nmol/plate to 1,1 mmol/ plate (0,9 - 90 310 µg/plate) ⁽ⁱ⁾	Negative ^(a)	(Aeschbacher et al., 1989)	Study reported by JECFA at the 65th meeting.
	DNA damage	<i>B. subtilis</i> H17 (rec ⁺) and M45 (rec ⁻)	0.16, 16 or 1600 µg/disc	Negative/positive ^(a,m)	(Shinohara et al., 1986)	Study reported by JECFA at the 65th meeting.
	Chromosomal aberration	CHO cells	0 - 150 mmol/l (0 - 12315 µg/ml) ⁽ⁱ⁾	Positive ^(a,n)	(Stich et al., 1981b)	Study reported by JECFA at the 65th meeting.
(2,5-Dimethylfuran [13.029])	Reverse mutation	<i>S. typhimurium</i> TA98 and TA100	0.165, 0.330, 0.495 or 0.660 µmol/plate (13.5, 27.1, 40.6 or 54.2 µg/plate) ^(o)	Negative ^(a)	(Shinohara et al., 1986)	Study reported by JECFA at the 65th meeting.
	Reverse mutation	<i>S. typhimurium</i> TA98 and TA100	Not specified	Negative ^(a)	(Lee et al., 1994)	Study reported by JECFA at the 65th meeting.
	Reverse mutation	<i>S. typhimurium</i> TA97, TA98, TA100 and TA1535	Up to 3333 µg/plate	Negative ^(a,k,l)	(Zeiger et al., 1992)	Study reported by JECFA at the 65th meeting.
	DNA damage	<i>B. subtilis</i> H17 (rec ⁺) and M45 (rec ⁻)	190, 1900 or 9500 µg/disc	Negative/positive ^(a,p)	(Shinohara et al., 1986)	Study reported by JECFA at the 65th meeting.

Table 4: Genotoxicity Data (*in vitro*) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)

Chemical Name [FL-no:]*	Test system	Test Object	Concentration	Result	Reference	Comments
	Chromosomal aberration	Chinese hamster V79 cells	1 mmol/l (96.13 µg/ml) ^(o)	Negative	(Ochi and Ohsawa, 1985)	Study reported by JECFA at the 65th meeting.
	Chromosomal aberration	CHO cells	0 - 20 mmol/l(0 - 1923 µg/ml) ^(o)	Positive ^(a,n)	(Stich et al., 1981b)	Study reported by JECFA at the 65th meeting.

*: Substances listed in brackets are the JECFA evaluated supporting substances in FGE.13Rev2

NR: Not Reported.

(a): With and without S9 metabolic activation.

(b): Without S9 metabolic activation.

(c): With S9 metabolic activation.

(d): Concentration that was added to the culture.

(e): Significant increases in % DNA-protein cross-links occurred only when cell viability was 40 % or less (i.e. high incidence of cell death).

(f): At concentrations of 12 mmol and greater, positive results were obtained without S9 metabolic activation. The dose dependent results were noted at concentrations known to be cytotoxic.

(g): Metabolic activation not reported.

(h): Effects occurred at concentrations inhibiting cellular growth.

(i): Dose levels above 300 µg/ml were cytotoxic.

(j): Calculated using relative molecular mass of 2-methylfuran = 82.1.

(k): Preincubation method.

(l): Occasional incidences of slight to complete clearing of the background lawn at the higher concentrations.

(m): Negative at all concentrations with metabolic activation; positive without metabolic activation.

(n): Clastogenic activity decreased with metabolic activation (statistical significance of results was not specified).

(o): Calculated using relative molecular mass of 2,5-dimethylfuran = 96.13.

(p): Positive at every concentration without metabolic activation; with metabolic activation, negative at 190 µg/disc, but positive at higher concentrations.

(q): Calculated using relative molecular mass of 2-furyl methyl ketone = 110.11.

(r): Positive only in strain TA98 with an increase in the presence of metabolic activation.

(s): Negative at 550 µg/disc; positive at 5500 and 55 000 µg/disc (with and without metabolic activation).

(t): Cytotoxicity was observed at 12 398 µg/ml (112.6 mmol/l) in the presence of metabolic activation.

(u): Clastogenic activity increased with metabolic activation (statistical significance of results was not specified).

(v): Positive only at the highest concentration tested with significant decrease in cell viability.

(w): Positive at high concentration with significantly reduced cell viability.

(x): Cytotoxic at the two highest doses.

(y): 20 hours of exposure.

(z): Weakly positive but statistically significant at each concentration.

Table 5: Genotoxicity (*In Vivo*) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)

Chemical Name [FL-no:]*	Test system	Test Object	Route	Dose	Result	Reference
(Furfuryl alcohol [13.019])	Sex-linked recessive lethal test	<i>D. melanogaster</i>	Injection	Up to 6500 mg/kg	Negative	(Rodriquez-Arnaiz et al., 1989)
	Sister chromatid exchange	Adult Human Lymphocytes	Inhalation (occupational atmosphere)	32300 mg/m ³	Negative	(Gomez-Arroyo and Souza, 1985)
	Chromosomal aberration assay	Adult Human Lymphocytes	Inhalation (occupational atmosphere)	32300 mg/m ³	Negative	(Gomez-Arroyo and Souza, 1985)
	Chromosomal aberration assay	Mouse bone marrow cells	Drinking water	0.5 mg/kg 1 - 2 mg/kg	Negative Positive	(Sujatha and Subramanyam, 1994)
	Sister chromatid exchange	Mouse bone marrow cells	IP injection	300 mg/kg	Negative	(NTP, 1999a)
	Chromosomal aberration assay	Mouse bone marrow cells	IP injection	300 mg/kg	Negative	(NTP, 1999a)
	Micronucleus assay	Mouse bone marrow cells	IP injection	250 mg/kg	Negative	(NTP, 1999a)
	Mouse bioassay	Tg.AC transgenic mice	Dermal exposure	1.5 mg; 5 day/week for 20 weeks	Negative	(Spalding et al., 2000)
(Furfural [13.018])	Sex-linked recessive lethal test	<i>D. melanogaster</i>	Diet	1000 mg/kg	Negative	(Woodruff et al., 1985)
	Sex-linked recessive lethal test	<i>D. melanogaster</i>	Injection	100 mg/kg	Positive	(Woodruff et al., 1985)
	Sex-linked recessive lethal test	<i>D. melanogaster</i>	Injection	Up to 6500 mg/kg	Negative	(Rodriquez-Arnaiz et al., 1989)
	Chromosome Loss	<i>D. melanogaster</i>	Oral or injected	3750 - 5000 mg/kg. Mated with repair-proficient females	Negative	(Rodriquez-Arnaiz et al., 1992)
	Chromosome Loss	<i>D. melanogaster</i>	Oral or injected	3750 - 5000 mg/kg. Mated with repair-deficient females	Positive	(Rodriquez-Arnaiz et al., 1992)
	Reciprocal translocations	<i>D. melanogaster</i>	Injection	100 mg/kg	Negative	(Woodruff et al., 1985)
	Nondisjunction assay	<i>D. melanogaster</i> (females)	Inhalation	1.5 %	Negative ^(a)	(Muñoz and Barnett, 1999)

Table 5: Genotoxicity (*In Vivo*) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)

Chemical Name [FL-no:]*	Test system	Test Object	Route	Dose	Result	Reference
	Sister chromatid exchange	Mouse bone marrow cells	Injection	50 - 200 mg/kg	Negative	(NTP, 1990)
	Sperm head abnormalities	Mouse	Oral	4000 mg/kg daily for 5 weeks	Negative	(Subramanyam et al., 1989)
	Somatic chromosome mutations	Swiss albino mouse (bone marrow cells)		1000 - 2000 mg/kg, 4000 mg/kg for 5 days	Negative Positive	(Subramanyam et al., 1989)
	Sister chromatid exchange	Adult Human Lymphocytes	Inhalation (occupational atmosphere)	9454 mg/m ³	Negative	(Gomez-Arroyo and Souza, 1985)
	Chromosomal aberration assay	Adult Human Lymphocytes	Inhalation (occupational atmosphere)	9454 mg/m ³	Negative	(Gomez-Arroyo and Souza, 1985)
	Unscheduled DNA synthesis	Mouse	Oral	50 - 320 mg/kg	Negative	(Edwards, 1999)
	Unscheduled DNA synthesis	F344 Rat	Oral	5 - 50 mg/kg	Negative	(Phillips et al., 1997)
	Gene mutation in the <i>lacZ</i> -gene in liver	Transgenic mouse CD2F ₁ (BALB/c x DBA/2)	Oral	75 - 300 mg/kg	Negative	(CIVO-TNO, 2003)
(2-Furyl methyl ketone [13.054])	SCE ^(g)	Mouse bone marrow		1000, 2000 or 3000 mg/l (20, 40 or 60 mg/kg bw) ^(b)	Positive	(Sujatha, 2007)
	UDS ^(g)	Rat liver		7 or 21 mg/kg bw	Negative	(Durward, 2007b)
	Chromosomal aberration ^(h)	Mouse bone marrow		1000, 2000 or 3000 mg/l (20, 40 or 60 mg/kg bw) ^(b)	Positive ^(c,d)	(Sujatha et al., 1993)
	Chromosomal aberration ^(h)	Mouse spermatocytes		1000, 2000 or 3000 mg/l (20, 40 or 60 mg/kg bw) ^(b)	Negative ^(e)	(Sujatha et al., 1993)
(2-Methylfuran [13.030])	Chromosomal aberration ^(h)	Mouse bone marrow cells and spermatocytes		1000, 2000 or 4000 mg/kg (100, 200 or 400 mg/kg bw per day) ^(f)	Negative	(Subramanyam et al., 1989)

Table 5: Genotoxicity (*In Vivo*) Evaluated by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)

Chemical Name [FL-no:]*	Test system	Test Object	Route	Dose	Result	Reference
5-Hydroxymethyl- furfural [13.139]	Micronucleus assay	Mouse peripheral blood cells		47, 94, 188, 375 or 750 mg/kg bw per day	Negative	(NTP, 2010)

*: Substances listed in brackets are the JECFA evaluated supporting substances in FGE.13Rev2

- (a): Exposure to 1 % solutions did not affect the flies' behaviour and they had a 95 % survival rate. At dose concentrations of 1.3 and 1.5 % the results indicate a threshold for the induction of nondisjunction.
- (b): Two experimental protocols were utilised. In one experiment, animals received single oral dose administrations of the test compound. In the other experiment, the test compound was orally administered once per day at the same concentrations as in the single-dose study for 5 consecutive days with 24-hour intervals between doses.
- (c): No effects observed at 20 mg/kg bw dose level and only mild, but significant ($P < 0.05$) effects seen at higher concentrations in bone marrow cells.
- (d): Chromosomal aberrations were observed in the presence of significant mitodepression.
- (e): A single statistically significant occurrence of increased chromosomal aberrations observed 3 weeks following a single dose administration in the 60 mg/kg bw test group; statistically significant increases in polyploidy and XY univalents observed at weeks 3 and 4 at 60 mg/kg bw in multipledose-treated rats.
- (f): Mice received 2-methylfuran in the diet for 5 consecutive days at 24 hours intervals.
- (g): New study submitted to JECFA for the 69th meeting.
- (h): Study reported by JECFA at the 65th meeting.

Table 6: Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by JECFA (JECFA, 2001)

Chemical name FL-no/JECFA-no	End-point	Test system	Concentration	Results	Reference
Furfuryl alcohol 13.019/451	Reverse mutation	<i>S. typhimurium</i> TA98, TA100, TA1535, TA1537	294 µg/plate	Negative ^(a,b)	(Florin et al., 1980)
	Reverse mutation	<i>S. typhimurium</i> TA98, TA100, TA1535	Up to 10 000 µg/plate	Negative ^(a,b)	(Mortelmans et al., 1986)
	Reverse mutation	<i>S. typhimurium</i> TA100	2500 - 12500 µg/ml	Negative ^(a,b)	(Stich et al., 1981a)
	Reverse mutation	<i>S. typhimurium</i> TA98, TA100, TA102	Up to 198000 µg/plate	Negative ^(a,b)	(Aeschbacher et al., 1989)
	Reverse mutation	<i>S. typhimurium</i> TA98, TA100	81 - 323 µg/plate	Negative ^(a,b)	(Shinohara et al., 1986)
	Reverse mutation	k TA1535, TA100, TA1537 (modified assay)	200000 µg/ml	Positive ^(a,b)	(McGregor et al., 1981)
	DNA repair and H17 (rec ⁺)	k M45 (rec ⁻) µg/disc	2000 - 20000	Positive ^(a,b)	(Shinohara et al., 1986)
	Sister chromatid exchange	Chinese hamster ovary cells	245 µg/ml	Positive ^(a,b)	(Stich et al., 1981b)
	Sister chromatid exchange	Human lymphocytes	Up to 196 µg/ml	Negative	(Jansson et al., 1986)
	Sister chromatid exchange	Human lymphocytes	Up to 970 µg/ml	Negative	(Gomez-Arroyo and Souza, 1985)
	Chromosomal aberration	Chinese hamster ovary cells	2000 µg/ml	Positive	(Stich et al., 1981b)
	Gene conversion	<i>S. cerevisiae</i> strain D7	13500 - 16000 µg/ml	Positive ^(a)	(Stich et al., 1981a)
	Sex-linked recessive lethal mutation	<i>D. melanogaster</i>	Up to 6500 mg/kg by injection	Negative	(Rodriguez-Arnaiz et al., 1989)
	Sister chromatid exchange	Adult human lymphocytes	32300 mg/m ³ in occupational atmosphere	Negative	(Gomez-Arroyo and Souza, 1985)
	Sister chromatid exchange	Adult human lymphocytes	32300 mg/m ³ in occupational atmosphere	Negative	(Gomez-Arroyo and Souza, 1985)
	Chromosomal aberration	Mouse bone-marrow cells	0.5 mg/kg bw in drinking-water 1 - 2 mg/kg bw in drinking-water	Negative Positive	(Sujatha and Subramanyam, 1994)

Table 6: Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by JECFA (JECFA, 2001)

Chemical name FL-no/JECFA-no	End-point	Test system	Concentration	Results	Reference
Furfuryl acetate 13.128/739	Reverse mutation	<i>S. typhimurium</i> TA1535, TA98, TA100	33 - 666 µg/plate	Positive ^(a,b)	(Mortelmans et al., 1986)
Furfural 13.018/450	Reverse mutation	<i>S. typhimurium</i> TA 1535, TA100, TA1537, TA1538, TA98	0.1 - 1000 µg/ml	Negative ^(a,b)	(McMahon et al., 1979)
	Reverse mutation	<i>S. typhimurium</i> TA100, TA98, TA1535	Up to 3460 µg/plate 5766 µg/plate	Negative ^(a,b) Positive ^(a) (weakly)	(Loquet et al., 1981)
	Reverse mutation	<i>S. typhimurium</i> TA100, TA98, TA102	Up to 115 320 µg/plate	Negative ^(a,b)	(Aeschbacher et al., 1989)
	Reverse mutation	<i>S. typhimurium</i> TA100, TA98	15 - 63 µg/plate	Negative ^(a,b)	(Shinohara et al., 1986)
	Reverse mutation	<i>S. typhimurium</i> TA104	5 - 500 µg/plate	Positive ^(b)	(Shane et al., 1988)
	Reverse mutation	<i>S. typhimurium</i> TA100, TA102	5 - 500 µg/plate	Negative ^(b)	(Shane et al., 1988)
	Reverse mutation	<i>S. typhimurium</i> TA104, TA102	96 µg/plate	Negative	(Marnett et al., 1985)
	Reverse mutation	<i>S. typhimurium</i> TA98, TA100, TA1535	Up to 6667 µg/plate	Negative ^(a,b)	(Mortelmans et al., 1986)
	Reverse mutation	<i>S. typhimurium</i> TA98, TA100	Up to 1000 µg	Negative ^(a)	(Osawa and Namiki, 1982)
	Reverse mutation	<i>S. typhimurium</i> TA98, TA100, TA1535, TA1537	33 - 6666 µg/plate	Negative ^(a,b) Equivocal in TA100 ^(a)	(NTP, 1990)
	Reverse mutation	<i>S. typhimurium</i> TA100	8000 µg/plate	Positive ^(a,b)	(Zdzienicka et al., 1978)
	Reverse mutation	<i>S. typhimurium</i> TA98	8000 µg/plate	Negative ^(a,b)	(Zdzienicka et al., 1978)

Table 6: Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by JECFA (JECFA, 2001)

Chemical name FL-no/JECFA-no	End-point	Test system	Concentration	Results	Reference
	Reverse mutation	<i>S. typhimurium</i> TA100, TA102	100 - 10000 µg/plate	Negative ^(a)	(Dillon et al., 1998)
	Reverse mutation	<i>S. typhimurium</i> TA104	100 - 10000 µg/plate	Equivocal ^(a)	(Dillon et al., 1998)
	Reverse mutation	<i>S. typhimurium</i> TA102, TA104	100 - 10000 µg/plate	Negative ^(b)	(Dillon et al., 1998)
	Reverse mutation	<i>S. typhimurium</i> TA100	100 - 10000 µg/plate	Equivocal ^(b)	(Dillon et al., 1998)
	Reverse mutation	<i>S. typhimurium</i> TA100 (modified assay)	426 µg/plate	Negative ^(a,b)	(Kim et al., 1998)
	Reverse mutation	<i>S. typhimurium</i> TA100, TA1535, TA1537 (modified assay)	200000 µg/ml	Negative	(McGregor et al., 1981)
	Reverse mutation	<i>E. coli</i> WP2, WP2 uvrA (modified assay)	0.1 - 1000 µg/ml	Negative ^(a,b)	(McMahon et al., 1979)
	SOS induction	<i>S. typhimurium</i> TA1535/ pSK1002	1932 µg/ml	Negative ^(a,b)	(Nakamura et al., 1987)
	DNA repair	<i>B. subtilis</i> H17 (rec+) and M45 (rec-)	Up to 1000 µg	Negative ^(a)	(Osawa and Namiki, 1982)
	DNA repair	<i>B. subtilis</i> H17 (rec+) and M45 (rec-)	0.6 ml	Negative ^(a,b)	(Matsui et al., 1989)
	DNA repair	<i>B. subtilis</i> H17 (rec+) and M45 (rec-)	1700 - 17000 µg/disc	Positive ^(a,b)	(Shinohara et al., 1986)
	Forward mutation	L5178Y mouse lymphoma cells, Tk+/- locus	25 - 100 µg/ml 200 µg/ml	Negative ^(a) Positive ^(a)	(McGregor et al., 1988)
	Sister chromatid exchange	Chinese hamster ovary cells	2500 - 4000 µg/ml	Positive ^(a,b)	(Stich et al., 1981b)
	Sister chromatid exchange	Chinese hamster ovary cells	Up to 1170 µg/ml	Positive ^(a,b)	(NTP, 1990)
	Sister chromatid exchange	Human lymphocytes	Up to 0.035 mmol/L ^(a) 0.07 - 0.14 mmol/L ^(c)	Negative ^(a,b) Positive ^(a,b)	(Gomez-Arroyo and Souza, 1985)

Table 6: Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by JECFA (JECFA, 2001)

Chemical name FL-no/JECFA-no	End-point	Test system	Concentration	Results	Reference
	Chromosomal aberration	Chinese hamster ovary cells	500 µg/ml 1000 - 2000 µg/ml	Negative Positive	(Nishi et al., 1989)
	Chromosomal aberration	Chinese hamster ovary cells	Up to 40 mmol/L (3840 mg)	Positive ^(a,b)	(Stich et al., 1981b)
	Chromosomal aberration	Chinese hamster ovary cells	3000 µg/ml	Positive	(Stich et al., 1981a)
	Chromosomal aberration	Chinese hamster ovary cells	Up to 1230 µg/ml	Positive ^(a,b)	(NTP, 1990)
	Unscheduled DNA synthesis	Human liver slices	0.005 - 10 mmol/L	Negative	(Adams et al., 1998)
	Sex-linked recessive lethal mutation	<i>D. melanogaster</i>	1000 mg/kg of diet	Negative	(Woodruff et al., 1985)
	Sex-linked recessive lethal mutation	<i>D. melanogaster</i>	100 mg/kg by injection	Positive	(Woodruff et al., 1985)
	Sex-linked recessive lethal mutation	<i>D. melanogaster</i>	Up to 6500 mg/kg by injection	Negative	(Rodriquez-Arnaiz et al., 1989)
	Chromosomal loss	<i>D. melanogaster</i>	Oral or injected dose of 3750 - 5000 mg/kg of diet. Mated with repair-proficient females	Negative	(Rodriquez-Arnaiz et al., 1992)
	Chromosomal loss	<i>D. melanogaster</i>	Oral or injected dose of 3750 - 5000 mg/kg of diet. Mated with repair-deficient females	Positive	(Rodriquez-Arnaiz et al., 1992)
	Reciprocal trans- location	<i>D. melanogaster</i>	100 mg/kg by injection	Negative	(Woodruff et al., 1985)
	Sister chromatid exchange	Mouse bone-marrow cells	50 - 200 mg/kg bw by injection	Negative	(NTP, 1990)
	Spermhead abnormalities	Mice	4000 mg/kg of diet daily for 5 weeks	Negative	(Subramanyam et al., 1989)
	Somatic chromo-somal mutation	Swiss albino mouse bone-marrow cells	1000 - 2000 mg/kg of diet 4000 mg/kg bw for 5 days	Negative Positive	(Subramanyam et al., 1989)

Table 6: Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by JECFA (JECFA, 2001)

Chemical name FL-no/JECFA-no	End-point	Test system	Concentration	Results	Reference
5-Methylfurfural 13.001/745	Sister chromatid exchange	Adult human lymphocytes	9454 mg/m ³ in occupational atmosphere	Negative	(Gomez-Arroyo and Souza, 1985)
	Chromosomal aberration	Adult human lymphocytes	9454 mg/m ³ in occupational atmosphere	Negative	(Gomez-Arroyo and Souza, 1985)
	Unscheduled DNA synthesis	B6C3F1 mice	50 - 320 mg/kg bw orally	Negative	(Edwards, 1999)
	Unscheduled DNA synthesis	Fischer 344 rats	5 - 50 mg/kg bw orally	Negative	(Phillips et al., 1997)
	Reverse mutation	<i>S. typhimurium</i> TA1537, TA100, TA1535	288 µg/plate	Negative ^(a,b)	(Florin et al., 1980)
	Reverse mutation	<i>S. typhimurium</i> TA98, TA100, TA102	96100 µg/plate	Negative ^(a,b)	(Aeschbacher et al., 1989)
	Reverse mutation	<i>S. typhimurium</i> TA98, TA100	79 - 316 µg/plate	Negative ^(a,b)	(Shinohara et al., 1986)
	DNA repair	<i>B. subtilis</i> H17 (rec ⁺) and M45 (rec ⁻)	0.55 - 5500 µg/disk	Positive ^(a,b)	(Shinohara et al., 1986)
	Sister chromatid exchange	Chinese hamster ovary cells	2200 - 4070 µg/ml	Positive ^(a,b)	(Stich et al., 1981b)

(a): Without metabolic activation from a 9000 g supernatant of rat liver.

(b): With metabolic activation

(c): Concentration added to culture

Table 7: Summary of Toxicity Data Evaluated by the Panel in FGE.67Rev2

Chemical Name [FL-no:]	Species; Sex No/group	Route	Doses (mg/kg bw per day)	Duration (days)	NOAEL (mg/kg bw per day)	Reference	Comments
3-(5-methyl-2-furyl) butanal [FL-no: 13.058]	Rat; M & F 3/sex perdose level	Diet	0 (dietary control), 50, 300 and 750	14		Kappeler, 2013a	Study not suitable for derivation of a NOAEL
	Rat; M & F 10/sex perdose level		0, 5.9, 30 and 150	98	5.9	Kappeler, 2013b	

Appendix B. Overview of Evaluation Status

The conclusions for the substances in the various subgroups are summarized in the table below. In addition, in this table it is indicated for which substances additional data (EU production volumes, genotoxicity data, 90-day toxicity study) is required, and the substance with which additional toxicity testing should be performed (EFSA, 2012b, 2014).

Table 8: Overview of Evaluation Status

Subgroup	FL-no of candidates in the present FGE	genotoxicity status	NOAEL required?
I	13.116 13.190	Not of concern	NOAELs available
II	13.006	Not of concern	NOAEL available
III	13.021 13.022 13.023 13.024 13.047 13.058	Not of concern	NOAELs available
IV	13.059 13.069 13.103 13.106 13.148	Awaiting evaluation of 2-pentylfuran	NOAEL required for 2-pentylfuran [FL-no: 13.059]
V-A	13.052 13.061 13.123	Awaiting submission of further data	NOAEL required for [FL-no: 13.052]
V-B	13.031 13.074	Not of concern	NOAELs available
VI-A	13.034 13.043 13.044 13.046 13.137 13.150	Under consideration in FGE.222	No NOAELs available. NOAEL required for [FL-no: 13.034 and 13.044]
VI-B	13.045 13.054 13.066 13.070 13.083 13.101 13.105 13.138 13.163	Further data required	NOAEL required for 13.054; NB: No EU production volumes available for [FL-no: 13.066 and 13.070]

Appendix C. Summary of Safety Evaluations

Table 9: Summary of Safety Evaluation of Furan derivatives evaluated by the JECFA (JECFA, 2001; JECFA, 2009a)








FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI (µg/capita per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound (d or e)	EFSA conclusion on the named compound (Procedure steps, intake estimates, NOAEL, genotoxicity)	EFSA conclusion on the material of commerce
13.029 1488	2,5-Dimethylfuran		0.012 0.02	Class II No evaluation		Genotoxicity data required. No longer supported by industry.	
13.030 1487	2-Methylfuran		0.21 0.3	Class II No evaluation		Genotoxicity data required. No longer supported by industry.	
13.045 1508	1-(2-Furyl)-propan-2-one		0.037 0.02	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	
13.052 1520	Furfuryl methyl ether		0.024 0.09	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	
13.054 1503	2-Acetylfuran		46 13	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	
13.059 1491	2-Pentylfuran		0.18 0.03	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	
13.061 1522	Difurfuryl ether		0.12 0.09	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	

Table 9: Summary of Safety Evaluation of Furan derivatives evaluated by the JECFA (JECFA, 2001; JECFA, 2009a)








FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI (µg/capita per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound (d or e)	EFSA conclusion on the named compound (Procedure steps, intake estimates, NOAEL, genotoxicity)	EFSA conclusion on the material of commerce
13.069 1492	2-Heptylfuran		0.012 0.9	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	
13.083 1504	2-Acetyl-5-methylfuran		0.37 0.1	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	
13.092 1489	2-Ethylfuran		0.061 0.5	Class II No evaluation		Genotoxicity data required. No longer supported by industry.	
13.101 1505	2-Acetyl-3,5-dimethylfuran		0.0012 0.002	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	
13.103 1490	2-Butylfuran		0.24 0.5	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	
13.105 1507	2-Butyrylfuran		0.12 0.2	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	
13.106 1493	2-Decylfuran		0.0012 0.002	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	

Table 9: Summary of Safety Evaluation of Furan derivatives evaluated by the JECFA (JECFA, 2001; JECFA, 2009a)








FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI ($\mu\text{g/capita}$ per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound (d or e)	EFSA conclusion on the named compound (Procedure steps, intake estimates, NOAEL, genotoxicity)	EFSA conclusion on the material of commerce
13.123 1521	Ethyl furfuryl ether		0.0012 0.002	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	
13.138 1510	1-(2-Furyl)butan-3-one		2.2 3	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	
13.148 1494	3-Methyl-2(3-methylbut-2-enyl)furan		0.12 0.2	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	Register name to be changed to: 3-Methyl-2-(3-methylbut-2-enyl)furan.
13.163 1509	2-Pentanoylfuran		0.061 0.09	Class II No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists	
13.031 751	2-Benzofurancarboxaldehyde		0.012 0.01	Class III B3: Intake below threshold B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.047 1518	Propyl 3-(2-furyl)acrylate		2.2 1	Class III No evaluation		No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.058 1500	3-(5-Methyl-2-furyl) butanal		0.0012 0.5	Class III No evaluation		No safety concern at the estimated level of intake based on the MSDI approach..	No safety concern at the estimated level of intake based on the MSDI approach.

Table 9: Summary of Safety Evaluation of Furan derivatives evaluated by the JECFA (JECFA, 2001; JECFA, 2009a)






FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI (µg/capita per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound (d or e)	EFSA conclusion on the named compound (Procedure steps, intake estimates, NOAEL, genotoxicity)	EFSA conclusion on the material of commerce
13.066 1506	3-Acetyl-2,5- dimethylfuran		ND 2	Class III No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists. No EU production volume available.	
13.070 1512	2-Hexanoylfuran		ND 0.9	Class III No evaluation		Genotoxicity data required. Toxicity data required. No adequate NOAEL exists. No EU production volume available.	
13.107 1496	2,4-Difurfurylfuran		0.0012 0.002	Class III No evaluation		Genotoxicity data required. No longer supported by industry.	
13.190 1525	3-((2-Methyl-3-furyl)thio)-2-butanone		0.012 0.02	Class III No evaluation		No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach. Register name to be changed to 3-((2-Methyl-3-furyl)thio)-2-butanone. Racemate (The Good Scents Company, 2011).
13.191 1526	o-Ethyl S-(2-furylmethyl)thiocar bonate		0.61 0.9	Class III No evaluation		Genotoxicity data required. No longer supported by industry.	

Table 9: Summary of Safety Evaluation of Furan derivatives evaluated by the JECFA (JECFA, 2001; JECFA, 2009a)








FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI (µg/capita per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound (d or e)	EFSA conclusion on the named compound (Procedure steps, intake estimates, NOAEL, genotoxicity)	EFSA conclusion on the material of commerce
13.006 1517	Phenethyl 2-furoate		0.012 0.2	Class III No evaluation		No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.021 1516	Isopentyl 4-(2-furan)butyrate		0.24 0.09	Class III No evaluation		No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.022 1513	Ethyl 3-(2-furyl)propionate		0.012 0.07	Class III No evaluation		No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach. Register name to be changed to: Ethyl 3-(2-furyl)propionate
13.023 1515	Isopentyl 3-(2-furan)propionate		0.24 0.09	Class III No evaluation		No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.024 1514	Isobutyl 3-(2-furyl)propionate		0.12 24	Class III No evaluation		No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.074 1495	2,3-Dimethylbenzofuran		0.52 0.01	Class III No evaluation		No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.

Table 9: Summary of Safety Evaluation of Furan derivatives evaluated by the JECFA (JECFA, 2001; JECFA, 2009a)

FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI ($\mu\text{g/capita}$ per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound (d or e)	EFSA conclusion on the named compound (Procedure steps, intake estimates, NOAEL, genotoxicity)	EFSA conclusion on the material of commerce
13.116 1523	2,5-Dimethyl-3- thioacetoxymuran		3.0 4	Class III No evaluation		No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.

(a): EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = $\mu\text{g/capita}$ per day.

(b): Thresholds of concern: Class I = 1800 $\mu\text{g/person}$ per day, Class II = 540 $\mu\text{g/person}$ per day, Class III = 90 $\mu\text{g/person}$ per day.

(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.

(d): No safety concern based on intake calculated by the MSDI approach of the named compound.

(e): Data must be available on the substance or closely related substances to perform a safety evaluation.

ND: not determined

Table 10: Summary of Safety Evaluation of 27 Furan derivatives by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)











FL-no	EU Register name	Structural formula	MSDI ^(a) (µg/capita per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound (d or e)	Outcome on the material of commerce (f, g or h)	Evaluation remarks
13.122	Ethyl 2-furoate		0.39	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.130 759	Furfuryl butyrate		0.24	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.136	2-Furoic acid		0.013	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.139	5-Hydroxymethylfurfuraldehyde		0.39	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.145	Methyl 5-methylfurfuryl sulfide		0.0024	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.155	2-Methyl-5-propionylfuran		0.011	Class II No evaluation			a
13.125	2-Ethyl-5-methylfuran		0.011	Class II No evaluation			b
13.162	2-Octylfuran		0.011	Class II No evaluation			b
13.011	Ethyl furfuracrylate		0.12	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.102	Butyl 2-furoate		0.12	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	

Table 10: Summary of Safety Evaluation of 27 Furan derivatives by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)










FL-no	EU Register name	Structural formula	MSDI ^(a) (µg/capita per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound (d or e)	Outcome on the material of commerce (f, g or h)	Evaluation remarks
13.108	4,5-Dihydro-3-mercapto-2-methylfuran		37	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.113	2,5-Dimethyl-3-(methylthio)furan		0.0012	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.114	2,5-Dimethyl-3-(methylthio)furan		0.0024	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.124	Ethyl furfuryl sulfide		0.18	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.127	Furfuryl 2-methylbutyrate		0.73	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.129	Furfuryl but-2-enoate		0.11	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.132	Furfuryl hexanoate		0.58	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.133	Furfuryl isobutyrate		0.89	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.135	1-(2-Furfurylthio)propanone		0.61	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	

Table 10: Summary of Safety Evaluation of 27 Furan derivatives by EFSA in FGE.13Rev2 (EFSA CEF Panel, 2011c)

FL-no	EU Register name	Structural formula	MSDI ^(a) (µg/capita per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound (d or e)	Outcome on the material of commerce (f, g or h)	Evaluation remarks
13.141	Methyl (2-furfurylthio)acetate		0.011	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.143	Methyl 3-(furfurylthio)propionate		0.011	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.144	Methyl 5-methylfurfuryl disulfide		0.0024	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.146	Methyl furfuryl trisulfide		0.0024	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.149	5-Methyl-2-furanmethanethiol		0.37	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.178	3-(Furfuryldithio)-2-methylfuran		0.24	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.185	2-Furfuryl 3-oxo-2-butyl disulphide		0.011	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	
13.199	3-[(2-Methyl-3-furyl)thio]-butanal		1.2	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	f	

(a): EU MSDI: Amount added to food as flavour in (kg / year) × 10⁹ / (0.1 × population in Europe (= 375 × 10⁶) × 0.6 × 365) = µg/capita per day.

(b): Thresholds of concern: Class I = 1800 µg/person per day, Class II = 540 µg/person per day, Class III = 90 µg/person per day.

(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.

(d): No safety concern based on intake calculated by the MSDI approach of the named compound.

(e): Data must be available on the substance or closely related substances to perform a safety evaluation.

(f): No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach).

- (g): Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism.
- (h): No conclusion can be drawn due to lack of information on the purity of the material of commerce.

Table 11: Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015)






FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI ($\mu\text{g/capita per day}$)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound ^{(d),(e)}	EFSA conclusion on the named compound ^(f)	EFSA conclusion on the material of commerce
13.016 1066	bis-(2-Methyl-3-furyl) disulfide		0.27 0.7	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.026 1072	2-Furan- methanethiol		29 11	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.050 1081	Difurfuryl disulfide		3.3 0.7	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.053 1076	Methyl furfuryl sulfide		0.97 0.1	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.055 1060	2-Methylfuran-3- thiol		0.52 0.9	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	According to JECFA: Min. assay value is "95" and secondary components "Bis(2- methyl-3- furyl)disulfide". No safety concern at the estimated level of intake based on the MSDI approach.

Table 11: Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015)







FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI (µg/capita per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound ^{(d),(e)}	EFSA conclusion on the named compound ^(f)	EFSA conclusion on the material of commerce
13.064 1078	Methyl furfuryl disulfide		0.85 0.04	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.152 1061	2-Methyl-3- (methylthio)furan		1.2 0.1	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.015 1067	bis-(2,5- Dimethyl-3-furyl) disulfide		0.012 0.7	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.017 1068	bis-(2-Methyl-3- furyl) tetrasulfide		0.97 0.7	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.032 1077	Furfuryl isopropyl sulfide		0.0012 0.1	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.033 1074	S-Furfuryl acetothioate		0.43 0.05	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.

Table 11: Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015)





FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI ($\mu\text{g/capita per day}$)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound ^{(d),(e)}	EFSA conclusion on the named compound ^(f)	EFSA conclusion on the material of commerce
13.040 1071	(S)-2,5-Dimethyl- 3-thiofuroylfuran		0.012 0.01	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	JECFA evaluated (S)- 2,5-dimethyl-3- thiofuroylfuran (CASrn as in Register). No safety concern at the estimated level of intake based on the MSDI approach.
13.041 1070	2,5-Dimethyl-3- (isopentylthio)furan		0.49 0.7	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	Registername to be changed to 2,5-dimethyl- 3-(isovalerylthio)furan. No safety concern at the estimated level of intake based on the MSDI approach.
13.051 1073	S-Furfuryl thioformate		1.3 0.02	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.056 1080	Difurfuryl sulfide		0.73 0.005	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	Toxicity data are required. No adequate NOAEL exists.	The Panel is aware that data were not submitted before the deadline as indicated in Commission Implementing Regulation (EC) No 872/2012. This substance is in the process of being deleted from the Union List (DG SANCO, 2015).

Table 11: Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015)





FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI (µg/capita per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound ^{(d),(e)}	EFSA conclusion on the named compound ^(f)	EFSA conclusion on the material of commerce
13.063 1075	S-Furfuryl propanethioate		0.012 0.005	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.065 1062	2-Methyl-5- (methylthio)furan		1.1 0.02	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.071 1063	2,5- Dimethylfuran-3- thiol		0.024 0.7	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.075 1086	2,6-Dimethyl-3- ((2-methyl-3- furyl)thio)heptan- 4-one		1.8 0.7	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	According to JECFA: Min. assay value is "94" and secondary components "2,6- Dimethyl-2-[(2-methyl- 3-furyl)thio]-4- heptanone". No safety concern at the estimated level of intake based on the MSDI approach.

Table 11: Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015)





FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI (µg/capita per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound ^{(d),(e)}	EFSA conclusion on the named compound ^(f)	EFSA conclusion on the material of commerce
13.077 1085	3-((2-Methyl-3-furyl)thio)heptan-4-one		2.9 0.7	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.078 1087	4-((2-Methyl-3-furyl)thio)nonan-5-one		0.73 0.7	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.079 1064	Methyl 2-methyl-3-furyl disulfide		0.73 0.05	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	According to JECFA: Min. assay value is “97” and secondary components “up to 3% bis(2-methyl-3-furyl)disulphide”. No safety concern at the estimated level of intake based on the MSDI approach.
13.082 1065	Propyl 2-methyl-3-furyl disulfide		0.12 0.7	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	According to JECFA: Min. assay value is “97” and secondary components “up to 2% bis(2-methyl-3-furyl)disulfide and propyl disulfide”. No safety concern at the estimated level of intake based on the MSDI

Table 11: Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015)






FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI (µg/capita per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound ^{(d),(e)}	EFSA conclusion on the named compound ^(f)	EFSA conclusion on the material of commerce
13.086 1089	4,5-Dihydro-2- methyl-3- thioacetoxymethoxyfuran		0.49 0.7	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	approach. No safety concern at the estimated level of intake based on the MSDI approach.
13.093 1088	Ethyl 3-(2- furfurylthio)propi onate		0.012 0.2	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.142 1083	S-Methyl 2- furanthiocarboxyl ate		0.37 0.1	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.151 1082	2-Methyl-3,5 and 6- (furfurylthio)pyra zine	 2 or 5 or 6 -Methyl-3-(furfurylthio)pyrazine	0.37 0.7	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	According to JECFA: Min. assay value is "99" and "Mixture of isomers: 70 % 2,3-; 29 % 2,6-; trace 2,5-". No safety concern at the estimated level of intake based on the MSDI approach.
13.153 1069	2-Methyl-3-furyl thioacetate		0.012 0.07	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	According to JECFA: Min. assay value is "92" and secondary components "cis- and trans-2-Methyl-3- tetrahydrofuranthiol acetate".

Table 11: Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015)






FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI ($\mu\text{g/capita per day}$)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound ^{(d),(e)}	EFSA conclusion on the named compound ^(f)	EFSA conclusion on the material of commerce
13.160 1090	2-Methyltetrahydrofuran-3-thiol		55 0.7	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI.	According to JECFA: Min. assay value is “97” and “71 % trans and 26 % cis isomer”.
13.193 1091	2,5-Dimethyl- tetrahydro-3- furanthiol		0.012 0.9	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI.	According to JECFA: Min. assay value is “96 (mixture of 4 stereoisomers)”. Composition of stereoisomeric mixture to be specified.
13.194 1092	2,5- Dimethyltetrahydr o-3-furyl thio acetate		0.012 2	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI.	According to JECFA: Min. assay value is “90 (mixture of 4 stereoisomers)” and secondary components “2,5-Dimethyl- tetrahydrofuran-3-thiol, Dimethyltetrahydro-3- furyl dithioacetate”. Composition of stereoisomeric mixture to be specified.
13.196 1084	4-[(2- Furanyl)methyl]thi o]-2-pentanone		0.012 0.6	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.

Table 11: Summary of Safety Evaluation of 33 Sulphur Substituted Furan Derivatives Considered in FGE.65Rev1 (EFSA CEF Panel, 2015)

FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI ($\mu\text{g/capita}$ per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound ^{(d),(e)}	EFSA conclusion on the named compound ^(f)	EFSA conclusion on the material of commerce
13.197 1079	Furyl propyl disulfide		0.024 3	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.

(a): EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = $\mu\text{g/capita}$ per day.

(b): Thresholds of concern: Class I = 1800 $\mu\text{g/capita}$ per day, Class II = 540 $\mu\text{g/capita}$ per day, Class III = 90 $\mu\text{g/person}$ per day.

(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.

(d): No safety concern based on intake calculated by the MSDI approach of the named compound.

(e): Data must be available on the substance or closely related substances to perform a safety evaluation.

Table 12: Summary of Safety Evaluation of 15 JECFA-Evaluated Furfuryl Derivatives considered in FGE.66Rev1 (EFSA CEF Panel, 2011b)






FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI ($\mu\text{g/capita per day}$)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound ^(d or e)	EFSA conclusion on the named compound (Procedure steps, intake estimates, NOAEL, genotoxicity)	EFSA conclusion on the material of commerce
13.001 745	5-Methylfurfural		180 25	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.002 746	Methyl 2-furoate		30 37	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach	No safety concern at the estimated level of intake based on the MSDI approach.
13.003 747	Propyl 2-furoate		0.061 0.1	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach	No safety concern at the estimated level of intake based on the MSDI approach.
13.018 450	Furfural		440 460	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach	No safety concern at the estimated level of intake based on the MSDI approach.
13.019 451	Furfuryl alcohol		180 24	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach. Evaluated by JECFA before 2000 - No EFSA consideration required	No safety concern at the estimated level of intake based on the MSDI approach.

Table 12: Summary of Safety Evaluation of 15 JECFA-Evaluated Furfuryl Derivatives considered in FGE.66Rev1 (EFSA CEF Panel, 2011b)










FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI ($\mu\text{g/capita}$ per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound ^(d or e)	EFSA conclusion on the named compound (Procedure steps, intake estimates, NOAEL, genotoxicity)	EFSA conclusion on the material of commerce
13.057 743	Furfuryl isovalerate		0.024 1	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach	No safety concern at the estimated level of intake based on the MSDI approach.
13.062 740	Furfuryl propionate		1.7 5	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach	No safety concern at the estimated level of intake based on the MSDI approach.
13.068 741	Furfuryl valerate		0.24 14	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach	No safety concern at the estimated level of intake based on the MSDI approach.
13.128 739	Furfuryl acetate		16 21	Class II B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach	No safety concern at the estimated level of intake based on the MSDI approach.
13.005 749	Hexyl 2-furoate		0.061 0.1	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach.	No safety concern at the estimated level of intake based on the MSDI approach.
13.025 748	Pentyl 2-furoate		0.36 0.1	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach	No safety concern at the estimated level of intake based on the MSDI approach.

Table 12: Summary of Safety Evaluation of 15 JECFA-Evaluated Furfuryl Derivatives considered in FGE.66Rev1 (EFSA CEF Panel, 2011b)

FL-no JECFA- no	EU Register name	Structural formula	EU MSDI ^(a) US MSDI ($\mu\text{g/capita}$ per day)	Class ^(b) Evaluation procedure path ^(c)	Outcome on the named compound ^(d or e)	EFSA conclusion on the named compound (Procedure steps, intake estimates, NOAEL, genotoxicity)	EFSA conclusion on the material of commerce
13.038 752	2-Phenyl-3- carbethoxyfuran		0.012 2	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach	No safety concern at the estimated level of intake based on the MSDI approach.
13.067 742	Furfuryl octanoate		0.012 6	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach	No safety concern at the estimated level of intake based on the MSDI approach.
13.073 750	Octyl 2-furoate		2.2 0.1	Class III B3: Intake below threshold, B4: Adequate NOAEL exists	d	No safety concern at the estimated level of intake based on the MSDI approach	No safety concern at the estimated level of intake based on the MSDI approach.

(a): EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = $\mu\text{g/capita}$ per day.

(b): Thresholds of concern: Class I = 1800 $\mu\text{g/capita}$ per day, Class II = 540 $\mu\text{g/capita}$ per day, Class III = 90 $\mu\text{g/person}$ per day.

(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.

(d): No safety concern based on intake calculated by the MSDI approach of the named compound.

(e): Data must be available on the substance or closely related substances to perform a safety evaluation.

Appendix D. Exposure

Table 13: Normal and Maximum Use Levels (mg/kg) Available for JECFA Evaluated Substances in FGE.67Rev2

FL-no	Food Categories																	
	Normal use levels (mg/kg)																	
	Maximum use levels (mg/kg)																	
	01.0	02.0	03.0	04.1	04.2	05.0	06.0	07.0	08.0	09.0	10.0	11.0	12.0	13.0	14.1	14.2	15.0	16.0
13.031	-	-	2.5	-	-	5	-	-	-	-	-	-	5	-	-	-	-	-
	-	-	0	-	-	0	-	-	-	-	-	-	0	-	-	-	-	-
13.047	2	-	-	-	-	8.8	0.74	-	-	-	-	-	0.0044	-	0.013	-	0.015	-
	0	-	-	-	-	18	9.9	-	-	-	-	-	0	-	0.11	-	0	-
13.058	-	0.25	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	-	1.8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13.066	-	0.0094	-	-	-	1.7	-	-	-	-	-	-	-	-	0.085	-	-	-
	-	0.019	-	-	-	2.8	-	-	-	-	-	-	-	-	0.28	-	-	-
13.070	0.04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	0.08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13.074	0.43	0.5	0.17	-	-	0.017	-	-	-	-	-	-	0.43	-	0.23	0.54	-	-
	0	1.4	0	-	-	0.043	-	-	-	-	-	-	0	-	1.4	2.9	-	-
13.101	3	2	3	2	-	10	5	10	2	2	-	-	5	10	-	10	15	5
	15	10	15	10	-	50	25	50	10	10	-	-	25	50	-	50	75	25
13.103	3	2	3	2	-	4	2	5	1	1	-	-	2	3	-	4	5	2
	15	10	15	10	-	20	10	25	5	5	-	-	10	15	-	20	25	10
13.105	7	5	10	7	-	10	5	10	2	2	-	-	5	10	-	10	20	5
	35	25	50	35	-	50	25	50	10	10	-	-	25	50	-	50	100	25
13.106	3	2	3	2	-	4	2	5	1	1	-	-	2	3	-	4	5	2
	15	10	15	10	-	20	10	25	5	5	-	-	10	15	-	20	25	10
13.123	3	2	3	2	-	4	2	5	1	1	-	-	2	3	-	4	5	2
	15	10	15	10	-	20	10	25	5	5	-	-	10	15	-	20	25	10
13.138	3	2	3	2	-	4	2	5	1	1	-	-	2	3	-	4	5	2
	15	10	15	10	-	20	10	25	5	5	-	-	10	15	-	20	25	10
13.148	3	2	3	2	-	4	2	5	1	1	-	-	2	3	-	4	5	2
	15	10	15	10	-	20	10	25	5	5	-	-	10	15	-	20	25	10
13.163	3	2	3	2	-	4	2	5	1	1	-	-	2	3	-	4	5	2
	15	10	15	10	-	20	10	25	5	5	-	-	10	15	-	20	25	10

Table 14: Estimated Intakes Based on the MSDI- and the mTAMDI Approach for Substances in FGE.67Rev2

FL-no	EU Register name	MSDI – EU (µg/capita per day)	MSDI – USA (µg/capita per day)	mTAMDI (µg/person per day)	Structural class	Threshold of concern (µg/person per day)
13.045	1-(2-Furyl)-propan-2-one	0.037	0.02		Class II	540
13.052	Furfuryl methyl ether	0.024	0.09		Class II	540
13.054	2-Acetylfuran	46	13		Class II	540
13.059	2-Pentylfuran	0.18	0.03		Class II	540
13.061	Difurfuryl ether	0.12	0.09		Class II	540
13.069	2-Heptylfuran	0.012	0.9		Class II	540
13.083	2-Acetyl-5-methylfuran	0.37	0.1		Class II	540
13.101	2-Acetyl-3,5-dimethylfuran	0.0012	0.002	2200	Class II	540
13.103	2-Butylfuran	0.24	0.5	1000	Class II	540
13.105	2-Butyrylfuran	0.12	0.2	2300	Class II	540
13.106	2-Decylfuran	0.0012	0.002	1000	Class II	540
13.123	Ethyl furfuryl ether	0.0012	0.002	1000	Class II	540
13.138	1-(2-Furyl)butan-3-one	2.2	3	1000	Class II	540
13.148	3-Methyl-2(3-methylbut-2-enyl)furan	0.12	0.2	1000	Class II	540
13.163	2-Pentanoylfuran	0.061	0.09	1000	Class II	540
13.031	2-Benzofurancarboxaldehyde	0.012	0.01	670	Class III	90
13.047	Propyl 3-(2-furyl)acrylate	2.2	1	690	Class III	90
13.058	3-(5-Methyl-2-furyl) butanal	0.0012	0.5	33	Class III	90
13.066	3-Acetyl-2,5-dimethylfuran	ND	2	110	Class III	90
13.070	2-Hexanoylfuran	ND	0.9	5.3	Class III	90
13.190	3-((2-Methyl3-furyl)thio)-2-butanone	0.012	0.02		Class III	90
13.006	Phenethyl 2-furoate	0.012	0.2		Class III	90
13.021	Isopentyl 4-(2-furan)butyrate	0.24	0.09		Class III	90
13.022	Ethyl 3(2-furyl)propionate	0.012	0.07		Class III	90
13.023	Isopentyl 3-(2-furan)propionate	0.24	0.09		Class III	90
13.024	Isobutyl 3-(2-furyl)propionate	0.12	24		Class III	90
13.074	2,3-Dimethylbenzofuran	0.52	0.01	160	Class III	90
13.116	2,5-Dimethyl-3-thioacetoxyfuran	3.0	4		Class III	90

ABBREVIATIONS

AFC	Food Additives, Flavourings, Processing Aids and Materials in contact with Food
bw	body weight
CAS	Chemical Abstract Service
CEF	EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CHO	Chinese hamster ovary (cells)
CoE	Council of Europe
DNA	Deoxyribonucleic acid
DPXL	DNA protein cross-link
DSB	DNA strand breaks
EFFA	European Flavour and Fragrance Association
EPA	United States Environmental Protection Agency
FAO	Food and Agriculture Organization of the United Nations
FEMA	Flavor and Extract Manufacturers Association
FGE	Flavouring Group Evaluation
FLAVIS (FL)	Flavour Information System (database)
FR	Furan
GLP	Good laboratory practice
GSH	Glutathione
5HMF	5-Hydroxymethyl furfural
HPRT	Hypoxanthine Phosphoribosyl transferase
ID	Identity
IP	Intraperitoneal
IR	Infrared spectroscopy
JECFA	Joint FAO/WHO Expert Committee on Food Additives
MNBN	Micronucleated Binucleate cells
MS	Mass spectrometry
MSDI	Maximised Survey-derived Daily Intake
mTAMDI	Modified Theoretical Added Maximum Daily Intake

NCE	Normochromatic erythrocyte
NMR	Nuclear Magnetic Resonance
No	Number
NOAEL	No Observed Adverse Effect Level
NTP	National Toxicology Program
OECD	Organisation for Economic Cooperation and Development
PAPS	3'-Phosphoadenosine-5'-phosphosulfate
PCE	Polychromatic erythrocyte
2-PF	2-Pentylfuran
PK	Proteinase K
RI	Replication Index
SCE	Sister chromatic exchange
SCF	Scientific Committee on Food
SMF	[(sulphoxy)methyl]furfural
TK	Thymidine kinase
UDS	Unscheduled DNA Synthesis
VC	Vehicle controls
WHO	World Health Organization